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Résumé 
La sénescence cellulaire est une réponse aux stresses selon laquelle des cellules 
pouvant proliférer optent pour entrer dans un arrêt du cycle cellulaire en réponse à une variété 
de stimulations intrinsèques et extrinsèques telle que, par exemple, le raccourcissement des 
télomères, un stress oxydatif, des dommages à l’ADN ou l’activation constitutive 
d’oncogènes. Toutes ces stimulations ont en commun le potentiel d’initier ou de promouvoir 
une transformation néoplasique qui peut dégénérer en cancer. En fait, la sénescence est 
maintenant acceptée comme un mécanisme cellulaire autonome pour empêcher le 
développement du cancer et elle est reconnue, particulièrement dans les cellules humaines, 
pour s’établir et se maintenir à l’aide d’au moins deux voies de suppression tumorale 
majeures : les voies de p53/p21CIP et de p16INK4A/pRB. Ces deux voies sont capables d’activer 
et d’augmenter l’expression d’un autre suppresseur tumoral : la protéine PML. En tant que 
suppresseur de tumeur, PML est suffisant pour induire la sénescence dans des cellules 
normales, mais il n’arrive généralement pas à activer une réponse complète de sénescence 
dans les cellules cancéreuses. 
Considérant ces faits, le premier objectif de cette thèse était d’étudier le mécanisme de 
résistance des cellules cancéreuses contre la sénescence induite par PML. Nous avons trouvé 
que, dans des cellules normales, la surexpression de CDK4 ou de CDK6 (CDK4/6) est 
suffisante pour contourner la sénescence induite par PML. De même dans les cellules 
cancéreuses, l’expression de ces kinases, souvent retrouvées augmentées dans de nombreux 
cancers, prévient probablement l’induction d’une sénescence par PML. Effectivement, grâce à 
l’inhibition de l’expression et/ou de la fonction kinase des CDK4/6, nous avons réussi à 
restaurer un programme de sénescence dans des cellules cancéreuses. En fait, l’utilisation de 
palbociclib, un inhibiteur spécifique de CDK4/6 maintenant en essais cliniques, permet 
d’augmenter l’habileté de PML à induire un arrêt de croissance plus fort et plus durable dans 
des cellules en cultures ainsi qu’une meilleure réduction de la progression de tumeurs dans des 
souris. Cette sénescence plus complète corrèle avec une augmentation de la présence de 
marqueurs d’autophagie, une meilleure répression des gènes cibles des E2F et une signature 
d’expression de gènes correspondant à l’inhibition de la méthylation de l’ADN. Ce dernier 
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point découle du fait que l’inhibition de CDK4/6 par le palbociclib promeut une dégradation 
par autophagie de la DNA méthyltransférase DNMT1. Nous avons aussi démontré que CDK4 
est capable d’interagir avec DNMT1 et de le phosphoryler in vitro. Ces résultats soulignent la 
valeur potentielle des inhibiteurs de CDK4/6 en tant que modulateurs épigénétiques pour 
faciliter l’activation de la sénescence dans des cellules cancéreuses. 
La sénescence induite par PML est fortement liée aux modifications post-
traductionnelles. Parmi ces dernières, la SUMOylation joue un rôle important dans la fonction 
d’échafaudeur de PML et dans la formation des corps de PML. Les corps de PML sont des 
structures nucléaires dynamiques stimulées par des stresses, comme l’activation d’oncogènes 
menant à la sénescence, et dont la formation permet la séquestration de protéines spécifiques 
pour leur régulation et/ou pour leur modification post-traductionnelle. À travers le recrutement 
de protéines, les corps de PML régulent de nombreuses fonctions cellulaires telles que la 
sénescence, l’apoptose, la réponse antivirale, la réponse aux dommages à l’ADN et la 
régulation de l’expression de gènes. Compte tenu de cela, le deuxième objectif de cette thèse 
était de caractériser le rôle de la SUMOylation dans la sénescence induite par un oncogène, 
soit par l’expression de l’oncogène RAS. 
À l’aide d’une analyse du protéome de SUMO3 dans les cellules sénescentes versus 
des cellules en croissances, nous avons pu identifier 25 sites de SUMOylation dans 23 
protéines dont l’incidence était significativement régulée par la sénescence. Il est à noter que 
la plupart de ces protéines (un tiers) sont connues pour être associées au corps de PML. 
Curieusement, UBC9 (la seule enzyme E2 pour la SUMOylation) a été retrouvée plus 
SUMOylée dans la sénescence sur sa Lys-49. Des études fonctionnelles d’un mutant d’UBC9 
pour la Lys-49 ont démontré une diminution de son association aux corps de PML et la perte 
de la capacité d’UBC9 surexprimé à retarder la sénescence. De plus, la localisation forcée 
d’UBC9 dans les corps de PML gêne la sénescence induite par PML ou RAS. Ces résultats 
nous permettent de proposer des fonctions pro- et anti-sénescence de la SUMOylation des 
protéines, particulièrement pour UBC9. 
Mots-clés : Sénescence, PML, CDK4 et CDK6 (CDK4/6), méthylation de l’ADN, 
palbociclib, corps de PML, SUMOylation, UBC9 
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Abstract 
Cellular senescence is a stress response wherein proliferating competent cells undergo 
a stable cell cycle arrest in response to a variety of intrinsic and extrinsic stimuli, including 
telomere shortening, oxidative stress, DNA damage or the constitutive activation of oncogenes 
among others. All these stimuli have in common the potential to initiate or promote neoplastic 
transformation that can degenerate in cancer. Senescence, particularly in human cells, is 
established and maintained by at least two major tumor suppressor pathways: the p53/p21CIP 
and p16INK4A/pRB pathways and is now accepted as a potent cell-autonomous mechanism for 
suppressing the development of cancer. Both pathways are able to activate and increase the 
expression of the tumor suppressor protein PML. As a tumor suppressor, PML is sufficient to 
induce senescence in normal cells; however, upon the same stimuli, cancer cells fail to engage 
a complete senescence response.  
Given this, the first aim of this thesis is to investigate the resistance mechanisms of 
cancer cells to PML-induced senescence.   
We found that overexpression of the CDK4 and CDK6 (which are often up-regulated 
in cancer) are sufficient to bypass PML-induced senescence in normal cells. In cancer cells the 
expression of these kinases impairs the PML-induced senescence. By inhibiting the expression 
and/or function of CDK4/6 we were able to restore the senescence program in cancer cells. 
Also, the specific CDK4/6 inhibitor palbociclib (currently used in clinical trials) increased the 
ability of PML to regulate a stronger and more permanent growth inhibition in cell culture and 
decreased tumor progression in mice.  This complete senescence response correlated with an 
increase in autophagy markers, repression of E2F target genes and a gene expression signature 
of blocked DNA methylation. Furthermore, CDK4/6 inhibition by palbociclib promotes 
autophagy-dependant degradation of the DNA methyltransferase DNMT1. More important, 
we were able to demonstrate that CDK4 directly interacts and phosphorylates DNMT1 in 
vitro. These results highlight the potential value of CDK4/6 inhibitors as epigenetic 
modulators to facilitate activation of cellular senescence in cancer cells. 
PML-induced senescence is tightly regulated by post-translational modifications 
(PTMs). Among these PTMs, SUMOylation plays an important role in the scaffold function of 
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PML and the formation of the PML-NBs (PML-Nuclear Bodies). PML-NBs are dynamic 
structures triggered by stress such as oncogene-induced senescence, and its formation allows 
the sequestration of target proteins for their regulation and/or its post-translational 
modification. By protein recruitment, PML-NBs regulate several cellular functions such as 
senescence, apoptosis, antiviral response, DNA repair and gene regulation. Given this; the 
second aim of this thesis is to characterize the role of SUMOylation in oncogene mediated 
cellular senescence, specifically by the expression of the oncogene RAS. 
By a SUMO3 proteome analysis of senescent cells we were able to identify 25 SUMO 
sites in 23 proteins that were significantly regulated during senescence. Importantly, most of 
these proteins were PML-NB associated. Interestingly, UBC9 (the only SUMO E2 enzyme), 
was found more SUMOylated in senescence on its Lys-49. Functional studies of a UBC9 
mutant in Lys-49 showed a decreased association to PML-NBs and the loss of UBC9’s ability 
to delay senescence. Moreover, forced localization of UBC9 into PML-NBs counteracted RAS 
and PML-induced senescence. These results allowed us to propose a pro- and an anti-
senescence function of protein SUMOylation, specifically for UBC9. 
 
Keywords: Senescence, PML, CDK4/6, DNA methylation, palbociclib, PML-NBs, 
SUMOylation, UBC9 
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1.1  Introduction to cancer 
1.1.1  Origin of cancer 
The adult human is composed of approximately 1015 cells, many of which are required 
to divide and differentiate in order to repopulate organs and tissues which require cell 
turnover. This exquisite control over cell multiplicity is achieved by a network of overlapping 
molecular mechanisms which govern cell proliferation on one hand and cell death on the 
other; thereby ensuring a homeostasis of cell number and thus maintenance of normal tissue 
architecture and function (1-3). Any factor which alters this balance between birth and death 
has the potential if not corrected, to alter the total number of cells in a particular organ or 
tissue. After many cell generations this increased cellular multiplicity would be clinically 
detectable as aberrant cell proliferation and cancer (1, 4). Cancer is a leading cause of death 
worldwide and encompasses more than 100 distinct diseases with diverse risk factors and 
epidemiology which originate from most of the cell types and organs of the human body and 
which are characterized by relatively unrestrained proliferation of cells that can invade beyond 
normal tissue boundaries and metastasize to distant organs (5, 6). 
Cancer has been defined in many ways. Starting from Hippocrates observations of 
angiogenesis, the word cancer itself refers to the thick blood vessels that feed the tumours and 
that resemble the claws of a crab. Since the time of Laennec, pathologists have viewed cancer 
as acquiring properties of cells at different developmental stages, but appearing 
inappropriately in the tumours. In the past century the genetic model of cancer has 
predominated, beginning with Boveri who first suggested a role for abnormal chromosomes in 
cancer formation (7). Later on, Peter Nowell proposed the clonal evolution of tumor cell 
populations to explain how malignant tumors arise over time (8). Tumor progression results 
from genetic variability within the tumor cell population that allows clonal expansion of more 
aggressive tumor phenotypes with distinctive karyotypes and biology (9), including genomic 
instability (10). A common finding of recent studies is that the majority of tumours are 
genetically heterogeneous, harbouring sub-clonal populations of cells (10). This is a parallel to 
Darwinian natural selection, with cancer clones as the equivalent of asexually reproducing, 
unicellular quasi-species. Modern cancer biology and genomics have validated cancer as a 
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complex, Darwinian, adaptive system raising the fact that the evolution of cancer clones takes 
place within tissue ecosystem habitats. These habitats have evolved over a billion years to 
optimize multicellular function but restrain clonal expansion of renegade cells (6).  
1.1.2  Cellular transformation 
The transformation of a normal cell into a malignant one involves processes by which 
genes involved in normal homeostatic mechanisms that control proliferation and cell death 
suffer mutational damage. Mutations can activate genes stimulating proliferation or protecting 
against cell death, called oncogenes, or can inactivate genes which would normally inhibit 
proliferation, called tumor suppressor genes (1, 11, 12). The experimental transformation of 
human cells indicates that the disruption of a limited number of cellular regulatory pathways is 
sufficient to impart a tumorigenic phenotype to a wide variety of normal cells, which suggest a 
series of genetic and cellular principles that may govern the formation of most, if not all, types 
of human cancers (11).  
Much of our current understanding of cancer is based on the central dogma that it is a 
genetic disease, arising as a clone of cells that expands in an unregulated fashion because of 
mutations that can be either inherited or somatically acquired due to environmental and life-
style factors (5, 13). These mutations include point mutations which cause amino acid 
substitutions; frame-shift mutations or mutations to stop codons which either truncate the 
protein product or scramble its sequence; chromosomal imbalance or instability resulting in 
amplification, overexpression or inappropriate expression of a particular gene; loss of a gene 
or its fusion with another gene as a result of chromosomal breakage and rearrangement 
resulting in a chimeric protein with altered function. They also often include epigenetic 
changes that are stably inherited over DNA replication, such as hypomethylation of DNA and 
hypoacetylation of chromatin, as well as gene specific hypomethylation and hypermethylation 
that could lead to differential gene expression (1, 7, 14). All these mutations mentioned above 
usually occur to alter function of oncogenes, tumor suppressor genes or other genes that 
control, directly or indirectly, cell proliferation (Fig. 1.1). 
The products of oncogenes can be classified into six broad groups: transcription 
factors, chromatin remodelers, growth factors, growth factor receptors, signal transducers, and 
 4 
apoptosis regulators (15, 16). In contrast to the cellular proliferation stimulating function of 
oncogenes to drive the cell cycle forward, tumor suppressor genes code for proteins that 
normally operate to restrict cellular growth and division or even promote programmed cell 
death (apoptosis). These include inhibitors of cell cycle progression, factors involved in 
maintenance of cell cycle checkpoints, and proteins required for apoptosis induction (16). 
Figure 1.1: Progression to malignant transformation. 
 Abnormal activation of oncogenes or loss of tumor suppressor function can promote an 
unbalance between cell growth and death that can lead to aberrant cell proliferation. This 
aberrant proliferation induces the activation of tumor suppressor mechanisms that 
premalignant cells need to bypass in order to become malignant and progress to cancer. 
Inspired from Narita M & Lowe SW (2005) (17) .  
 
One of the best studied tumor suppressors is a protein known as Retinoblastoma 
Protein (pRB) and its corresponding gene, RB1, the first tumor suppressor gene to be 
identified. Since pRB activity stops the expression of genes required for progression into S 
phase of the cell cycle, its inactivation allows for uncontrolled cell division. In fact, this 
principle applies to all tumor suppressors: genetic alterations in the gene leading to 
tumorigenesis prevent the regulatory protein from inhibiting cell proliferation (16). Another 
tumor suppressor well characterized is p53, which is a transcription factor that activates 
 5 
programmes such as apoptosis, senescence, and DNA repair in response to a variety of cellular 
stresses, including DNA damage, hypoxia, and nutrient deprivation (3) 
1.1.3  Characteristics of a tumor cell 
Cancer cells often show alterations in the signal transduction pathways that lead to 
proliferation without mitogenic signals or less stringent requirements than those of normal 
cells (18). Indeed, many growth factors and their receptors, as well as their membrane, 
cytoplasmic and nuclear downstream effectors give to cancer cells special characteristics to 
allow them to change their cell physiology with new capabilities that contribute to 
unscheduled proliferation (11, 19). In addition, most cancer cells acquire genomic instability 
that leads to additional mutations and chromosomal aberrations as well as chromosomal 
instability, a defect responsible for numerical changes in chromosomes (20-22). Cancer cells 
can enable signals that convey in large part by growth factors that bind cell surface receptors, 
typically containing intracellular tyrosine kinase domains. The latter proceed to emit signals 
via branched intracellular signaling pathways that regulate progression through the cell cycle 
as well as cell growth; often these signals influence yet other cell biological properties, such as 
cell survival and energy metabolism (2). All these attributes include the ability of cancer cells 
to generate their own mitogenic signals, to resist exogenous growth-inhibitory signals, to 
evade apoptosis, to proliferate without limits (undergo immortalization), to acquire vasculature 
(undergo angiogenesis), and in more advanced cancers, to invade and metastasize (11, 23). 
Rather than lacking function, cancer cells reproduce at a rate far beyond the normally 
tightly regulated boundaries of the cell cycle. Cancer can be distinguished from many other 
human diseases because its root cause is not a lack of, or reduction in, cell function, its roots 
cause is gain of cell functions that give them the properties to alter a normal biological 
process: cell division (16). 
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1.2 Cell cycle and Cancer  
1.2.1 General perspective 
Multicellular organisms require an adequate control of cell division and differentiation 
to coordinate multiple different cell types in functional tissues. The cell division cycle entails 
the tightly regulated transduction of mitogenic signals to a series of biochemical machineries 
that control the duplication of DNA and its proper segregation to daughter cells (24). The cell 
cycle plays a prominent role in development, from egg fertilization to the adult organism. 
Such key role also holds in pathological conditions, because deregulation of the cell cycle is 
associated with aberrant cell proliferation and cancer (4). The most critical decision that every 
proliferating mammalian cell must make is whether to continue another round of cell division 
or to exit the cell cycle and reach a quiescent state. Likewise, quiescent cells must decide 
whether to continue in their non proliferative state or to re-enter the cell cycle. All cells have 
the capacity to enter quiescence and all quiescent cells, except those that have reached a state 
of terminal differentiation, have the capacity to re-enter the cycle (25). 
The phases of the mammalian cell division cycle include two major periods of activity 
in which the genome is first duplicated (DNA synthesis or S phase) and the two newly 
replicated genomes are then distributed between the daughter cells (mitosis). Stages of mitosis 
include prophase, metaphase, anaphase and telophase. Additional gap periods, G1, during 
which the cell is preparing for DNA synthesis (preceding S phase) and G2, during which the 
cell prepares for mitosis, are required to coordinate DNA synthesis and segregation with 
mitogenic signals and to synthesize and assemble the required proteins and cellular structures. 
Cells in G1 can, before commitment to DNA replication, enter a resting state called G0. Cells 
in G0 account for the major part of the non growing, non proliferating cells in the human body 
(24, 26). Thus the cell cycle can be defined as the process by which cells monitor proper 
conditions for cell division, activate the required biochemical machineries for DNA replication 
and chromosome segregation, and monitor these steps to generate two healthy genomically 
stable daughter cells. All these processes are orchestrated by a family of kinases: the Cyclin-
Dependent Kinases (CDKs) (20, 24, 27). CDKs serve as focal points for the cells and respond 
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to proliferative and non proliferative signals and to various forms of genotoxic stress at 
specific checkpoints, in order to ensure faithful DNA replication and mitosis (28). 
1.2.2 The Cyclin Dependant Kinases  
Cyclin Dependent Kinases (CDKs) are the catalytic subunits of a large family of 
heterodimeric serine/threonine kinases whose activity depends on a regulatory subunit: a 
Cyclin, which control kinase activity and substrate specificity. CDKs play important roles in 
the control of cell division progression and modulate transcription in response to several extra- 
and intracellular cues (21, 29, 30).  In most cases, the concentration of the kinase subunit is 
relatively constant; whereas the concentration of the Cyclin subunit oscillates (this oscillation 
gave their Cyclin name). The kinase is completely inactive without its Cyclin partner, but in 
addition to the binding of Cyclin, activation of the holoenzyme requires the phosphorylation of 
a key residue in the activating T-loop of the kinase subunit (31). The CDK family is 
characterized by a conserved catalytic core made up of an ATP-binding pocket, a PSTAIRE-
like Cyclin-binding domain and an activating T-loop motif. Collectively, these features 
participate in CDK activation, which involves the association with Cyclins via the PSTAIRE 
helix to: first, displace the T-loop and expose the substrate-binding interface; and second, 
realign critical residues within the active site thereby priming it for the phospho-transfer 
reaction. Most CDK family members also possess inhibitory (Thr-14; Tyr-15) and activating 
(Thr-161) phosphorylation sites. Phosphorylation at Thr-14 and Tyr-15 within the ATP-
binding site by inhibitory kinases WEE1 and MYT1 interferes with proper ATP alignment, 
whereas T-loop phosphorylation at Thr-161 by CDK Activating Kinases (CAKs) improves 
substrate binding and complex stability to enable full CDK activation (32). The consensus 
sequence for the phosphorylation site in the amino acid sequence of a CDK substrate is 
[S/T*]PX[K/R], where S/T* is the phosphorylated serine or threonine, P is proline, X is any 
amino acid, K is lysine, and R is arginine (33). Based on the sequence of the kinase domain, 
CDKs belong to the CMGC group of kinases which include also: Mitogen Activated Protein 
Kinases (MAPKs), Glycogen Synthase Kinase-3 beta (GSK3β) and members of the Dual-
Specificity Tyrosine-Regulated Kinase (DYRK) family and CDK-like kinases (34). 
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Figure 1.2: Functional Diversity of CDKs and the pathways that regulate.  
The Cyclin-Dependant Kinases can modulate several cellular processes such as 
metabolism, hematopoiesis, angiogenesis, proteolysis, epigenetics DNA damage and 
DNA repair, cell cycle regulation, lipogenesis, neuronal function and transcription. 
Inspired from Peyressatre, M. et al., 2015 (35). 
 
CDKs were first discovered by genetic and biochemical studies in model organisms 
such as yeasts and frogs, and from these studies, it has been clearly established the importance 
of CDKs function as the major eukaryotic protein kinase family involved in the integration of 
extracellular and intracellular signals to modulate gene transcription and cell division (34).   
Twenty different CDK exist in mammal cells (24). The evolutionary expansion of the CDK 
family have led to the division of CDKs into two cell-cycle-related subfamilies: Mitotic CDKs 
which include CDK1 and Interphase CDKs, which include CDK2, CDK4 and CDK6 and the 
transcriptional subfamily, which include: CDK7, CDK8, CDK9, CDK11 and CDK20. Unlike 
the prototypical Cdc28 kinase of budding yeast, most of these CDKs bind one or a few 
Cyclins, consistent with functional specialization during evolution (29). There are ten Cyclins 
that belong to four different classes: the A-, B-, D- and E-type Cyclins (19).  
 9 
Protein kinases mediate most of the signal transduction in eukaryotic cells by 
modification of substrate activity, and also, control many other cellular processes, including 
metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell 
movement, apoptosis, and differentiation (Fig. 1.2) (34, 36). Tumour associated mutations 
frequently deregulate certain CDK/Cyclin complexes, resulting in either continued 
proliferation or unscheduled re-entry into the cell cycle, two properties characteristic of most 
human tumour cells (19). 
1.2.3 The function of the CDKs during the cell cycle 
According to the ‘classical’ model for the mammalian cell cycle, specific CDK/Cyclin 
complexes are responsible for driving the cell cycle in a sequential and orderly fashion (20) 
(Fig. 1.3). Extracellular signals, including stimulatory mitogens, inhibitory cytokines, 
differentiation inducers, cell–cell contacts and growth factors induce the expression of D-type 
Cyclins (D1, D2 and D3). The three D-type Cyclins are differentially expressed, alone or in 
combination, in distinct cell lineages, where they assemble with CDK4 and CDK6 to form 
enzymatically active holoenzyme complexes during G1. CDK4/6 complexes are able to 
partially phosphorylate and inactivate pRB pocket of proteins (pRB, p107 and p130), which 
are the only well characterized substrates to date (37, 38). In its phosphorylated state, the pRB 
pocket proteins represses the transcription of genes that are necessary for cell cycle 
progression by binding to the transactivation domain of the E2F transcription factor family of 
proteins. This reduced inhibition of E2F transcription factors initiates a positive feedback loop, 
where E2F transcription factors promote transcription of the E-type Cyclins, which activate 
CDK2 and other proteins that are important for initiation of S phase and DNA synthesis. 
Pocket proteins phosphorylation process is then completed by Cyclin E (E1 and E2)/CDK2 
complexes expressed in late G1, leading to their complete inactivation, preventing their 
binding and complete inactivation of the E2F family of transcription factors (39-41). Given 
this functions, CDK4/6-Cyclin D and CDK2–cyclin E complexes are essential to drive the 
G1/S transition. The availability of E-Cyclins during the cell cycle is tightly controlled and 
limited to the early stages of DNA synthesis. Later during G1, E- Cyclins (Cyclins E1 and E2) 
become upregulated and activate CDK2 (and, to a lesser extent, CDK1 and CDK3), resulting 
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in phosphorylation of a broader range of cell cycle-related proteins. CDK1 and CDK2 are 
subsequently activated by Cyclin A2 during the late stages of DNA replication to drive the 
transition from S phase to mitosis (G2 phase). Throughout the process of progression through 
S phase and G2 phase of the cell cycle, the pocket proteins remain hyper-phosphorylated, 
returning to its hypo-phosphorylated state only following mitosis. The subsequent induction in 
S phase and the activation of Cyclin B1/ CDK1 at the onset of mitosis, drive the progression 
of cells through the phosphorylation of a large number of proteins that are involved in DNA 
replication, as well as in centrosome and chromosome function (42). Following nuclear 
envelope breakdown, A-type Cyclins are degraded, facilitating the formation of the 
CDK1/Cyclin B complexes responsible for driving cells into mitosis (30). 
1.2.4 Cellular regulation of CDKs by CDK Inhibitors and its role in 
cancer formation 
Besides the modulation of the CDKs by the Cyclins, the CDK activity is also 
negatively regulated by small polypeptides, the CDK-Inhibitors (CKIs). Whereas most Cyclins 
promote CDK activity, CKIs restrain CDK activity, so, close cooperation between this trio is 
necessary for ensuring orderly progression through the cell cycle. In addition to their well 
established function in cell cycle control, it is becoming increasingly apparent that mammalian 
CDKs, Cyclins and CKIs play indispensable roles in many processes such as transcription, 
epigenetic regulation, metabolism, stem cell self-renewal, neuronal functions, apoptosis and 
spermatogenesis (32). 
In mammals, CKIs are subdivided into two classes based on their structure and CDK 
specificity. 
- The CIP/KIP (CDK-Interacting Protein/Kinase Inhibitory Protein) family which 
comprises: p21CIP1 (Cdkn1a), p27KIP1 (Cdkn1b), and p57KIP2 (Cdkn1c). This family of 
CKIs are encoded by the Cyclin-Dependent Kinase Inhibitor 1 (CDKN1) genes and 
bind to most Cyclin–CDK complexes and prevent their activation.  
- The INK4 (Inhibitors of CDK4) family which includes: p16INK4A (Cdkn2a), p15INK4B 
(Cdkn2b), p18INK4C (Cdkn2c), and p19INK4D (Cdkn2d), encoded by the Cyclin-
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Dependent Kinase Inhibitor 2 (CDKN2) gene that primarily target CDK4 and CDK6 
and block their association with the D-type Cyclins (25, 32, 43, 44).  
Among the INK4 family, p16INK4A is the best known inhibitor of CDK4, and contributes to 
G1 arrest in two ways. Firstly, to become functional, CDK4 requires cytoplasmic, post-
translational folding in a complex involving the Heat Shock Protein 90 (HSP90), an 
interaction that is disrupted by p16INK4A. In addition, p16INK4A can bind to CDK4 directly and 
inhibit its catalytic activity. The combination of these two mechanisms results in G1 arrest in 
cells with functional pRB, but not in pRB-deficient cells (45). 
Whereas CIP/KIP proteins act as negative regulators of Cyclin E- and Cyclin A-CDK2 and 
Cyclin B-CDK1 holoenzymes in a 1:1 stoichiometry, they also act as positive regulators of 
Cyclin D-CDK4/6 complexes by mediating their assembly early in G1. This results in the 
titration of p27KIP1 from Cyclin E-CDK2, and the activation of this complex. In turn, p27KIP1 is 
phosphorylated by Cyclin E-CDK2, targeting it for degradation. Instead, INK4 proteins 
compete with D-type Cyclins for binding CDK4/6. Enforced expression of INK4 proteins can 
lead to G1 arrest by promoting the redistribution of CIP/KIP proteins and blocking Cyclin E-
CDK2 activity. For example; CDK4 can sequester p27KIP1 and controls its availability for 
inhibition of CDK2 activity (46). Thus, in cycling cells, there is a reassortment of CIP/KIP 
proteins between CDK4/6 and CDK2 as cells progress through G1 alternately acting as 
positive or negative regulators of CDK activity (25, 44, 47). 
Owing to their inhibition of CDKs and cell proliferation, CKI are tumour suppressors, 
and deletion of the CDKN2A–CDKN2B locus, which encodes p16INK4A, p15 INK4B and another 
protein p14 (ARF; which is involved in the activation of the p53 tumour suppressor), is one of 
the most frequent mutations in human tumours (42). Intriguingly, increased expression of 
p16INK4A is a hallmark of tumours in which pRB function has been lost suggesting a negative 
feedback regulation (25). Not surprisingly, many components of the cell cycle regulatory 
machinery, including CDKs, CKI and CDK substrates, are important targets of mutations that 
lead to human malignancy (37). CDK4 and CDK6 hyperactivity has been well documented in 
a wide variety of cancers, in fact, genetic alterations in components of the pRB-CDK4/6-
Cyclin D-p16INK4A pathway are amongst the most frequently occurring anomalies reported. 
There are found in more than half of all human tumours being Cyclin D1 gene (CCND1) the 
second most frequently amplified locus across all human cancers. (35). Together with 
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amplification and overexpression of Cyclin-D, CDK4 gene amplification has been 
documented in rhabdomyosarcoma (48) osteosarcoma (49, 50), well-differentiated and 
de-differentiated liposarcomas  (51, 52), and cancer of the uterine cervix (53). Over expression 
of CDK4 protein has been reported in breast cancer (54), colorectal carcinoma (55), Non-
Small-Cell-Lung-Carcinoma (NSCLC) (56), uterine cervical carcinoma (53), glioblastoma 
(57, 58) and melanoma (59, 60). CDK6 gene amplification and overexpression have been 
demonstrated in squamous-cell oesophageal carcinoma (61) lymphomas (35), leukemias (62), 
and gliomas (63). Moreover, CDK6 is overexpressed in medulloblastoma, which is the most 
common brain tumor in children (64). Also, homozygous deletions of CDKN2A (gene 
encoding for p16INK4A), are seen in tumours of the pancreas, bladder, breast, prostate and in 
glioblastoma (65, 66). Conversely, loss of pRB function results in constitutive activation of 
E2F, Cyclin E1 and CDK2 expression, and therefore loss of reliance on CDK4/6 to initiate the 
G1/S transition (66-68). 
Although the canonical role of Cyclins and CDKs as essential drivers of cell cycle entry 
and progression has been firmly established, as mentioned before; additional functions of the 
CDK4 and CDK6 complexes are involve in many other cellular process, and the elucidation of 
how signal transduction pathways activate CDK4/6 and the substrates that theses kinases are 
able to regulate in different tumor types should give a rational to create combinatorial 
therapies to improve therapeutic responses. 
From now on, I will refer to CDK4 and CDK6 as an active complex, implying their 
association with Cyclin D. 
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Figure 1.3: CDKs regulation and phosphorylation levels of pRB during the cell cycle.  
Cell cycle regulation by CDK/cyclins: CDK1/cyclin B during the mitosis (M), CDK4 and 
6/cyclin D for progression through G1 phase, CDK2/cyclin E for G1/S transition, 
CDK2/cyclin A at the S phase and CDK1/cyclin A for progression through G2 phase. 
 
1.2.5 Non- canonical functions of CDK4 and CDK6  
It is clear that tumor proliferation requires an adapted metabolic response of the cells; 
hence, the regulation of the cell cycle must be linked to metabolic control. The impact that the 
activities of cell cycle regulators such as Cyclins, CDKs or E2F transcription factor have on 
cell metabolism are also being uncovered (41, 69). In this segment I will focus only on the 
non-canonical functions of CDK4 and CDK6.   
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Role in DNA methylation 
DNA methylation plays a central role in the epigenetic regulation of gene expression 
during development and progression of cancer diseases. The inheritance of specific DNA 
methylation patterns are acquired in the early embryo and are specifically maintained after 
cellular replication via the DNA Methyltransferase 1 (DNMT1). Recent studies have 
suggested that the enzymatic activity of DNMT1 is possibly modulated by phosphorylation of 
serine/threonine residues located in the N-terminal domain of the enzyme. It has been reported 
that CDK1, 2 and 5 can phosphorylate Ser-154 of human DNMT1 in vitro controlling its 
enzymatic activity and protein stability; suggesting that dysregulation of cell cycle via CDKs 
could induce abnormal phosphorylation of DNMT1 and lead to DNA hypermethylation often 
observed in cancer cells (70). 
Role in transcription 
CDK4 and CDK2 complexes phosphorylate Smad2 and Smad3 (Small Mother Against 
Decapentaplegic 2 and 3), inhibits its transcriptional activities and antiproliferative functions 
of signalling through the Transforming Growth Factor beta (TGF-β) pathway, thus inhibit cell 
cycle progression at transition of G1 phase to S. Mutation of the CDK phosphorylation sites of 
Smad3 increases its transcriptional activity, leading to higher expression of the CKI p15INK4B 
and increases its ability to downregulate the expression of c-Myc. (71). CDK4 and CDK6 
complexes phosphorylate, stabilize and activate the transcription factor FOXM1 (Forkhead 
Box Protein M1), thereby maintain expression of G1/S phase genes, suppress the levels of 
Reactive Oxygen Species (ROS), and protect cancer cells from senescence (72). FOXMI 
regulates the expression of various cell cycle regulators, including proteins that govern the 
G2/M transition phase (42). Also, it was shown by the group of Alan Diehl that CDK4 
phosphorylates and increases the activity of MEP50, a coregulatory factor of the Protein 
Arginine Methyltransferase 5 (PRMT5), an enzyme associated with histone methylation and 
transcriptional repression. Increased PRMT5 activity mediates key events associated with 
Cyclin D1-dependent neoplastic growth, including CUL4 repression, CDT1 overexpression, 
and DNA re-replication (73). 
CDK6 is specifically expressed in proliferating hematopoietic progenitor cells, and 
physically interact with and inhibit the transcriptional activity of Runt Related Transcription 
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Factor 1 (RUNX1) resulting in an increase proliferation of myeloid progenitors. Since 
RUNX1 transcription factors play central roles in hematopoietic, neuronal and osteogenic 
lineages, this CDK6 function may control terminal differentiation in multiple tissues and cell 
types (74). CDK6, is part of a transcription complex that induces the expression of p16INK4A 
and the Vascular Endothelial Growth Factor A (pro-angiogenic factor: VEGFA) through 
activation of JUN and STAT3 (Signal Transducer and Activator of Transcription 3). In the 
absence of p16INK4A, CDK6 can exert its full tumor promoting function by enhancing 
proliferation and stimulating angiogenesis (75). CDK6 can exert its pro-proliferative role only 
upon silencing of the gene encoding p16INK4A, an event that is frequently seen in human 
tumours (42, 76). CDK6 can also modulate the activity of the transcription factor EGR1 (Early 
Growth Response Protein 1) and regulate the balance between quiescence and proliferation in 
Hematopoietic Stem Cells (HSCs) and Leukemic Stem Cells (LSCs) (76).  
Role in DNA damage repair 
DNA damage causes stabilization of p53, leading to G1 arrest through induction of 
p21CIP1. This DNA damage causes an immediate and p53-independent G1 arrest, caused by 
rapid degradation Cyclin-D1 which leads to a release of p21CIP1 from CDK4/6 to inhibit 
CDK2 and induce cell cycle arrest. Interference with Cyclin-D1 degradation prevents 
initiation of G1 arrest and renders cells more susceptible to DNA damage (77). It has been 
shown that nuclear accumulation of degradation resistant mutants of Cyclin D1/CDK4 
complexes triggers DNA re-replication, resulting from CDT1 (Chromatin Licensing and DNA 
Replication Factor 1) stabilization, which in turn triggers the DNA damage checkpoint and 
p53-dependent apoptosis. Loss of p53 through mutations or targeted deletion results in 
increased genomic instability and neoplastic growth and disturbance of critical cell cycle 
regulatory events will perturb DNA replication fidelity, thereby contributing to neoplastic 
transformation (78). 
Balancing cell proliferation and death 
The regulation of the cell cycle is tightly linked to the control of cell death. Indeed, 
early studies indicated that the pRB/E2F pathway could modulate the expression of multiple 
pro or anti apoptotic proteins (42). CDK4 interacts with the apoptosis inhibitor survivin, which 
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is a member of the IAP (Inhibitors of Apoptosis Proteins) family and is specifically expressed 
during embryogenesis and in tumor cells to suppress cell death signaling. The interaction of 
Survivin with CDK4 promotes CDK2/Cyclin E activation and pRB phosphorylation. As a 
result of Survivin/CDK4 complex formation, p21CIP1 is released from its complex with CDK4 
and interacts with mitochondrial procaspase 3 to suppress FAS-mediated cell death (79). 
In cultured postmitotic neurons, activation of CDKs is a signal for death rather than 
cell division. In a rat model of stroke, CDK4/Cyclin D1 levels and phosphorylation of pRB 
increase after the injury, along with deregulated levels of E2F1, which correlates with 
neuronal death. After administration of a pan-CDK inhibitor (Flavopiridol) into brain 
ventricles, levels of pRB phosphorylation are blocked and dramatically reduces neuronal death 
by 80%; suggesting that CDKs could be an important therapeutic target for the treatment of 
reperfusion injury after ischemia (80). 
Control of cell differentiation and migration 
In general, cell proliferation and differentiation show an inverse relationship, and are 
regulated in a coordinated manner during development. Terminal differentiation is usually 
coupled to permanent exit from the cell cycle. The levels of Cyclins typically decline when 
cells exit the cell cycle and undergo differentiation. Moreover, induction of the expression of 
CKIs during cell differentiation prevents activation of CDK complexes in terminally 
differentiated cells. On the other hand, expression of Cyclin–CDK complexes in proliferating 
cells inhibits pRB function, thereby promoting proliferation and inhibiting differentiation. An 
example of this is that pRB binds to and regulates the activity of several cell type-specific 
transcription factors, including MYOD (Myogenic Differentiation), MEF2 (Myocyte-Specific 
Enhancer Factor 2) and RUNX2 (Runt Related Transcription Factor 2 ), thereby linking cell 
cycle arrest and differentiation (42). CDK4 phosphorylate RUNX2 and target it to degradation 
inhibiting bone differentiation (81). CDK4 also prevent transcriptional activation mediated by 
MYOD and hence inhibit myoblast differentiation (82). According to this, CDK4 can also 
suppress the skeletal muscle differentiation program in proliferating myoblasts and inhibit the 
activity of the MEF2  family of transcriptional regulators (83). Analysis of transgenic mice 
with mutant JARID2 (Jumonji and AT-Rich Interaction Domain Containing 2), revealed that 
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CDK4/6 complexes directly phosphorylate and promote degradation of GATA4 inhibiting 
then differentiation of cardiomyocytes (84). 
Cell migration and the actin cytoskeleton are also modulated by Cyclins and CDKs at 
different levels. CDK6 was shown to localize to the ruffling edges of spreading fibroblasts 
prior to the formation of filamentous actin and to promote migration in a αvβ3 integrin-
dependent manner (85). 
Role in metabolism  
Multiple cellular functions of CDK4 and CDK6 converge to control the generation of 
cellular energy and metabolism at both the cellular and organismal levels, a physiological role 
for cell cycle proteins in metabolism has been documented by the observations that CDK4-
deficient mice are viable, but small in organ and body size and infertile. These mice also 
develop insulin-deficient diabetes due to the loss of pancreatic islet β-cells (86-88). Similarly, 
CDK6-deficient mice are also viable, but with lower number of cells in the thymus and spleen, 
and with a small reduction in the abundance of peripheral blood cells (89).  These results show 
that CDK4 and CDK6 are not only involved in controlling proliferation of specific cell types 
but may play a wider role in establishing homeostatic cell numbers. The lack of phenotypes 
with more severe consequences for survival in these single knockout (KO) mice is assumed to 
reflect functional compensation between CDK4 and CDK6. Surprisingly, although CDK4/6 
double knockout mice succumbed to anaemia in the late stages of embryonic development, 
many non haematological cell types from these mice were able to proliferate normally (89). In 
addition, quiescent KO CDK4/6 fibroblasts exhibit a delay in S phase entry. This cell cycle 
perturbation by CDK4/6 disruption is associated with an increase binding of p27KIP1 to CDK2 
and a lower activation of CDK2 that lead to an impaired pRB phosphorylation (88). CDK4-
pRB-E2F1 axis are robustly expressed in non-proliferating β cells, suggesting that besides the 
control of β-cells, the CDK4 has a role in its function and is involve in glucose homeostasis. 
Inhibition of CDK4, or inactivation of E2F1, results in a decrease expression of KIR6.2, which 
impairs insulin secretion and glucose intolerance (90). An independent mechanism linking 
insulin signalling to CDK4 was provided by the observation that insulin-mediated 
upregulation of Cyclin D1 (and the subsequent activation of CDK4) in hepatocytes leads to 
phosphorylation and activation of the histone acetyltransferase GCN5 (General Control Non-
 18 
Repressed Protein 5) and suppresses hepatic glucose production independently of cell cycle 
progression (91). 
The functions of Cyclins and CDKs in modulating metabolic pathways contribute to 
the ability of these proteins to affect differentiation (42). Cell cycle regulators such as E2F1 
and pRB play crucial roles in the control of adipogenesis, mostly by controlling the transition 
between preadipocyte proliferation and adipocyte differentiation (92). Since this pathway is 
regulated by the CDKs, is not surprise that these kinases have a pivotal role in control 
adipogenesis. During terminal differentiation of mouse preadipocytes, the level of CDK4 
remains constant and Cyclin D3 is the predominant Cyclin partner of CDK4 in mature 
adipocytes. Knockdown of Cyclin D3 inhibits adipogenesis in vitro (93) and CDK4 inhibition 
impairs adipocyte differentiation and function. Consistent with this, mice lacking Cyclin D3 or 
CDK4 are protected from diet-induced obesity, have smaller adipocytes and reduced 
expression of adipogenesis genes. CDK4 also participates in adipocyte differentiation by 
directly interacting with and activating PPARγ, the master regulator of adipogenesis (92).  
Some of the proposed non-canonical roles may not reflect a normal physiological 
protein function, but rather a gain of function event that occurs in tumour cells as a 
consequence of Cyclin and/or CDK overexpression (42).  
1.2.6 CDK Inhibitors and its implication in Cancer Treatment 
Given the critical role that CDKs play in cell cycle control they have been actively 
considered as targets for anticancer therapy. However, this strategy has found some practical 
limitations. For instance, some CDKs may have functions not directly related to cell cycle 
progression and others, which were believed to be essential for this process, may actually be 
dispensable. One example to support the latter theory is CDK2. Recent research in animal 
models suggests that this kinase is not required for mitotic cell division and could be 
dispensable for cancer cell progression, rendering this CDK not suitable as a treatment target 
(18, 94). In the same context, emerging evidence suggests that tumour cells may also have 
specific requirements for individual CDKs. In particular, CDKs that promote transition 
through the cell cycle are expected to be key therapeutic targets because many tumorigenic 
events ultimately drive proliferation by impinging CDK4 or CDK6 complexes in the G1 phase 
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of the cell cycle (20, 95). According to this, amplification, genetic rearrangements and/or 
overexpression of Cyclin or CDK genes have been documented in nearly all human tumour 
types. Given that several inhibitors of CDK4/6 kinase activity are currently in clinical trials, it 
will be important to elucidate which of these cell cycle independent roles of Cyclins and 
CDKs truly contribute to tumorigenesis in vivo. According to the prevailing model, the main 
role of CDK4 and CDK6 is to inactivate pRB. Indeed, inhibition of CDK4 and CDK6 has no 
effect on the proliferation of tumour cells that have lost pRB expression. Given the increasing 
number of reported CDK4/6 substrates, it remains to be seen whether CDK4/6 inhibition in 
pRB-negative tumour cells affects other functions of CDK4/6 kinases besides the cell cycle 
control and, by doing so, contributes to the therapeutic effect (42). The low expression in 
p16INK4A, the high expression of the D type Cyclins, and the overexpression of CDK4/6 itself, 
indicates that CDK4/6 are potentially useful drug targets for breast, cervical, colorectal, 
esophageal, kidney, liver, lung, pancreatic, and prostate carcinomas, NSCLC, acute 
lymphoblastic lymphoma, mantle cell lymphoma, liposarcoma, melanoma, medulloblastoma, 
and multiple myeloma (95, 96). 
Over the past 20 years, several CDK Inhibitors (CDKIs) have been developed as 
potential cancer therapeutics and tested in numerous trials and in several tumour types. Some 
of these compounds target regulatory pathways implicated in CDK function, whereas other 
exerts direct effects on the catalytic CDK subunit through interaction with the ATP binding 
site of the enzyme (18, 95). The first generation of CDKIs developed were relatively 
nonspecific and therefore are referred to as ‘pan-CDKIs’; example of which are: flavopiridol 
(alvocidib), olomucine (not commercially developed) and roscovitine (seliciclib) (95). Of 
these first-generation inhibitors, flavopiridol is the most extensively investigated CDKI so far, 
with >60 clinical trials carried out between 1998 and 2014. Flavopiridol is a semi-synthetic 
flavonoid derived from rohitukine, a chromone alkaloid, it competitively binds to the ATP 
binding pocket of CDK1, although it has shown a broad inhibitory capacity of several CDKs, 
including CDK2, 4, 6, 7 and 9. Some of the documented characteristics of this CDKI are: high 
rate of apoptosis, especially in leukemic cells; synergy with the antitumoral activity of many 
cytostatics; independence of its efficacy on pRB, p53 and Bcl-2 expression; lack of 
interference with the most frequent multidrug resistance proteins (P-glycoprotein and MRP-
190); and a strong antiangiogenic activity (97). 
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Although flavopiridol can induce cell cycle arrest in G1 and G2 phases in human 
tumor xenografts, in certain contexts it also induces a cytotoxic response, probably as a result 
of CDK1, CDK7 and CDK9 inhibition, proteins critical for proliferation and survival (98) and 
without efficacy for the treatment of cancer in human patients (99). Consequently, flavopiridol 
did not meet the initial high expectations for a CDKI, low levels of clinical activity were seen 
in Phase II studies in several solid tumour types and also was found to be toxic to non cancer 
cells (66). Also most of the first generation compounds inhibit multiple CDKs with CDK2 
being a common target in drug discovery programs, however mammalian cells can continue to 
proliferate in the absence of CDK2 activity possibly due to compensation by CDK4 and/or 
CDK6 (89, 100). It has been well documented that, despite the high frequency of mutations 
targeting the pRB signaling pathway in cancer cells, inactivation of the individual Ccnd1, 
Cdk4/6, and Cdkn2a genes in mice, while leading to specific developmental defects when 
disrupted alone or in combination, established that their functions were non essential for the 
cell cycle per se. In contrast, the demonstration that inactivation of these genes can prevent 
oncogene-induced tumor development in mouse models reinforced the view that CDK4 and 
CDK6 might be suitable cancer specific drug targets (41).  However, based on the several 
findings from mechanistic studies and studies of CDK4 and CDK6 deregulation in cancer, 
three important features and expectations arose for CDK4 and CDK6 inhibitors in the clinic. 
First, it would be expected that a pure CDK4 or CDK6 inhibitor would elicit a single 
phenotype in tumours: cytostatic G0/G1 arrest. Second, this effect would be a direct reflection 
of the engagement of pRB to suppress gene expression and proliferation. Third, such effects 
would be particularly actionable in tumours that exhibit deregulation of CDK4 and CDK6 
activity as opposed to other CDKs. Initial data from mouse models seeded confusion as to 
whether CDK4 and CDK6 were therapeutic targets because many tissues in the mouse 
developed normally despite the absence of CDK4 and/or CDK6 and in the absence of D-type 
Cyclins, which reflect substantial compensatory plasticity with other CDKs (95).  
Subsequently, multiple independent groups have demonstrated that specific CDK4 and CDK6 
inhibitors arrest the cell cycle through the downstream blockade of phosphorylation of pRB, as 
well as the related p107 and p130 proteins. This blockade results in the loss of expression of 
S-phase cyclins, nucleotide biosynthesis, DNA replication machinery and mitotic regulatory 
genes (95). All these rational served as a breakthrough for the creation of a second generation 
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of CDKIs that selectively inhibit CDKs 4 and 6 activities by binding within the ATP-binding 
pocket of these specific CDKs (35). CDK4 and CDK6 are similar in structure and function, 
and mediate transition from G0/G1phase to S phase of the cell cycle. These second generation 
of CDKIs include: ribociclib, abemaciclib and palbociclib (41, 66). 
Palbociclib (Ibrance® or PD0332991) is an orally bioavailable, low nanomolar and 
highly reversible specific inhibitor for CDK4 (IC50, 0.011 Mmol/L) and CDK6 (IC50, 0.016 
Mmol/L), with no significant activity against a wide panel of other kinases; including Cyclin E 
and A/ CDK2 and Cyclin B/CDK1. The preclinical trial showed that Palbociclib arrest 
proliferation of tumor cell lines that retain functional pRB, blocking its phosphorylation on 
Ser-780/Ser-795 on the pRB protein (CDK4/6-specific sites). Cancer cell lines like breast, 
colon, and lung, which are primarily driven by Cyclin D1/CDK4, as well as myeloid and 
lymphoid leukemia cells that primarily depend on Cyclins D2/D3 and CDK6, accumulated in 
G1 phase, exhibited loss of the proliferation marker Ki-67, and downregulated canonical E2F 
target genes when treated with palbociclib. In several xenograft models, including breast, 
colon, glioblastoma, prostate, and lung; the drug successfully induced tumor stasis or 
regression and was tolerated without significant toxicities at daily doses up to 150 mg/kg for 
up to 50 days of treatment (101, 102). These results indicated that inhibition of CDK4/6 alone 
may be sufficient to cause tumor regression and a net reduction in tumor burden in some 
tumors (101). Interestingly, tumor suppression and significant improvement in survival is 
observed in myeloma cell lines when palbociclib is administrated with the proteasome 
inhibitor bortezomib (103).  In the same context it has been proven that specific mutations, 
such as those affecting the Receptor Tyrosine Kinases (RTK), RAS, RAF, PI3K, or PTEN, or 
genetic alterations leads to aberrant hormone and cytokine receptor signaling that can enhance 
CDK4/6 activity. Conversely, cell type specific RTK, RAF/MEK/ERK, and PI3K/AKT 
inhibitors, particular hormone or interleukin antagonists, or antiproliferative cytokines, such as 
TGF-β, can increase the threshold for CDK4/6 activation and synergize with CDK4/6 
inhibitors to induce G1 phase cell-cycle arrest (41, 104).  
Among the entire tree new CDKIs (which all are currently in phase III trials) only 
palbociclib has progressed furthest towards the clinic, having received accelerated approval 
from the FDA in February 2015. Results of pivotal phase III trials investigating palbociclib in 
patients with advanced-stage o Estrogen Receptor (ER)-positive breast cancer (in which 
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signalling of the Cyclin D/CDK4 axis is known to be critical) have demonstrated a substantial 
improvement in progression free survival, with a well tolerated toxicity profile (41, 66). As 
inhibitors of CDKs involved in the cell cycle, it is not surprising that one of their most 
common toxicities is myelo suppression with decreased neutrophil production (96). The 
effectiveness of  palbociclib monotherapy is under study also in patients with liposarcoma, 
oligodendroglioma, oligoastrocytoma, endometrial and ovarian carcinomas, mantle cell 
lymphoma, urothelial carcinoma, acute leukemias, NSCLC, and numerous primary childhood 
brain tumors (96, 105). Phase II and III studies using palbociclib in combination with 
endocrine therapy (such as PI3K and/or MAPK inhibitors) demonstrated remarkable clinical 
activity in women with Hormone Receptor (HR)-positive, Human Epidermal Growth Factor 
Receptor 2 (HER2)-negative advanced breast cancer, resulting in two separate FDA approvals 
in 2015 and 2016 (106). Along with this, other combination studies include palbociclib with 
cetuximab (a monoclonal antibody directed toward EGFR/HER1/ErbB1) for the treatment of 
head and neck cancers, with dexamethasone for the treatment of multiple myeloma, with  
AZD2014 (an mTOR inhibitor) for the treatment of ER-positive breast cancer, with ibrutinib 
for the treatment of mantle cell lymphoma and with PD-0325901 (a MEK antagonist) for the 
treatment of NSCLC and other solid malignancies (41, 96).  
A fundamental question concerns how continuous administration of a seemingly 
cytostatic drug can sometimes lead to tumor regression, whether in xenograft models or in 
patients. An issue is whether reversible G1 arrest (quiescence), which occurs in all pRB-
positive cell lines exposed to CDK4/6 inhibitors, can lead to a durable state of cell-cycle exit 
(senescence) marked by resistance to mitogenic stimulation or oncogenic challenge (41). 
Consistent with early findings indicating that the cellular life history of D-type Cyclins is 
highly dependent on RAS signaling, preclinical synergistic effects of CDK4/6 inhibition and 
MAP kinase inhibition in melanoma and pancreatic cancer models have stimulated substantial 
interest in the development of these combinations. Possibly, the predominantly cytostatic 
effects of CDK4/6 inhibitors might be reprogrammed to induce senescence or apoptosis in 
response to drugs targeting RTKs and/or downstream RAS signaling pathways that are 
essential for cell viability (41). Another study showed that palbociclib treatment in RB-
positive liposarcoma cell lines with amplified expression of CDK4 and Mdm2 (Mouse Double 
Minute 2 Homolog), arrested in a G1 state within 48 hours of drug exposure. Three of the cell 
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lines subsequently expressed several senescence biomarkers and failed to resume proliferation 
when palbociclib was withdrawn. Proteolytic turnover of Mdm2 was required for the 
induction of senescence, whereas cell lines that only underwent transient G1 arrest did not 
reduce Mdm2 in response to palbociclib. Mdm2 turnover was found to depend on its E3 ligase 
activity and the expression of ATRX. Senescence induced by CDK4 inhibitors and associated 
with loss of Mdm2 expression have been observed also in breast cancer, lung cancer and 
glioma cell lines (107), however the exact mechanism remains to be uncover.  
Besides the tangible evidence of effectiveness with palbociclib treatment on several kind of 
cancers, mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge 
that, although unwelcome, might enable rational post-CDK4/6 inhibitor therapeutic strategies 
to be identified. Extending the use of CDK4/6 inhibitors beyond ER-positive breast cancer is 
challenging, and will likely require biomarkers that are predictive of a response, and the use of 
combination therapies in order to optimize CDK4/6 targeting (106). For example, it has been 
published that pRB-deficient tumors in transgenic mice models for prostate and mammary 
cancer (C3-Tag mice) are resistant to palbociclib and co-administration of palbociclib plus 
carboplatin had no effect on in vivo tumor growth (68). So far, loss of pRB function results in 
supra physiological expression of p16INK4A, which is an established mechanism of primary 
resistance to CDK4/6 inhibitors in vitro (108). Whether dual assessment of pRB loss and 
induction of p16INK4A expression is better than either biomarker alone is uncertain. There 
remains a considerable need to identify other predictive markers for tumours with CDK4 
and/or CDK6 dependence or ‘addiction’ that can be selectively targeted. Examples of other 
predictive markers could be the amplification of Cyclin D1 or CDK4 and CDK6, loss of 
p16INK4A or other genetic alterations leading to the deregulation of CDK4 or CDK6 activity. 
This concept has been incorporated into ‘basket trial’ designs with palbociclib (LUNG-MAP) 
and LEE011 (SIGNATURE), in which patients with specific signature mutations that would 
be expected to deregulate CDK4 and CDK6 activity can be enrolled for treatment with these 
inhibitors (41, 95).  
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1.3 Cellular Senescence  
1.3.1 Senescence and Cancer 
Cellular senescence is a stress response wherein proliferating competent cells undergo 
a stable cell cycle arrest in response to a variety of intrinsic and extrinsic stimuli, including 
progressive telomere shortening, changes in cell morphology, telomeric structure, metabolism 
and epigenetic state, and other forms of genotoxic as well as non genotoxic stress such as 
activated oncogenes, disrupted chromatin organization, DNA damage and oxidative stress 
(109, 110).  
These stimuli have in common the potential to initiate or promote neoplastic 
transformation. The senescent state is accompanied by a failure to re-enter the cell division 
cycle in response to mitogenic stimulation and by an acquired resistance to oncogenic 
challenge due to changes in cellular organization and gene expression that help the senescent 
cells to remain viable and metabolically active (111, 112). Senescence is considered as a 
remodelling program that is active in embryonic development and acts as a key tumour 
suppressor mechanism during the reproductive stage in early adult life by leading to the 
removal of potentially cancerous cells and maintaining organ homeostasis. However, in later 
adult life, it promotes organismal aging by compromising tissue repair and regeneration due to 
the accumulation of senescent cells, depletion of stem/progenitor cells and secretion of an 
array of inflammatory cytokines, chemokines and matrix metalloproteases that can promote 
tumour progression and metastasis in neighbouring cells (25, 109).  
Senescence, particularly in human cells, it is established and maintained by at least two 
major tumor suppressor pathways: the p53/p21CIP and p16INK4A/pRB pathways and is now 
accepted as a potent cell-autonomous mechanism for suppressing the development of cancer 
(113). p53 and pRB pathways suffer mutations in most, if not all, mammalian cancers and 
human cells that lose p53 and pRB function are generally refractory to multiple senescence-
inducing stimuli, suggesting that senescence is a collective phenotype of  multiple effectors, 
and their intensity and combination can be different depending on triggers and cell types, 
conferring a complex and diverse nature to senescence (114). 
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Over the years the senescence arrest has been considered to be an irreversible arrest 
because no known physiological stimuli can stimulate senescent cells to re-enter the cell cycle 
(113). However, now a day’s, the concept of irreversibility has been challenged. It has been 
shown that senescence caused by telomere dysfunction (maintained primarily by p53), can be 
reversed by p53 inactivation (115). In this context, it has been also demonstrated that upon 
oncogenic stimulation by Her2 and RAS, Human Mammary Epithelial Cells (HMEC) are able 
to display morphological changes associated to the senescence response but fail to trigger 
permanent growth arrest. This condition was called Senescence With Incomplete Growth 
Arrest (SWING) (116). Activation of oncogenes in finite lifespan cells can cause true 
senescence resulting in block of tumorigenesis but also, senescent markers are observed in non 
tumorigenic nevi. These different responses of finite and immortalized cells to oncogenes 
support the concept that cellular senescence represents a set of subprograms with independent 
end points. Accordingly, in response to activation of oncogenes, immortalized cells may 
trigger some of the senescence markers while having impaired capability to execute the 
permanent growth arrest because of the multiple checkpoint deficiencies (116). 
Derived from the Latin senex, meaning “old man”, “old age” or “advanced in age”; 
cellular senescence was first formally described by Leonard Hayflick and Paul Moorhead in 
1960s. They showed that normal Human Diploid Fibroblast (HDFs) cultured in vitro have 
limited replicative capacity and, later, are able to undergo into a cell cycle arrest (replicative 
senescence). The number of divisions that cells complete upon reaching the end of their 
replicative life span has been termed the “Hayflick limit” (117, 118). This phenomenon was 
initially associated with the shortening of telomeres at each division. Due to the fact that 
polymerases that copy DNA templates are unidirectional and require a labile primer, the ends 
of linear DNA molecules cannot be completely replicated. As a result, the ends of 
chromosomes progressively shorten, causing the cell to lose its capacity to divide due to the 
loss of essential genes or the ends of chromosomes being recognised as DNA Double-Strand 
Breaks (DSBs) which elicit a DNA Damage Response (DDR) (109, 119). The DDR response 
is involved in both the induction and maintenance of senescence in many cases. The DDR is 
composed of DNA damage sensing, amplification of activities of upstream kinases Ataxia-
Telangiectasia-Mutated (ATM) and Ataxia Telangiectasia and Rad3-Related Protein (ATR), 
the signal transduction through downstream kinases Checkpoint kinases 1 and 2 (CHK2 and 
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CHK1), and effector proteins such as p53 and Cell Division Cycle protein 25 (CDC25), 
thereby preventing genomic instability (120). Persistent DDR in particular, which is 
represented by Telomere Dysfunction-Induced Foci (TIF) and DNA Segments with Chromatin 
Alterations Reinforcing Senescence (DNA-SCARs), has been associated with the maintenance 
of senescence primarily through p53 activation (121). Thus, telomere shortening and induction 
of a senescence response has a tumour suppressor function which cancer cells must overcome 
prior to immortalisation (109, 119). 
Other cell intrinsic and extrinsic stimuli can also induce senescence independently of 
telomere length by acting alone or in combination. These signals include DNA damage, 
oxidative stress, oncogene activity, over-activation of mitogenic pathways, activation of tumor 
suppressor pathways, lack of nutrients, lack of growth factors and improper cell contacts 
(122). All these different triggers are linked to various physiological functions of the growth 
arrest response and, although their contribution may vary depending on the specific trigger, at 
least four linked pathways of signals and effectors are well documented to be at the heart of 
the cell senescence program. These are: oncogene-signaling, DNA damage signaling, and the 
p53/p21 and/or p16INK4A/pRB tumor suppressor pathways (123) (Fig. 1.4). 
DNA damage induces senescence by generating persistent DDR which activate either 
the apoptosis or the growth arrest pathways. DNA damage can be caused by ionizing 
radiation, topoisomerase inhibitors, oxidative stress and other agents such as cytotoxic 
chemotherapies (113, 124), however, as mentioned before is not the only senescence inductor. 
Strong, chronic, or unbalanced mitogenic signals and downstream inhibition of CDKs can also 
induce senescence. This kind of senescence is commonly known as Oncogen Induced 
Senescence (OIS) and includes a hypermitogenic arrest that defines cell senescence as a 
functionally active, stable and conditionally reversible state (125, 126). Mitogenic signals have 
in common the induction of a persistent DDR that ultimately engage the p53 and/or pRB 
pathways. Both pathways are complex; each has multiple upstream regulators, downstream 
effectors, and modifying side branches. Moreover, the pathways cross-regulate each other and 
control the senescence response mainly by implementing widespread changes in gene 
expression (127). 
Although many different oncogenes and growth regulatory molecules can trigger 
senescence one of the best-studied examples of OIS is oncogenic RAS (K- RAS, N- RAS, or 
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H- RAS) and its effectors (123, 128). H- RAS, induces senescence in HDFs accompained by 
accumulation of p53 and p16 INK4A (129), increased expression of the Promyelocytic Leukemia 
(PML) protein (127) and stimulation of the MAPK signaling pathway (130).  
Other forms of chronic or high-intensity mitogenic stimulation such as activation of the 
p16INK4A/pRB pathway (131) and/or decrease of the CDKs expression (like CDK4) (132, 133) 
it has been also reported to induce senescence. Senescent cells arrest in a G1 state; and the 
maintenance of senescence is not dependent on p21CIP1 but relies heavily on persistent 
p16INK4A expression, CDK4 and CDK6 inactivation and active, hypo-phosphorylated RB 
(111). It has been reported also that loss of the tumor suppressor PTEN (Phosphatase and 
Tensin Homolog); which truncates growth factor signaling, provokes p53-dependent 
senescence in Mouse Embryo Fibroblasts (MEFs) and rise prostatic intraepithelial neoplasia 
(134), a pre-neoplastic lesion of the prostate.   
Unlike apoptotic cells, which rapidly disintegrate, senescent cells remain viable in 
culture for long intervals and are found with increasing frequency in aged tissues and at sites 
of age-related pathology, including pre-neoplastic lesions (135, 136).  
Senescence is a complex multifaceted cellular phenotype, without an exclusive 
hallmark, with a broad range of proposed effectors’ mechanisms, and, still, with an ambiguous 
definition (110). Although senescent cells remain arrested even when stimulated by growth 
factors, these cells are metabolically active (112); for this reason, several features and 
molecular markers are used to identify senescent cells. However, like the growth arrest, no 
single characteristic is exclusive to the senescent state and not all senescent cells display all 
the senescence markers that have so far been identified. Thus, senescent cells are generally 
identified by a constellation of characteristics (119, 137) (Fig. 1.5). 
These senescence associated markers (Table 1.1) have been demonstrated in vivo in 
normal tissues and in pre-neoplastic lesions, suggesting that senescence can be activated in the 
early phases of tumorigenesis (138). 
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Figure 1.4: Molecular pathways involved in cellular senescence. 
Multiple stressors and damaging agents activate signalling pathways that converge on the 
activation of CKIs: p21CIP1 and p16INK4A and the tumour suppressor pRB which triggers the 
senescence response. A number of genes associated with regulation of senescence have been 
shown to be part of either the p53 or pRB pathways. The proteins involved in these signalling 
cascades, mainly p53 and pRB will determine how a cell will respond to the stress factor(s). 
This response is most commonly balanced between cells entering senescence or undergoing 
apoptosis, as both mechanisms are used to control unsolicited cell growth. Inspired from 
Munoz-Espin D & Serrano M. 2014. (136).  
 
 
  For example, a “typical senescent phenotype” is generally characterized by a large and 
flat morphology, vacuolized and, occasionally, multinucleated. However, in vivo senescent 
cells retain the normal morphology dictated by tissue architecture. The most widely used 
assay for senescence is the histochemical detection of β-galactosidase, known as the 
Senescence-Associated β-Galactosidase activity (SA-β-Gal) (139, 140). This activity is based 
on the increased lysosomal content of senescent cells, which enables the detection of 
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lysosomal β-GAL at a suboptimal pH (pH 6.0) (121) and is used extensively to identify 
senescent cells both in culture and in a variety of tissues (113). 
As cellular senescence is based on a stable cell cycle arrest, the absence of proliferative 
markers or DNA synthesis markers, such as Ki-67 protein or 5-Bromo-2’Deoxyuridine (BrdU) 
incorporation respectively, can be an essential condition to document senescence (136); 
however, assays based on DNA synthesis would also identify other non-replicative cells, such 
as quiescent cells and post-mitotic cells, which make such markers sub-optimal if used alone 
(137). Other canonical senescence markers comprise the most common mediators of 
senescence, including p16INK4A, ARF, p53, p21CIP1, p15INK4B, p27KIP1 and hypophosphorylated 
pRB (136).  De-repression of the INK4/ARF locus which behaves as a sensor that links stress 
detection response with activation of key tumor suppressor networks, is sufficient to trigger a 
senescence response. The expression of p16INK4A is low or undetectable in most normal cells 
but is readily detectable in cells induced to senescence by many stimuli, which make it a 
common marker used in vivo (111, 112). In fact, p16INK4A is strongly expressed during aging 
and in cancer cells. It has been revealed in a luciferase knockin mouse (p16LUC), which 
faithfully reports expression of p16INK4A; that the lifelong assessment of luminescence in 
p16+/LUC mice has an exponential increase with aging. Also, in all tested tumor models, 
expression of p16LUC was focally activated by early neoplastic events and the activation of 
p16INK4A was noted in the emerging neoplasm and surrounding stromal cells; suggesting that 
p16INK4A activation is a characteristic of all emerging cancers (141). 
In addition to the senescent phenotype, senescent cells show widespread changes in 
chromatin organization and gene expression that give rise to the Senescence-Associated 
Heterochromatin Foci (SAHF), an specific heterochromatin profile that contribute to silencing 
of proliferative genes in senescent cells (142, 143). These foci contain hallmarks of 
heterochromatin, such as trimethylation at Lys-9 of histone 3 (H3K9me3), Heterochromatin 
Protein 1 Homologue-γ (HP1γ) and macroH2A (140). Of note, SAHF are preferentially 
formed during oncogene-induced senescence but not during replicative senescence or upon 
ageing (112, 144); also, SAHFs per se may not serve as a senescence marker across species, 
but enrichment of H3K9me3 modifications and HP1γ binding, particularly at E2F target 
genes, has been used to demonstrate enrichment of senescent cell populations in culture (111). 
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Many senescence inducers cause genomic damage, resulting in lasting DNA damage 
foci and DDR signaling. The persistent foci are termed Telomere Dysfunction–Induced Foci 
(TIF) when present at telomeres and used to describe telomeres which accumulated various 
DNA damage factors, such as γH2AX, ATM and MRE11 (Homolog, Double Strand Break 
Repair). TIF has been shown to increase in fibroblasts that undergo replicative senescence and 
also has an effect on the metabolic status of the cell (137, 145). Furthermore, many senescent 
cells express foci of DNA damage at non-telomeric sites, which similarly generate persistent 
ATM–p53–p21CIP1 signalling that is required for growth arrest (119). In precancerous lesions, 
DSBs, possibly arising from unrepaired replication errors or exposure to a wide range of 
genotoxins than cause DNA damage, activate p53 and p21CIP1 to induce either apoptosis or 
senescence (146). These DNA damage foci include the recruitment of proteins such as 
γH2AX, ATM, 53BP1, RAD51, and the MRE11/RAD50/NBS1 complex, which accumulate 
and/or are modified in the vicinity of a chromosomal DSBs (147) and are commonly used as 
conditional markers of cellular senescence (148).  
Even though γH2AX staining is a marker for DSBs and is frequently visible in 
senescent cells, is neither necessary for nor exclusive to cellular senescence (124, 149), given 
the fact that compounds such as chloroquine and histone deacetylase inhibitors that alter 
chromatin structure can also induce ATM–p53–p21CIP1 signalling, p16INK4A and SA-β-Gal 
without telomere dysfunction or overt DNA damage (111).  
Rodier, F. et al., described recently a persistent form of DNA damage foci called DNA 
Segments with Chromatin Alterations Reinforcing Senescence (DNA-SCARS). These DNA-
SCARS associate with PML nuclear bodies, but they lack the DNA repair proteins RPA and 
RAD51, and accumulate activated forms of the DDR mediators such as CHK2 and p53. These 
DNA-SCARS can be formed independently of  p53,  pRB and several other checkpoint and 
repair proteins, but require p53 and pRB to trigger the senescence growth arrest (135).  
Beyond transcriptional regulatory networks that characterize senescence (150-152), 
direct control of protein levels also appears strikingly affected. In this sense, a more general 
function of protein degradation has emerged as critical to reorganize the proteome of cells 
undergoing senescence. A study performed in human normal fibroblasts found that aberrant 
RAS/ERK signaling leads to a proteasome-dependent protein degradation process targeting 
proteins required for cell cycle progression, cell migration, mitochondrial functions, RNA 
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metabolism, and cell signaling. This unique form of protein degradation was named 
Senescence-Associated Protein Degradation (SAPD) and it was also conserved in mouse 
fibroblasts, human mammary epithelial cells expressing oncogenic RAS and in senescent 
human fibroblasts. It was also uncovered that, depletion of some individual SAPD targets was 
sufficient to trigger senescence, thereby illustrating the relevance of this protein degradation 
for the onset and/or maintenance of senescence (110, 153). 
 
Table 1.1: Senescence markers 
Senescence Markers 
• Phenotypic markers 
 
• Molecular markers 
Lack of cell proliferation Increased levels of p16INK4A 
Large and flat morphology of cells Increased levels p53 
Lack of response to growth factors pRB phosphorylation levels 
Resistance to oncogenic transformation DEC1 
PML nuclear bodies 
Senescence Associated Heterochromatin 
Foci (SAHF) 
Senescence Associated Secretory Phenotype 
(SASP) 
Senescence Associated Protein Degradation 
(SAPD) 
Telomere Dysfunction Induced Foci (TIF) 
Telomere Associated Foci (TAF) 
DNA Segments with Chromatin Alterations 
Reinforcing Senescence (DNA-SCARS) 
DCR2 
DNA Damage Response (DDR): ATM, 53BP1, 
γ-H2AX 
HMGA proteins 
Heretochromatin markers: HP1, H3K9me3 
Lamin B1 reduction 
Autophagy proteins increase: LC3B, p62 
 
 
In addition to the SAPD, senescent cells secrete a number of extracellular factors, 
including members of Wnt family, Insulin-like Growth Factor 1 (IGF-1) -binding proteins, 
Plasminogen Activator Inhibitor 1 (PAI-1), TGF-β, and also the interferon pathway. These 
signalling cascades collectively called the Senescence-Messaging Secretome (SMS) and/or the 
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Senescence-Associated Secretory Phenotype (SASP) may converge first at the level of several 
plasma membrane signalling receptors allowing communication between senescent cells and 
their microenvironment (154). This secretory phenotype, allow to senescent cells to secrete a 
plethora of inflammatory cytokines, chemokines, proteases, cancer-related factors, including 
interleukins and other extracellular factors, that can reinforce and propagate senescence in an 
autocrine and paracrine manner (155).  
The SASP has powerful paracrine activities, the nature of which suggests that the 
senescence response is not solely a mechanism for preventing cancer. Rather, cellular 
senescence and the SASP likely evolved both to suppress the development of cancer and to 
promote tissue repair or regeneration in the face of injury. The paracrine activities of senescent 
cells can be either beneficial or deleterious, depending on the physiological context (113, 136, 
156). The SASP increases immune surveillance of damaged cells, thus maintaining tissue 
homeostasis. With age or persistent damage, however, the SASP from accumulated senescent 
cells is thought to cause chronic inflammation that may contribute too many human diseases 
including cancer. In addition to the cell cycle and the SASP, the senescence program also 
controls other cellular processes and among these is the activation of autophagy (157).   
1.3.2 Autophagy as a senescent marker 
Autophagy is an evolutionary ancient process involving the sequestration of 
endogenous or exogenous cytoplasmic material within a double membraned organelle (called 
autophagosome), followed by fusion to lysosomes and degradation of its content by lysosomal 
enzymes (158). This process improves the survival of both normal and cancer cells under 
metabolic stress by maintaining the availability of building blocks in order to preserve 
essential cellular functions and homeostasis. In addition to supporting cell viability in 
established tumors, autophagy has specific tumor-suppressor functions (110, 157). Indeed, 
autophagy continuously operates at baseline levels to ensure the disposal of potentially 
dangerous structures that may accumulate as a consequence of normal cellular functions, like 
damaged mitochondria or noxious protein aggregates (159). 
Autophagy not only constitutes a robust barrier against malignant transformation at the 
cell intrinsic level, but also contributes to the organismal control of potentially oncogenic 
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cells. Recent data provide molecular insights into the mechanisms whereby oncogene 
hyperactivation induces autophagy to establish cellular senescence (159). Both senescence and 
autophagy are thought to play key mechanistic roles in the development of multiple diseases 
and especially human cancers (158). 
For example, along similar lines, the downregulation of essential components of the 
autophagic machinery like the Autophagy Related proteins 5 and 7 (ATG5 or ATG7) prevents 
HDFs to undergo cellular senescence following oncogene hyperactivation (159).  
It has been reported also, that upon acute induction of senescence in HDFs, autophagy 
is activated, and facilitates SAHF, SASP and SA-β- gal activity. In contrast to replicative 
senescence, OIS is a rapid and dynamic process. The initial response of cells to oncogene 
activation is hyperproliferation and senescent cell cycle arrest is established over the course of 
several days. Given this, between these two extremes, the initial mitotic burst and the 
senescence phase, comes the “transition phase” called the Autophagy-Senescence Transition 
(AST) where presumably the most drastic alterations in transcription, cell signaling and cell 
morphology occur (158, 160). Such alteration in cell signaling includes the triggering of 
negative feedback regulation in the PI3K/AKT/mTOR pathway, a signaling pathway 
downstream of RAS. Consistently during the mitotic phase, when mTOR, is active, autophagy 
is inhibited. However, activating autophagy during the transition phase correlates with the 
downregulation of mTOR activity (160).  
OIS is a very early event during tumorigenesis and is thought to be a critical step in 
tumor suppression if it is successful. Autophagy might thus contribute to tumor suppression by 
controlling the senescence phenotype. However, if tumor cells somehow bypass senescence, 
autophagy would then help such cells to survive metabolic stress, unwittingly facilitating their 
transformation and contributing to resistance to chemotherapy (161). Thus it is important to 
interpret the role of autophagy in the context of the stage of tumorigenesis. It is also possible 
that senescence-associated autophagy has a distinct role and is differentially regulated. In fact, 
triggers of senescence (oncogenic RAS or DNA damage) and a metabolic trigger of autophagy 
(amino acid starvation) seem to differentially regulate autophagy. In RAS-senescent cells, 
many autophagy associated genes, as well as lysosomal genes, are upregulated during the 
transition phase, but also, these cells contain far more protein than non senescent cells and 
produce a large amount of secretory proteins, suggesting that protein synthesis is also active in 
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senescent cells. These secretory proteins include, among others, IL-6 and IL-8, (components 
of the SASP) that reinforces senescence. In contrast to typical senescence marker genes, such 
as p16INK4A, the expression pattern of many SASP components is very similar to that of 
autophagy-associated genes, which show a sharp induction during the transition phase of 
senescence. Knockdown of ATG5 or ATG7 delays synthesis of IL6 and IL8. Thus, during 
senescence, autophagy facilitates the production of IL6/8 at the protein level. It is conceivable 
that rapid protein turnover during autophagy, coupled with active translation, could handle the 
sudden demand for these abundant secretory proteins, supporting the idea that autophagy 
facilitates senescence establishment, at least in part, through promoting SASP (161). 
OIS, not only relies on autophagy (160, 162), but also proceeds along with the 
degradation of nuclear Lamin Protein B1 (LMNB1), with the consequent activation of p53 and 
pRB (163). The autophagy protein LC3/ATG8, which is involved in autophagy membrane 
trafficking and substrate delivery, is present in the nucleus and directly interacts with the 
LMNB1, and binds to lamin-associated domains on chromatin (164). This LC3–LMNB1 
interaction mediates its degradation upon activation of oncogenic RAS. LMNB1 degradation 
is achieved by nucleus-to-cytoplasm transport that delivers LMNB1 to the lysosome to be 
degradated by the autophagic machinery. When autophagy is inhibited by the depletion of 
ATG7, RAS expression failed to stimulate the degradation of cytoplasmic LMNB1 and the 
consequent transition of HDFs into senescence (165). 
Another report identified the transcription factor GATA4, as a key regulator of the 
SASP and senescence. GATA4 accumulates during cellular senescence, mainly due to its 
increased protein stability regulated by autophagy. The autophagic receptor protein 
SQSTM1/p62 mediates the degradation of GATA4 under normal conditions. However, once 
the cell experiences senescence-inducing stimuli, the interaction between GATA4 and p62 
decreases, and GATA4 escapes from autophagy and accumulates favoring the transcription of 
NF-κB and the SASP, reinforcing then the senescence response. GATA4 activation depends 
on the DNA damage response regulators ATM and ATR, but not on p53 or p16INK4A (166). In 
other hand, p62 dynamically associates with DNA Damage Foci (DDF), which induces 
senescence, and regulates DNA repair (167). 
A recent report showed that p62 is required for poly-ubiquitinated protein interaction 
with PML-NBs (PML-Nuclear Bodies) involved in multiple DNA damage repair proteins such 
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as BLM/WRN, DNA helicases and the MRE11 complex. Increased p62 expression caused by 
deficient autophagy may be responsible for the defective DNA damage repair with consequent 
increase in cell death following DNA damage-inducing agents in Hela cells (168). 
Another study showed that in senescent fibroblasts and breast cancer cells 
overexpressing CKIs, such as p16INK4A, p19INK4D or p21CIP1, there is an increased susceptibility 
toward the induction of autophagy, significant mitochondrial dysfunction, as well as reduced 
growth. This same cellular response is obtained in breast cancer cells treated with palbociclib 
and with cellular stressors such as hydrogen peroxide or starvation; showing that autophagy 
and senescence are two closely linked biological phenomena, and implying that they are part 
of the same coordinated metabolic program (158). 
 
Figure 1.5: The Senescence response and the senescence markers.  
Schematic representation of the senescence response and its markers. When a stress signal is 
sensed into the cell, several effecror pathways are activated in order to trigger the senescence 
response. As an integreated response, several markers can be detected into the cell that either 
alone or in combination displays the senescence phenotype.   
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Anticancer chemotherapy induces also cellular senescence named Therapy-Induced 
Senescence (TIS). In an Eµ-myc transgenic mouse lymphoma model in which TIS depends on 
the H3K9 histone methyltransferase Suv39h, was shown that after senescence inducing 
chemotherapy, TIS-competent lymphomas but not TIS incompetent Suv39h1–lymphomas 
show increased glucose utilization and much higher ATP production. This response is linked 
to massive proteotoxic stress, which is a consequence of the SASP. SASP producing TIS cells 
exhibited endoplasmic reticulum stress, an Unfolded Protein Response (UPR), and increased 
ubiquitination, thereby targeting toxic proteins for autophagy in an acutely energy consuming 
fashion. Accordingly, TIS lymphomas, unlike senescence models that lack a strong SASP 
response, were more sensitive to blocking glucose utilization or autophagy, which led to their 
selective elimination through caspase-12- and caspase-3-mediated endoplasmic reticulum-
related apoptosis. Consequently, pharmacological targeting of these metabolic demands on 
TIS induction in vivo prompted tumour regression and improved treatment outcomes further 
(169).  
1.4. The PML protein 
1.4.1  Characteristics of PML  
The promyelocytic leukemia (PML) gene encodes a putative tumor suppressor protein 
involved in different process that control apoptosis, senescence and stem cell self-renewal 
(170, 171). PML was initially identified as a fusion partner of human Retinoic Acid Receptor 
alpha (RARα) as a result of a chromosomal translocation t(15;17) found in the Acute 
Promyelocytic Leukemia (APL) patients (172, 173). PML is expressed and conserved in all 
mammals and is the key organizer of the PML- NBs (PML-Nuclear Bodies).  
PML-NB are spheres of 0.1–1.0 nm in diameter embedded in the nuclear matrix and 
are found in most cell lines and many tissues.  These dynamic structures are triggered by DNA 
damage, oxidative stress, transformation and viral infection (174).  More than 150 proteins 
have been identified as PML interacting partners or components of the PML NBs and their 
involvement is implicated in a wide range of cellular functions including:  DNA replication, 
transcription, epigenetic silencing, cell cycle control, post translational modification, anti-viral 
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response, DNA damage response and repair, cell migration, apoptosis, senescence and 
metabolism in response to different kind of stress (Fig. 1.6) (174-176).  
 
 
Figure 1.6: The PML-NBs, its interacting proteins and regulating pathways. 
PML-NBs have been described as structures that regulate several cellular functions by 
identification and storage of proteins, which give rise to post-translational modification and 
regulation of nuclear activities such as transcriptional regulation and chromatin 
organization. 
 
1.4.2 Structure of the PML protein 
PML belongs to the family of the Tripartite Motif (TRIM). The RBCC/TRIM motif is 
present in all PML isoforms and is encoded by the exons 1-3. The RBCC domain is composed 
of a RING finger domain (R), two cysteine-rich domains named B-boxes 1 and 2 (B1 and B2) 
and an α-helical Coiled-Coil domain (CC). The RING finger motif is a conserved cysteine-
rich zinc-binding domain and is involved in the formation of the PML NBs. Adjacent to the 
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RING domain lay the B1 and B2 boxes which have been proposed to work as second zinc-
binding domain and they are also involved in PML-NBs formation and in several others PML 
functions. The CC domain mediates PML homo- and hetero-dimerization. All PML isoforms 
contain the SUMO interacting motif (SIM) which is required for the recognition and binding 
of SUMOylated proteins (177). 
Several PML isoforms, designated PML I to PML VII, are expressed by alternative 
splicing of a single PML gene and most of the protein isoforms, PML-I to PML-VI, contain a 
Nuclear Localization Sequence (NLS), for nuclear homing. PML-VII in contrast, lacks a NLS 
and is therefore likely to localize in the cytoplasm. However, alternative splicing of exon 6, 
which contains the NLS, has been reported for many isoforms, suggesting the possibility that 
all PML isoforms can also exist in a cytoplasmatic form (178). Notably, PML-I contains a 
Nuclear Export Sequence (NES), which along with the NLS may lead PML-I to localize in 
both nucleus and cytoplasm (174, 179). All known PML isoforms share a common N-terminal 
domain and differ in their C-terminus; and this C-terminus region confers the specific 
functions of each PML isoforms. For example: For example: PML-I have been implicated in 
senescence, PML-IV in apoptosis, cell cycle regulation and senescence, PML-V in 
adenovirus-mediated oncogenic transformation, PML-VI and PML-VII in apoptosis (Fig. 1.7) 
(127, 174, 180). 
PML functions are tightly regulated at post-translational level in response to stress and 
environmental cues. These Post-Translational Modifications (PTMs), such as SUMOylation, 
phosphorylation, acetylation, and ubiquitination regulate the ability of PML to interact with 
various partners and confer stress and signal-dependent regulation of PML or its binding 
proteins (176). 
The SIM domain contains the PML degron involved in the Casein Kinase 2 (CK-2) 
direct phosphorylation of PML at Ser-517 promoting its ubiquitin-mediated degradation (181). 
Among the post-translational modifications, SUMOylation is the most intensely studied. Both, 
the Small Ubiquitin-like Modifier-1 and 2/3 (SUMO1 and SUMO2/SUMO3) bind covalently 
to PML. SUMOylation facilitates PML-NBs formation promoting tumor suppressive response 
in a PML-dependent manner, and promotes leukemogenesis by the SUMOylation of PML-
RARA. SUMOylation can also promote ubiquitin-mediate degradation of PML and PML-
RARA fusion protein. PML can be phosphorylated by several kinases on serine and threonine 
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residues regulating then its functions. Also, ubiquitination regulates PML functions and 
activity (176, 182).  
At the protein level, multiple PML degradation pathways have been described, several 
enforced by oncogenic proteins. For example, proteins such as E6AP ubiquitin ligase, E2F-
BP1, or Pin-1 isomerase promote PML degradation or disrupt NBs formation. Loss or down-
regulation of these proteins causes PML stabilization and tumor suppression by senescence 
induction in human primary fibroblasts or in cancer cells (183-186).  
The PML gene rarely undergoes somatic mutations in tumours other than APL, and its 
promoter does not undergo epigenetic silencing. Deregulated RNA splicing is a possible 
source of isoform variation, but has not been extensively studied. Aberrant PML post-
translational modifications are the most characterized mechanism accounting for PML loss in 
cancer. PML is a promising candidate for restoration as an approach to tumor suppression. 
Consequently, intense research is currently directed toward delineating its regulation at the 
post-translational level (187). Molecular pathways that promote PML degradation are 
therefore potential targets for its restoration. PML degradation is promoted by PTMs including 
ubiquitination, phosphorylation, acetylation and SUMOylation (174). 
1.4.3 Role of PML as a tumor suppressor 
PML is an established tumor suppressor gene with critical functions in growth 
suppression, induction of apoptosis, and cellular senescence. Its tumor suppressor function is 
strongly supported in genetically engineered mouse cancer models (188). PML knockout mice 
are moderately tumor prone. Ablation of murine PML protein results in increased proliferation 
in mouse embryonic fibroblasts and a reduced sensitivity to the growth suppressive effects of 
Retinoic Acid, controlling then cell growth and tumorigenesis (189, 190).  
The tumor suppressor activity of PML is better observed in the presence of other 
oncogenic events. For example, PML deficiency in the context of PTEN+/- mice results in 
invasive colon adenocarcinoma (134, 191). Also, tumour burden and aggressiveness of K- 
RAS-induced NSCLC is significantly increased in the absence of PML (192). Most recently, 
PML tumour suppressive capacity has been demonstrated in a mouse model of B-lymphoma 
driven by c-Myc. B-cell lymphomas deficient for E6AP express high levels of PML and PML-
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NB with a concomitant increase in markers of cellular senescence, including p21CIP1, 
H3K9me3, and p16INK4A. Consistently, PML deficiency accelerates the rate of Myc-induced 
B-cell lymphomagenesis (186). 
 
 
Figure 1.7: Structure of the PML gene and the PML isoforms generated by 
alternative splicing. 
The human promyelocytic leukaemia (PML) gene is located on chromosome 15q22. 
Alternative splicing of C-terminal exons leads to the generation of several PML isoforms, 
some of which partially retain intronic sequences. Most PML isoforms show a 
predominantly nuclear localization because exon 6 contains a Nuclear Localization 
Sequence (NLS). However, alternative splicing of exons 4, 5 and 6 has been reported for 
many isoforms, making it possible that all PML isoforms exist in a cytoplasmic form. All 
PML isoforms contain the first three exons, which encode the RBCC/TRIM motif. This is a 
tripartite structure that contains a zinc-finger called the RING motif (R), two additional 
zinc-finger motifs (B-boxes; B) and a coiled-coil domain (CC). The RBCC motif promotes 
homo-multimerization and the formation of the PML-NBs. 
 
As mentioned previously, neoplastic transformation requires (among other processes), 
the elimination of key tumor suppressors. Down regulation of PML and p53 mutations are 
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common genetic alterations in human cancers. In healthy cells these two key tumor 
suppressors exist in a positive regulatory loop, promoting cell death and cellular senescence. 
In a mouse model harboring a p53 mutation frequently found in human sporadic and Li-
Fraumeni cancers, loss of PML expression resulted in a marked alteration in tumor profile; 
males exhibited a high incidence of soft tissue sarcomas and reduced survival, while females 
largely developed osteosarcomas, without impact on survival (193). 
Supporting PML tumour suppressive role, it has been also reported that in a broad 
spectrum of human tumours of different histological origins (hematopoietic and solid 
tumours), there is a transcriptional down-regulation, or loss of PML protein expression 
compared with the corresponding normal tissues (187, 194).  
Of note, PML displays an altered expression pattern during human oncogenesis. It is 
widely expressed in cell lines and is cell cycle regulated. Overexpression of PML protein 
induces a sharp reduction in growth rates in vitro and in vivo. However, in normal tissues 
(including those that rapidly proliferate) only a few cells have detectable PML levels which 
can be upregulated by soluble factors such as interferons or estrogens (194, 195). Human 
epithelial tumors show a gradual increase of PML levels as the lesion progresses from benign 
dysplasia to carcinoma, but when malignant cells turn invasive, usually, they lose PML 
expression (194). In addition, low expression of PML correlates with a bad prognosis and 
high-grade tumours for breast adenocarcinomas and prostate carcinomas (187). 
1.4.4   Role of PML in Apoptosis 
As a tumor suppressor, PML is able to promote key apoptotic pathways by regulation 
at the transcriptional level. PML inhibits transcription of the anti-apoptotic protein Survivin 
(196) and can also modulate apoptotic signaling pathways by binding to transcription 
regulators of apoptotic genes including HDACs (197), the TNFα-induced NF-κB targets A20 
and RelA/p65, and the transcriptional activator involved in the regulation of cellular responses 
to growth factors, Nur77(198). Furthermore, PML was demonstrated to interact with Myc, 
inducing its destabilization and re-activation of Myc-repressed target genes, including the 
genes of the tumor suppressive cell cycle inhibitors: p21CIP1 and p15INK4 (199). 
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1.4.5 Role of PML in senescence 
To date, the most studied PML isoform in the context of tumor suppression mediated 
through the nucleus is PML-IV (named just PML subsequently) (174). It was originally 
described as the only PML isoform to be involved in the induction of premature senescence 
given the fact that it can physically and functionally interact with both p53 and pRB, 
suggesting that PML may be a key regulator role of these pathways (200, 201). Since all PML 
isoforms are able to recruit p53 into the PML-NBs (at least when over-expressed), the ability 
of PML to stabilize p53 is implied to result from its additional capacity to also recruit critical 
partners of p53 modification (200). PML can activate p53 by different means, via acetylation 
and stabilisation (202).  
In response to DNA damage, PML enhances p53 stability by sequestering Mdm2 
(which is the major p53 E3 ubiquitin ligase) to the nucleolus in an Arf-independent manner 
(193, 203). This facilitates p53 association with kinases that confer stabilization via post-
translational modifications such as: Homeodomain-Interacting Protein Kinase-2 (HIPK-2) at 
p53 Ser-46, Checkpoint 2 kinase (CHEK-2) at p53 Ser-20 and Casein kinase 1 (CK-1) at p53 
Thr-18 (204-206).  
PML can also facilitate stabilization p53, allowing it to transcriptionally activate 
growth suppressive targets like p21CIP1 (138). PML is induced by p53 activation but is also a 
p53 target, suggesting the existence of a positive feedback that may lock affected cells into 
permanent replicative arrest. Cells lacking PML show a reduced propensity to undergo 
senescence or apoptosis in response to p53 activation, despite the induction of several p53 
target genes (207). Under stress conditions the p53-PML network propels itself through a 
positive regulatory loop leading to a cytotoxic or cytostatic response, unless the loop is 
interrupted by an inhibitor of the loop, such as E6AP or Mdm2 (174).  
PML is able to regulate the p53 response to oncogenic signals. PML expression levels 
are increased during RAS-induced cellular arrest and during replicative senescence, leading to 
an increase in the size and number of PML-NB. PML expression is sufficient to promote 
premature senescence, and also, like oncogenic RAS, PML increases the levels of p16INKA4, 
the hypophosphorylation pRB, the phosphorylation at Ser-15 p53, and the expression of p53 
transcriptional targets (127). It has been shown that upon Ras expression, p53 is acetylated at 
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Lys-382 and is re-localized along with the CREB Binding Protein (CBP) acetyltransferase 
within the PML-NBs allowing the formation of a trimeric p53–PML–CBP complex. p53 
acetylation, p53–CBP complex stabilization and senescence are PML-dependant, which 
indicates that the integrity of the PML-NBs is required for p53 acetylation and senescence 
upon oncogene expression (208). However, it has been demonstrated also, that the 
upregulation of PML by oncogenic RAS is mediated by the activation of the 
RAS/MEK1/mTOR/eIF4E pathway even in the absence of p53. Thus far, the increase in PML 
protein levels in conditions of oncogenic stress it can be attributed to upregulation of PML 
gene transcription itself (192). 
As mentioned before, the mechanism of PML-induction during senescence includes 
increased PML gene transcription by p53, but also by transcription factors of the 
Interferon/JAK/STAT pathway. PML is known to be regulated by the interferon pathway via 
the STAT transcription factors. Treatment of primary human cells with β-interferon leads to 
the induction of p53, PML and senescence (195). In fact, constitutive STAT5 signaling can 
activate PML expression and induce a p53- and pRB-dependent cellular senescence response, 
connecting cytokine stimulation with the senescence program (209, 210). STAT5A expression 
leads to a down-regulation of Myc and its targets, including CDK4. Down-regulation of Myc 
correlates with its localization to PML-NBs, which are abundant during STAT5-induced 
senescence (211). 
PML can also induce senescence in primary human and mouse fibroblasts in a p53-
independent manner through a mechanism that depends upon the pRB pathway (212). PML 
over-expression results in the accumulation of hypo-phosphorylated pRB and potentiates its 
function through a Histone Deacetylases (HDAC)-dependent mechanism (127).  
Several studies have clearly shown that overexpression of PML induces cell cycle 
arrest in normal cells but also it has been proven to have an effect in cancer cell lines. Breast 
cancer cell lines and xenograft models have shown that PML expression can cause cell cycle 
arrest at the G1 phase associated with a significant decrease in Cyclin D1 and CDK2, an 
increased expression of p53, p21CIP1 and Cyclin E and a predominantly hypo-phosphorylated 
pRB state. This indicate that, PML exerts its growth suppressing effects by modulating several 
key G1 phase regulatory proteins (213). 
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Recent studies have added a further level of complexity by proposing that PML-NBs 
are involved in chromatin reorganisation during senescence. The senescent phenotype requires 
the formation of SAHF which are specialised domains associated with transcriptionally silent 
chromatin. These domains are thought to repress the expression of genes involved in cell cycle 
progression (143). Interestingly, a number of E2F target genes acquire heterochromatic 
features during senescence, and active pRB binds their promoters. Furthermore, pRB is 
required for SAHF formation and the repression of E2F target genes during senescence. Both 
SAHF and PML-NBs are induced during cellular senescence (142). It has been reported that 
prioir to SAHF formation, a known chromatin regulator, HIRA, enters PML-NBs and 
transiently co-localises with Heterochromatin-1 (HP-1) proteins, which are involved in the 
formation of heterochromatin. Disruption of either HIRA or PML function results in impaired 
SAHF formation, thus suggesting that transient accumulation of HP-1 in PML-NBs is required 
for SAHF generation (214).  
One possible mechanism for these changes in chromatin during senescence would be 
that chromatin modifiers undergo post-translational modifications as they transit through 
PML-NBs, which are in turn required for SAHF formation. In this respect, phosphorylation of 
one of the HP1 proteins, HP1γ, is known to be required for its localisation to SAHF but not to 
PML-NBs, a circumstance easily explained if its phosphorylation occurs in PML-NBs to 
promote its loading into SAHF (123, 215). Perhaps the co-localisation of pRB in the PML-
NBs of senescent cells also permits the post-translational modifications necessary for the 
repression of E2F release and subsequent chromatin alteration. For example, PML is able to 
control the activity of the E2F transcription factors. The pRB/E2F complexes are re-localized 
into PML-NBs along with heterochromatin proteins when senescence is induced by PML 
expression or by oncogenic RAS. PML overexpression is sufficient to inhibit E2F target gene 
expression, block cell proliferation, and induce DNA damage and senescence. Importantly, the 
localization of E2Fs into PML bodies is dependent on the pRB protein family. Overall, these 
findings support the notion that PML-NBs are credible candidate sites for the modification of 
tumour suppressors and other proteins involved in senescence (150), this is achieved through 
regulation of the tumour suppressors, pRB and p53, however p53 and/or pRB independent 
mechanisms of growth inhibition and/or apoptosis have also been demonstrated for PML. 
PML positively regulates replicative senescence through regulation of telomerase activity by 
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sequestering the Telomerase Reverse Transcriptase (TERT) to PML-NBs, in response to IFN-
α treatment (216).   
1.5 SUMOylation 
1.5.1 Characteristics of the SUMOylation pathway 
SUMOylation is a post-translational modification consisting of covalent binding of 
Small Ubiquitin related Modifier (SUMO) onto a target protein. It is considered one of the 
major regulators of protein function including: protein stability, intracellular localization, 
transcriptional activity, and protein–protein interactions (176, 217). This modification 
regulates a wide range of cellular processes such as: transcription, replication, chromosome 
segregation, nuclear transport, cell-cycle progression, DNA repair, and signal transduction. 
Importantly, SUMO conjugation has been repeatedly associated to stress response (218, 219). 
Besides PML, a number of proto-oncogenes and tumor suppressors, such as Mdm2, c-Jun, c-
Myb, BLM, TEL, p73α, SMAD4, p53 and pRB, are subject to SUMOylation (220). 
SUMO proteins are ~10 kD in size and belong to the Ubiquitin-like protein (Ubl) 
family, having a very similar three-dimensional structure compared to ubiquitin, while sharing 
only 20% of sequence identity. All SUMO proteins carry an unstructured stretch of 10–25 
amino acids at their N termini and are not found in any other ubiquitin related proteins. The 
formation of SUMO chains is the only function that has been assigned to these N-terminal 
extensions (221, 222). 
SUMO proteins are expressed in an immature proform, in which they carry a C-
terminal stretch of variable length (2–11 amino acids) after an invariant Gly-Gly motif that 
marks the C-terminus of the mature protein. Removal of this C-terminal extension is made by 
the Sentrin/SUMO-Specific Proteases (SENPs), which is a prerequisite for the conjugation of 
SUMO to its targets. SENPs proteins remove 4 C‑terminal amino acids from SUMO1, 11 
amino acids from SUMO2 and 2 amino acids from SUMO3. The expression of the peptidic 
modifiers as precursors appears to be a common characteristic of ubiquitin-like modifiers 
(221). 
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In mammals, four SUMO paralogs have been identified. SUMO-1 shares 50% 
sequence identity with SUMO-2/3, and 86% with SUMO-4. SUMO-2 and 3 are usually 
pooled together as SUMO-2/3 as they are 95% identical to each other and cannot be separately 
identified. While SUMO-1 and SUMO-2/3 are ubiquitously expressed, SUMO-4 expression is 
mainly found in kidney, lymph node, liver and spleen (221, 223). 
SUMOylation is a dynamic process consisting of rapid conjugation and de-conjugation 
cycles. Target proteins are usually very transiently modified and their SUMOylated forms 
often constitute only a very small fraction of the total protein pool. SUMOylation involves the 
covalent attachment of SUMO family of proteins to Lys residues in specific target proteins via 
an enzymatic cascade analogous to, but distinct from, the ubiquitination pathway. SUMO 
conjugation is performed by specific enzymes in three steps: the SUMO peptides are 
maturated by SENP family, activated by the E1/E2 SUMO activating complex, and then 
transferred onto the E2 SUMO enzyme which then conjugates SUMO onto Lys residues of 
target proteins (217).  
In more detail: During each conjugation cycle, mature SUMO proteins with exposed 
C-terminal Gly-Gly motif, are first activated in an ATP-dependent manner by the activating 
enzyme complex, a heterodimer formed by SUMO-Activating Enzyme E1 and E2 
(SAE1/SAE2). This step involves the formation of a thioester bond between the active site 
Cys residue of SAE2 and the C-terminal Gly residue of SUMO. SUMO is then passed to the 
active site Cys of the conjugating enzyme Ubiquitin-Conjugating 9 (UBC9), also via a 
thioester linkage. Finally, an isopeptide bond is formed between the C‑terminal Gly residue of 
SUMO and a Lys residue in the substrate. This step is usually aided by an E3 SUMO-ligase 
(176, 224). To date, four types of SUMO E3 ligases have been identified, the PIAS (protein 
inhibitor of activated STAT) family of proteins including PIAS 1, PIAS 3, PIAS γ, PIAS xα 
and PIAS xβ, the PIAS-like proteins Nse2 and ZIMP10, RAN Binding Protein 2 (RanBP2) 
and the Polycomb Protein PC2 (225). 
Sumoylated targets serve as substrates for the SENPs family proteins including 
SENP1, SENP2, SENP3 and SENP6. Besides producing SUMO maturation products, SENP 
enzymes remove SUMOs from their targets, ensuring the reversibility and dynamic nature of 
SUMOylation (218, 221) (Fig. 1.8). 
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Importantly, UBC9 is the only known SUMO-conjugating enzyme and UBC9 itself 
binds directly to the consensus SUMOylation motif on substrate proteins. The target protein 
consensus motif comprises ψKxD/E (where ψ is a large hydrophobic residue). However, 
whereas ~75% of known SUMO substrates are modified within a consensus motif, 
SUMOylation can also occur at lysine residues outside this motif and not all ψKxD/E motifs 
are SUMOylated (217, 226). SUMO-2 and SUMO-3 contain a Lysine at position 11 that can 
be conjugated to themselves or with SUMO-1and usually form poly SUMOylation chains. By 
contrast, SUMO-1 does not contain Lys-11 and is conjugated to its substrates once or marks 
the end of poly SUMOylation chain (176). 
1.5.2 Role of SUMOylation in PML function and regulation 
SUMOylation plays an important role in the scaffold function of PML (227). Also, 
PML was identified as the first protein degraded by SUMO-dependent polyubiquitination after 
treatment with arsenic (228). PML is post-translationally conjugated by SUMO-1 (229, 230) 
and SUMO2/3 (231), and without SUMO-1 modification several protein partners are not 
recruited to the PML-NB (232).  
Three canonical SUMOylation sites at Lys-65, Lys-160, and Lys-490 on PML were 
first identified (229). Additionally, in response to arsenic trioxide treatment, another three 
poly-SUMO conjugation sites including Lys-380, Lys-400, and Lys-497 were identified (233).  
It has been proven also that endogenous PML, SUMO-1 and SUMO-3 co-localize in 
PML-NBs (230, 234). PML-NBs are thought to be a nuclear depot where SUMOylation elicits 
its various roles through modulating PML or components of PML-NBs. Although PML 
dimerization is the prerequisite for de novo PML-NB assembly, is thought that SUMOylation 
of PML is required for the recruitment of components of PML-NBs, the turn over and 
retention of PML in PML-NBs, and the integrity and normal function of the PML-NBs itself 
(171, 235). However, the group of Lallemand-Breitenbach proved that PML-NB nucleation 
does not rely primarily on intermolecular interactions between the SIM on PML and SUMO, 
but instead results from oxidation mediated PML multimerization. This report show that 
oxidized PML spherical meshes recruit UBC9, which enhances PML SUMOylation; this 
allows then partner recruitment through SIM interactions, and ultimately enhancing partner 
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SUMOylation. Intermolecular SUMO–SIM interactions then enforce partner sequestration 
within the PML-NB inner core, in a polarized and sequential manner. Some PML-NB-
associated SUMOylated partners also become polyubiquitinated by the Ring-Finger Protein 4 
(RNF4), leading to their proteasomal degradation. As several partners are protein-modifying 
enzymes, PML-NBs could act as sensors that facilitate and confer oxidative stress sensitivity 
not only to SUMOylation but also to other post-translational modifications, thereby explaining 
alterations of stress response upon PML or PML-NBs loss (236). 
According to this a report showed that MEFs cells derived from SUMO-1 KO mice 
have reduced SUMOylation of PML by SUMO2/3 and marked decreases in the number of 
PML-NBs compared to those in the wild type cells, suggesting that SUMO-1 conjugation of 
PML is important to maintain the integrity of PML-NBs (237). Also, SUMO-3 conjugation at 
K160 regulates nuclear localization of PML and PML-NB formation. Depletion of SUMO-3 
markedly reduces the number of PML-NBs and their integrity (234) (Fig. 1.9). 
As mentioned before, SUMOylation of PML regulates the localization of other 
components in PML-NBs (238). SUMOylation state or presence of a SIM motif in PML and 
in protein partners are proposed to be the major signals driving their recruitment into NBs 
(239). Moreover, other key players in the SUMO-conjugation pathway were proposed to 
accumulate in PML-NBs: several SENP and SUMO E3 ligases, as well as the SUMO-
dependent ubiquitin ligase RNF4 (228, 240). The ability of PML to interact with sumo-
conjugated moieties of other PML-NB components is necessary for PML-NB formation (235). 
In fact, SUMOylation of PML exhibits a cell cycle dependent pattern accumulation. It is 
elevated during interphase and declines during mitosis (241). Overall, PML-NBs are 
intimately associated with the SUMO pathway, and both, PML and SUMO overexpression 
induces senescence (176, 223).  
SUMOylation of PML also controls its stability in response to extracellular or 
intracellular stimuli. Arsenic trioxide (As2O3), mediates PML degradation by directly binding 
to the Cys-rich zinc fingers in the RING finger, B-box and CC domain of PML (230). These 
binding directs a conformational change of PML that promotes the interaction between PML 
and UBC9 (242). As2O3 induced sumoylated PML is targeted for ubiquitination by the E3 
ligase RNF4 prior to the proteasome-mediated degradation (228). DNA damage also triggers 
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PML SUMOylation, treatment with Adriamycin, a DNA-damaging chemotherapeutic agent, 
increases the amount of SUMO-conjugated PML (243). 
 
 
Figure 1.8: The SUMO pathway and regulating processes.   
Small Ubiquitin-related Modifier (SUMO) undergoes processing by SENPs proteases to give 
rise to its mature form. SUMO is then adenylated by the heterodimer formed by the SUMO-
Activating Enzymes subunit 1 and 2 (SAE1/2). Following activation, SUMO is transferred to 
the catalytic Cys of the E2 conjugating enzyme, Ubiquitin-like Conjugating Enzyme 9 
(UBC9). SUMO is then transferring to specific substrates by SUMO E3 ligases (PIAS or 
RANBP2). SUMO modification can modulate several processes including transcriptional 
activity, protein localization, protein-protein interaction and protein stability. Deconjugation is 
performed by SENP proteases and free SUMO may be recycled for another round of 
conjugation. 
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Figure 1.9: PML post-translational modifications. 
Modified residues in PML targeted by kinases, SUMOE3 ligases, or SUMO deconjugating 
enzymes. Arrows indicate the targeting site(s) of these enzymes and the functional 
consequences of these post-translational modifications are annotated adjacent to the 
corresponding enzyme. Poly-SUMO chains are observed at K160, K380, K400, K490 and. 
K65 is modified by either SUMO1 or a poly-SUMO chain. Inspired from Cheng, X. and 
Hung-Ying, K., 2013 (176) 
 
The regulators that modulate the extent of PML SUMOylation include E3SUMO 
ligases RanBP2 and the PIAS family as well as non E3 proteins. RanBP2 binds both PML and 
UBC9 to facilitate SUMO conjugation and mediates the SUMOylation of PML at Lys-490 
which is required for the maintenance of PML-NBs (244). Also, PIAS-1-dependent 
SUMOylation of PML at Lys-65 and Lys-160 increases CK2-PML interaction leading to PML 
phosphorylation at Ser-517, ubiquitination, and degradation. Down-regulation of PIAS-1 or 
mutation of Ser-517 stabilizes PML and provokes cell cycle arrest in APL cells, NSCLC cells 
and human primary tumor specimens (245). It been demonstrated that HDAC7 is required to 
maintain PML SUMOylation and PML-NBs, but it remains unclear whether HDAC7 is a 
SUMO E3 ligase (184). Beta-catenin, a protein whose gene is highly mutated in colorectal 
carcinomas, has recently been shown to inhibit RanBP2 mediated SUMOylation of PML by 
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inhibiting the interaction between RanBP2 and PML (244). The Deacetylase Sirtuin-1(Sirt1) 
also promotes PML SUMOylation independent of its deacetylase activity (246). 
Intuitively, both positive and negative regulators must exist to control PML 
SUMOylation. Even a single modulator could regulate PML SUMOylation bilaterally in 
response to different cellular signals. An intriguing question is how the PML–UBC9 complex 
directs these different modulators. Since PML SUMOylation is highly responsive to numerous 
stimuli, other cofactors that transducer signals to UBC9 may participate in its regulation (176). 
1.5.3 Role of SUMOylation in senescence 
SUMO overexpression also triggers senescence. In HEK3T3 and MEF cells, 
overexpression of SUMO-2/3 induces premature senescence through the p53 and pRB 
pathways. Both, p53 and pRB can be SUMOylated by SUMO-2/3 in vivo, and such 
modification may play roles in premature senescence and the stress response. This study also 
showed that non conjugable mutants of SUMO-2/3 fail to induce senescence, suggesting that 
the increase of SUMO2/3 conjugation on target proteins is responsible for senescence and not 
the increase of free SUMO2/3 in the cell. Indeed, down regulation of p53 or pRB by RNA 
interference counteracts the senescent phenotype induced by SUMO-2/3 overexpression (247).  
In primary human fibroblasts, it was found that ectopic expression of PIASγ induces a 
robust senescence response whereas other PIAS members had no pro-senescent effect. PIASγ 
partially colocalizes with SAHF. The protein levels of p53, p21CIP1 or p16INK4A are 
upregulated and pRB is found hypo-phosphorylated, corresponding to its growth inhibitory 
activated state (142). PIASγ interacts with p53 and pRB inducing a senescence arrest. By 
contrast, in pRB deficient fibroblasts, expression of PIASγ leads to p53-dependent apoptosis. 
PIASγ stimulates SUMOylation and transcriptional activity of p53 and increases pRB-
dependent co-repression through recruitment to E2F-responsive promoters. According to this 
fibroblasts lacking PIASγ exhibit a highly reduced propensity to undergo senescence in 
response to a pro-senescence stimulus (225). 
It has been shown also, that expression of endogenous PIASγ and SUMO-1/2 modified 
proteins in quiescent, pre-senescent and replicative senescent cells display different patterns. 
PIASγ expression was considerably increased along with the global SUMO pattern in 
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senescent cells. In fact, the onset of cellular senescence is significantly delayed in PIASγ KO 
mouse embryo fibroblasts (220).  
A report showed that in normal fibroblast there is a global increase in SUMOylated 
proteins and an increase in the number and size of PML-NBs after SENP-1 repression. 
Inactivation of the p53 pathway significantly attenuated the senescence response to SENP-1 
repression (248). 
Taken the key roles of SUMO and PML in tumor suppression and in the senescence 
response, and also the profound defects of SUMOs on PML biology and PML-NBs 
organization, it is tempting to propose that the two pathways could be connected. (Fig. 1.10). 
Low doses of Hydrogen Peroxide (H2O2) induce an increase of SENP-3, which 
removes SUMO2/3 from PML. SENP-3 co-localizes with PML-NBs and reduces its number. 
Under this mild oxidative stress conditions, de-conjugation of SUMO2/3 from PML cause an 
accelerated cell proliferation. PML mutant lacking its SUMOylation function is unable to 
induce cellular arrest, which indicates that only the SUMOylated PML can play an inhibitory 
role for cell proliferation. Furthermore, SENP3 is over-accumulated in a variety of primary 
human cancers including colon adenocarcinoma in which PML is hypo-SUMOylated (249).  
It has been suggested that PML can behave as an E3 SUMO ligase for p53 and Mdm2 
promoting its SUMOylation. PML bind UBC9 and the substrates p53 and Mdm2 and strongly 
enhance transfer of SUMOs from UBC9 to these substrates. PML overexpression can increase 
recruitment of SUMO machinery and consequently enhance global SUMOylation, provoking 
premature senescence (250). Indeed, PML-NBs concentrate a large amount of SUMOylated 
proteins compared to other cellular compartments (227). Then, the tumorigenic switch 
observed in cancer after loss of PML-NBs might either be explained by primary alterations of 
SUMOylation homeostasis leading to secondary defects in PML-NBs assembly or, 
alternatively, to altered global SUMOylation as a consequence of PML loss (223).  
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Figure 1.10: Crosstalk between SUMOylation and PML pathways to control    
senescence induction. 
SUMOylation process and PML-NBs functions are highly cross-connected, both processes are 
stress responses and the increase of both (SUMO and PML) levels induces senescence. 
SUMOylation enzymes regulate PML-NBs formation and partners’ recruitment. Conversely, 
PML-NBs can potentiate SUMOylation process and partners modification to reinforce the 
senescence response. Inspired from Ivanshitz, et al; 2013 (223). 
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2.1  Presentation of article 1. 
 
The first manuscript had as objective to elucidate the mechanisms underlying 
resistance to PML-induced senescence of cancer cells. Previous results from our laboratory 
showed that the overexpression of CDK4 bypass PML-induced senescence in normal cells. 
Importantly, the CDK4 senescence bypass relays completely in an integral function of this 
kinase. More importantly, expression of these kinases regulates the pRB/p16INK4A pathway 
and modulates the expression of the E2F target genes that control cell cycle progression.   
Given the fact that tumor cells are able to proliferate in an unscheduled way, they have 
deregulated expression of CDK4 and CDK6, and also have low expression levels of PML, it is 
possible that CDK4/6 expression in cancer cells could interfere with PML senescence 
mechanism. This article allowed uncovering a novel mechanism of the CDK4/6 kinases as 
epigenetic modulators that protect cancer cells from cellular senescence.   
This manuscript was published in Cancer Research on 29th March, 2016. (Acevedo et 
al., A CDK4/6-Dependant Epigenetic Mechanism Protects Cancer Cells from PML-induced 
Senescence. Cancer Res. 76(11):3252-64) (251). 
  
2.2 Author’s contribution for article 1  
Along with Veronique Bourdeau and Mathieu Vernier, I contributed to the general 
concept and experiment design. I realized most of the cell culture experiments including 
growth assays, reversibility assays, SA-β-Gal assays, western blots, immunofluorescence, 
statistical analysis and xenograft experiments. Veronique Bourdeau realized most of the 
qPCR, co-tratments with CPT and Palbociclib. Frederic Lessard realized the co-
immunoprecipitation experiments, the in vitro kinase assays and the mass spectrometry. 
Gerardo Ferbeyre realized the GSEA analysis.   
Veronique Bourdeau and I, we both realized most of the figure panels, figure legends, 
material and methods and supplementary data. Mathieu Vernier, Veronique Bordeau, Frederic 
Lessard, Gerardo Ferbeyre and me, we all contributed to revision and manuscript ensemble.  
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2.3.1 Abstract 
Promyelocytic leukemia (PML) plays a tumor suppressive role by inducing cellular 
senescence in response to oncogenic stress. However, tumor cell lines fail to engage in 
complete senescence upon PML activation. In this study, we investigated the mechanisms 
underlying resistance to PML-induced senescence. Here, we report that activation of the 
Cyclin-dependent kinases CDK4 and CDK6 are essential and sufficient to impair senescence 
induced by PML expression. Disrupting CDK function by RNA interference or 
pharmacological inhibition restored senescence in tumor cells and diminished their 
tumorigenic potential in mouse xenograft models. Complete senescence correlated with an 
increase in autophagy, repression of E2F target genes, and a gene expression signature of 
blocked DNA methylation. Accordingly, treatment of tumor cells with inhibitors of DNA 
methylation reversed resistance to PML induced senescence. Further, CDK inhibition with 
palbociclib promoted autophagy-dependent degradation of the DNA methyltransferase 
DNMT1. Lastly, we found that CDK4 interacted with and phosphorylated DNMT1 in vitro, 
suggesting that CDK activity is required for its stabilization. Taken together, our findings 
highlight a potentially valuable feature of CDK4/6 inhibitors as epigenetic modulators to 
facilitate activation of senescence programs in tumor cells. 
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2.3.2 Introduction 
 PML was originally identified as the target of chromosome translocations in acute 
promyelocytic leukemia (APL) (252) and as an important regulator of cellular senescence in 
response to oncogenes or short telomeres (253-255). PML-induced senescence underlies the 
success of the treatment of APL with retinoic acid (256). PML forms characteristic nuclear 
bodies that have been associated to its tumor suppressor functions enhancing the activities of 
the tumor suppressors’ p53 and RB and repressing the functions of the oncogenic kinase Akt 
(191, 253). The ability of PML to induce senescence in primary human cells hinges on the 
RB- dependent suppression of E2F-target genes expression (150, 212, 253, 257).  
 Senescence acts as a tumor suppression mechanism early during carcinogenesis by 
imposing a proliferation barrier to cells expressing oncogenic mutations. In addition, 
senescence cells activate immune-mediated mechanisms that result in their clearance (258). 
The senescence process induced by oncogenes in primary cells can be bypassed by mutations 
that inactivate the tumor suppressors p53, pRB or PML (258). However, tumor cells can enter 
senescence after conventional chemotherapy indicating that the program is not fully disabled 
(259). Although chemotherapy induced senescence in cancer cells share some biomarkers with 
the senescence response of primary cells, it is not yet clear whether its outcome is equally 
effective. In particular, it is still unknown how the multiple genetic and epigenetic changes 
present in tumor cells affect the efficacy of the senescence program in terms of the stability of 
the cell cycle arrest and the recruitment of an effective antitumor immune response. 
 Our current ability to study tumor cell senescence is limited by the still poor 
understanding of the senescence process and the lack of definitive, reliable biomarkers. The 
senescence-associated β-galactosidase (SA-β-Gal), the most used senescence marker, is in fact 
a lysosomal enzyme (260) whose activity is increased due to a general activation of autophagy 
in senescent cells (160, 166). In immortalized cells, oncogenic RAS can induce several 
senescence biomarkers without causing a complete growth arrest. This process, called 
senescence with incomplete growth arrest or SWING (261), suggests that there is more than 
one phenotype associated to what we call today cellular senescence. The phenomenon of 
senescent cell clearance in vivo may circumvent the requirement for a tight growth arrest to 
achieve tumor suppression. However, senescent cells in benign tumors can persist for years 
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without progression to malignant lesions (262) indicating that blocking cell cycle progression 
is an important part of the senescent tumor suppression mechanism. Several studies indicate 
that the tumor suppressors RB and PML control the reversibility of the senescence program by 
regulating the repression of E2F target genes (150, 152, 263, 264). In some cell types, this 
process involves the formation of heterochromatin structures known as senescence-associated 
heterochromatin foci or SAHF (265). SAHF require High Mobility-Group A (HMGA) 
proteins (266) and histone modifying enzymes that catalyze the introduction of 
heterochromatin marks (267). However, SAHF are not universal biomarkers of senescence 
and the heterochromatin modifications associated with them may also play a role protecting 
tumor cells from DNA damage signaling (144). It is thus clear that other regulatory layers 
remain to be identified to understand gene expression control in senescent cells. 
Here, we investigate the mechanism of resistance of tumor cells to PML-induced 
senescence. We first found that expression of CDK4 and CDK6 kinases inhibited PML-
induced senescence in normal cells. In tumor cells, where these kinases are deregulated, PML 
induced an incomplete senescence program, which was restored by knockdown of CDK4 and 
CDK6 or expression of the CDK inhibitors p21CIP1 or p16INK4A. The CDK inhibitors 
flavopiridol or palbociclib (PD0332991) also increased the ability of PML to regulate tumor 
cell senescence in culture and reduced tumor progression in vivo. Transcriptome analysis of 
cells expressing PML and treated with palbociclib showed that senescence correlated with a 
better repression of E2F target genes and unexpectedly with a gene expression signature 
previously described in cells exposed to a DNA methylation inhibitor. Inhibition of DNA 
methylation restored the full senescence response to PML in tumor cells. CDK inhibitors acted 
on this pathway by promoting the autophagy-dependent degradation of DNMT1. Conversely 
CDK4/6 interact with and phosphorylate DNMT1 increasing its stability. Together, the results 
indicate that CDK4/6 kinases maintain an epigenetic mechanism that protect tumor cells from 
senescence and provide a proof of concept for a senescence therapy of cancer using CDK4/6 
inhibitors. 
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2.3.3 Materials and methods 
Cells, retroviral gene transfer, plasmids and reagents 
PC3, U2OS, HEK-293T and normal human diploid fibroblasts IMR90 cells were 
obtained from American Type Culture Collection (ATCC). Phoenix ampho packaging cells 
were a gift from SW Lowe. PC3 cells were cultured in RPMI medium (Wisent, Montreal, Qc) 
supplemented with 10% fetal bovine serum (FBS; Wisent), 1% penicillin/streptomycin sulfate 
(Wisent) and 2mM L-glutamine (Wisent). All other cell lines were culture in DMEM medium 
(DMEM, Wisent, Montreal, Qc) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin sulfate. Retroviral-mediated gene transfer, growth curves and SA-β-
Gal activity were assayed as described in (253).  
Retroviruses pLPC, pLPC-PML, pWZL, pWZL-PML (isoform IV) were described in 
(253). pBABE-CDK4 and pBABE-CDK6 were a gift from SW. Lowe.  Retroviral vectors for 
WZL-CDK4 wild type and K35M mutant were a gift from G.J. Hannon. Flag variants for 
CDK overexpression of CDK2 (WT), CDK4 (WT) and mutant K35M were PCR amplified 
with a primer containing the 3xFLAG tag and subcloned in BamHI / EcoRI restriction sites to 
create pBABE-3xFLAG-CDK2 (WT), pBABE-3xFLAG-CDK4(WT) and pBABE-3xFLAG-
CDK4mut(K35M). Retroviruses pLPC-3xFLAG was described in (150). pcDNA3-Myc-
DNMT1 was purchased from Addgene. Retroviral vectors with shRNAs against RB or the RB 
pocket proteins were also obtained from SW Lowe and described in (152). CDK4 and/or 6 
shRNAs were cloned in retroviral vectors pMLP (MSCV based vector expressing shRNA in a 
miR30 context) or pMLPX (153). ShRNA mature sequences are in supplementary material. 
pBABE-ER vector was a gift from SW Lowe and PML (isoform IV) was obtained by PCR 
from pLPC-PML (253) and subcloned between BamHI/XhoI restriction sites to create 
pBABE-PMLIV-ER.  
The CDK inhibitor flavopiridol was purchased from Selleckchem. Palbociclib 
(PD0332991), 5-Aza-dC (5-Aza-2’-deoxycytidine), OHT (4-hydroxytamoxifen) and 
bafilomycin A1 were purchased from Sigma-Aldrich. Treatments at the indicated 
concentrations with flavopiridol, palbociclib and OHT were renewed every three days and 
treatments with 5-Aza-dC were added once for three days. 
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Immunoblotting and Immunofluorescence  
 Protein expression analysis was performed as in (150). Antibodies, 
immunoprecipitation protocol and in vitro protein kinase assay are described in supplementary 
materials and methods. For immunofluorescence studies, cultured cells were plated on 
coverslips and fixed as described in (150). For LC3B and p62 immunodetection cells were 
treated 24 hours with bafilomycin A1 (50nM) prior to fixation. The primary antibodies used 
were: Anti-53BP1 rabbit polyclonal (1:200, EMD millipore #PC712), anti-DNMT1 rabbit 
polyclonal (1:200, Cell Signalling #5032), anti-PML mouse monoclonal (1:400, Santa Cruz 
Biotechnology PG-M3), anti-LC3B rabbit polyclonal (1:400, Cell Signalling #2775) or anti-
SQSTM1/p62 rabbit polyclonal (1:400, Cell Signalling #5114). Secondary antibody 
combinations used were: Alexa-Fluor 488 goat anti-mouse and Alexa-Fluor 568 goat anti-
rabbit (1/2000, Molecular Probes-Invitrogen). We used as mounting media ProLong Gold 
Antifade Reagent with DAPI (Invitrogen). Images were collected on an upright microscope 
Axio Imager.Z2 (Zeiss) with the Zen Microscope and imaging software. 
 
Animals 
Mouse experiments were conducted in accordance with institutional and national 
guidelines and regulations. For xenografts, 30 BALB/c 6-week-old nude mice (Charles River) 
were injected subcutaneously in both flanks with 106 PC3 cells expressing empty vector (V) 
or PML. Cells were suspended in PBS mixed with Matrigel (BD Biosciences). Tumor 
formation was followed every 2 days for a period of 18 days. When tumors reached around 
150 mm3, mice were separated in three treatment groups for each condition: NT, nontreated 
(control); Fl, flavopiridol (5 mg/kg/day diluted in 0.9% NaCl-0.1% DMSO injected 
intraperitoneally); Pa, palbociclib (PD 0332991: 100 mg/kg/day diluted in sodium lactate 50 
mmol/L pH 4 administered by gavage). Mice were treated for 5 consecutive days. Tumor 
growth was measured every 2 days for the following 22 days without further treatments. 
Statistical analysis was performed using SPSS software 16.0 (SPSS, Inc.). The nonparametric 
Kruskal–Wallis test was used to show significant differences in tumor growth among groups. 
All values were expressed as SEM (Standard Error of the mean). A P value of less than 0.05 
was accepted as statistically significant. Mice were euthanized before the endpoint of the 
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experiment when tumor volume reached 2 cm3. Tumors were collected and either snap frozen 
(for later RNA extractions) or fixed in10%neutral-buffered formalin solution, paraffin 
embedded, and cut into sections for immunofluorescence analysis. 
 
Immunofluorescence from paraffin embedded samples 
Tumor sections from xenografts were deparaffinised and rehydrated. Antigen epitope 
retrieval was performed by heating for 25 min at 95°C in Sodium-Citrate Buffer (10mM 
Sodium Citrate, 0.05% Tween 20, pH 6.0). Samples were permeabilized with Triton 0.5%-
PBS 1X solution for 15 min and blocked with 3% BSA, 5% Goat Serum, 0.1% Tween20-PBS 
1X solution for 1 hr. Samples were incubated with the primary antibody at 4ºC over-night as 
follow: anti-PML (mouse monoclonal, PG-M3 SC966; Santa Cruz; 1:400); anti-LC3B (rabbit 
polyclonal, 2775S; Cell Signalling; 1:400); anti-SQSTM1/p62 (rabbit polyclonal, 5114; Cell 
signalling; 1:400). The next day, samples were washed in PBS 1X and incubated with goat 
anti-mouse AlexaFluor 488 (1:1000; A-11029, Molecular Probes, Invitrogen) or anti-rabbit 
AlexaFluor 568 (1:1000; A-11036, Molecular Probes, Invitrogen). For mounting, we used 
ProLong Gold Antifade Reagent with DAPI (P36931; Invitrogen). 
 
RNA expression analysis 
 Snap frozen tumor samples were transferred to RLT buffer (QIAGEN) for 
homogenization first with micropestels and then by passing the samples through QIA shredder 
column (QIAGEN) prior to RNA isolation with RNeasy Mini Kit (QIAGEN) according to 
manufacturer’s instructions. Cultured cells were collected in Trizol reagent (Invitrogen) for 
RNA extractions, according to the manufacturer’s instructions and RNA samples send for 
gene arrays (Human Gene 2.0 ST Array, at the McGill University and Génome Quebec 
Innovation Center, Montreal, QC) were further purified with RNeasy MinElute Cleanup kit 
(QIAGEN).  
The microarray data files from triplicates of the four conditions were analyzed with the 
Affymetrix Expression Console Software and Transcriptome Analysis Console 
(www.affymetrix.com).  Raw data were normalized with a Robust Multi-array Average 
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(RMA) algorithm. The microarray data were deposited in NCBI’s Gene Expression Omnibus 
(GEO) and are accessible through GEO Series accession numbers GSE70923.  
The Gene Set Enrichment Analysis (GSEA) software was used to match gene 
expression patterns in our four conditions with genes sets available in the Molecular Signature 
Database (MSigDB). The significance of enrichment values (NES) was determined by the 
False Discovery Rate (FDR; q-value) and by a nominal p-value calculated by using an 
empirical phenotype-based permutation test procedure as described (268). Only enriched gene 
sets with a p-value ≤ 0.05 and a q-value ≤ 0.25 were considered significant. A detailed 
explanation of our bioinformatic analysis was published in (269). 
 Quantitative real-time PCR were performed as described in (150). Primer sequences 
are available in supplementary Material and methods. 
2.3.4 Results 
Expression of cyclin-dependent kinases CDK4 and CDK6 suppresses PML-induced 
senescence 
 To investigate the mechanisms allowing tumor cells to evade senescence, we first 
tested whether expression of the kinases CDK4 and CDK6 can prevent PML-induced 
senescence in normal human fibroblasts. We found that these kinases efficiently blocked 
PML-induced growth arrest and senescence in normal cells (Fig. 2.1A and Supplementary Fig. 
S2.1A-C). One important function of PML during senescence involves RB and the repression 
of E2F targets genes (150). Accordingly, the expression of CDK4 or CDK6 was able to restore 
the expression of multiple E2F targets in PML expressing cells (Supplementary Fig. S2.1D). 
In a similar way, RB knockdown but not p107 or p130 knockdown suppressed PML-induced 
senescence and increased the expression of E2F-target genes (Supplementary Fig. S2.1E-H). 
Together, these experiments indicate that expression of CDK4 or CDK6 beyond a certain 
threshold can overcome the ability of PML to engage the RB pathway and induce senescence 
in normal cells.  
 Since cancer cells have defects in the RB pathway, we anticipated that PML could 
induce a better senescence response in tumor cells if the functionality of the RB pathway is 
strengthen. Thus, to investigate whether CDK inhibition could improve the ability of PML to 
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inhibit the growth of tumor cells, we co-expressed PML with shRNAs against CDK4, CDK6 
or a construct expressing simultaneously shRNAs against CDK4 and CDK6. In U2OS cells, 
PML reduced cell growth but shRNAs against CDK4 or CDK6 did not. Combining shCDK4 
and shCDK6 slightly reduced cell growth but in combination with PML expression we 
observed a stronger growth reduction (Fig. 2.1B). In PC3 prostate cancer cells, PML also 
inhibited cell growth and this effect was enhanced by co-expressing shRNAs against CDK4 or 
6 and even more when both shRNAs were co-expressed (Fig. 2.1C). ShCDK4 and shCDK6 
efficiently reduced the levels of their targets when used alone or when expressed together in 
the same vector (Fig. 2.1D). We also assessed RB levels in U2OS cells expressing PML and 
the different shRNAs. RB levels in senescent cells appear reduced in western blots (Fig. 2.1D 
and ref. (212). Another hallmark of senescence is the accumulation of DNA damage foci, 
which we measured with antibodies against the DNA damage response protein p53BP1. 
Downregulation of CDK4/6 with shRNAs (two different combinations of shRNAs against 
CDK4 and CDK6) increased the number of U2OS cells with several p53BP1 foci and 
expression of PML further increased the number of these foci (Fig. 2.1E). Senescence is also 
characterized by an increase in autophagy markers (160). The lipid-conjugated form of LC3 
known as LC3B accumulates in senescent cells when the autophagy flux is inhibited with 
vacuole ATPase inhibitors such as bafilomycin A1 (160). We found that cells expressing PML 
and shRNAs against CDK4/6 accumulate the autophagy markers LC3B and p62 (Fig. 2.1F). 
This is best illustrated using single cell analysis by immunofluorescence using antibodies 
specific for these markers. The number of cells having high numbers of LC3B and p62 foci is 
much higher after combining PML with shCDK4/6 (Fig. 2.1G and H). To confirm our shRNA 
results we next inhibited CDKs by forcing the expression of the CKIs p21 and p16INK4A 
(Supplementary Fig. S2.2 A and B). Both p21 and p16INK4A expression inhibited the growth 
of U2OS (Supplementary Fig. S2.2C) and PC3 cells (Supplementary Fig. S2.2D) and 
cooperated with PML to further inhibit cell growth.  
 Next we tested whether pharmacological inhibitors of CDKs also cooperated with 
PML to reduce cancer cell proliferation. We used flavopiridol, a drug that inhibits several 
CDKs (270) and palbociclib (PD0332991), a selective and potent inhibitor of CDK4 and 
CDK6 (271).  In PC3 cells, the combination flavopiridol-PML was slightly better than PML 
alone to reduce cell growth (Fig. 2.2A) and induce senescence (Fig. 2.2C). In contrast, 
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combining palbociclib with PML was dramatically more effective (Fig. 2.2B and C). The 
autophagy/senescence markers LC3B and p62 accumulated at higher levels in cells expressing 
PML and treated with the CDK inhibitors (Fig. 2.2 D-F). Similar results were obtained in 
U2OS cells (Supplementary Fig. S2.3). These results are consistent with the idea that CDK 
inhibitors potentiate the senescence tumor suppression functions of PML. 
 To obtain in vivo evidence that CDK inhibitors and PML cooperate in tumor 
suppression, we prepared PC3 cells expressing PML or a vector control and injected them in 
the flanks of nude mice. The animals were then divided in six groups each with five animals 
injected in each flank. Three groups have an empty vector and were treated for five 
consecutive days with vehicle (V/NT), flavopiridol (V/Fl) or palbociclib (V/Pa). The other 
groups expressed PML and were also treated for five days with vehicle (PML/NT), 
flavopiridol (PML/Fl) or palbociclib (PML/Pa).  Tumors with an empty vector or PML 
progressed without treatment, although PML moderately reduced tumor growth. Treatment 
with CDK inhibitors reduced tumor growth but the best results were obtained in PML-
expressing tumors after treatment with either flavopiridol or palbociclib (Fig. 2.3A-C). In fact, 
the combination of PML and CDK inhibitors completely eliminated the tumors in some 
animals suggesting either tumor cell death or clearance by the innate immune system. Of note, 
all tumors recovered from PC3-PML had a reduction in the expression level of retroviral 
transcripts (Fig. 2.3D) suggesting a preferential growth in vivo of cells with less transcription 
of the expression vector and explaining why in some animals the treatment did not totally 
eliminate the tumors.  As shown previously with cells in culture, the combination of PML with 
CDK inhibitors induced a higher accumulation of the autophagy markers LC3B and p62 when 
analyzed several days after treatment was stopped (Fig. 2.3E and F). 
 
Gene expression profile of cells expressing PML and treated with CDK inhibitors 
We next compared the transcriptome of PC3 cells expressing PML or a vector control 
and treated with palbociclib or vehicle. The comparisons of control cells with cells expressing 
PML or treated with palbociclib are described in the supplementary fig. S2.4. In general, both 
PML and palbociclib regulate cell cycle, E2F targets and interferon genes although obviously 
these changes were not sufficient to trigger a stable senescence response. Next, we compared 
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senescent cells (PML-expressing and palbociclib treated PC3 cells), with either PC3 cells 
expressing a vector control treated with palbociclib or PC3 cells expressing PML but not 
treated with palbociclib (Supplementary Fig. S2.5). These evaluations are expected to reveal 
the critical gene expression changes associated to stable senescence, especially those that are 
common to both comparisons. One hallmark of senescence is the upregulation of genes 
involved in inflammation and the immune response (272). Consistent with the senescence 
phenotype induced by the combination of PML and palbociclib, several cytokine genes were 
found upregulated in this condition in comparison with cells expressing PML alone or cells 
treated with palbociclib (Supplementary Fig. S2.5 A and B). Another characteristic of 
senescent cells is the downregulation of E2F target genes (150, 152). As mentioned above, 
both PML and palbociclib when used alone induced a downregulation of several E2F targets 
in PC3 cells (Supplementary Fig. S2.4D and H) but their combination was even more 
effective, increasing the number of E2F targets that are downregulated (Supplementary Fig. 
S2.5 C and D). Intriguingly, we found a downregulation of several E2F target genes that play 
a role in DNA repair in cells treated with PML and palbociclib (Supplementary Fig. S2.5 E 
and F). This is consistent with previous findings during PML-induced senescence in primary 
fibroblasts (150) suggesting a mechanism to explain the persistent DNA damage response seen 
in senescent cells.  
Remarkably, the gene expression pattern of PML/palbociclib treated cells overlaps 
with the pattern observed in pancreatic cancer cells treated with DNA methylation inhibitors 
(Fig. 2.4A and B). CDC2, CDC6, CENPF, FOXM1, LMNB1 and HMGB2, were among the 
genes downregulated in cells treated with DNA methylation inhibitors (273). We confirmed 
their enhanced downregulation in PML/palbociclib treated cells when compared with control 
growing cells expressing empty vectors, control cells treated with palbociclib or cells 
expressing PML alone (Fig. 2.4C). In addition, we confirmed that PML/palbociclib treatment 
increased the levels of several senescence regulatory genes repressed by DNA methylation. 
They include EDN1 (274), GADD45 (275), IFI44L (276), IL23A (277) and SerpinE1/PAI1 
(256) (Fig. 2.4D). Together, the gene expression pattern suggests that the pro-senescence 
interaction between PML and palbociclib involves the control of DNA methylation. 
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DNA methylation and DNMT1 control tumor cells resistance to senescence 
To investigate whether gene regulation due to DNA methylation plays a role in the 
resistance of tumor cells to PML-induced senescence, we treated PC3 prostate cancer cells 
with the DNA methyl transferase inhibitor 5-aza-2’deoxycytidine (5-Aza-dC). The drug 
decreased cell growth in control cells but the effect was more pronounced when combined 
with PML expression (Fig. 2.5A). Hence, DNA methylation inhibitors, like CDK inhibitors, 
cooperate with PML to induce growth arrest. Next we investigated whether 5-Aza-dC 
cooperated with PML to induce senescence. Treatment of PC3 cells with 5-Aza-dC at doses 
between 40 and 250 nM only slightly induced SA-β-Gal activity, similarly to PML expression 
alone. However, combining PML expression with the drug induced a dose dependent SA-β-
Gal activity in these cells (Fig. 2.5B). Similar results were found when using autophagy 
markers LC3B and p62, which were both more abundant in cells treated with 5-Aza-dC and 
expressing PML (Fig. 2.5C and D).  
To further confirm that PML and 5-Aza-dC cooperate to induce senescence we 
prepared PC3 cells expressing a PML fusion protein with the ligand binding domain of the 
estrogen receptor (PML-ER) that is active in the presence of 4-hydroxytamoxifen (OHT). In 
normal fibroblasts expressing PML-ER, treatment with OHT for one week induced a 
senescent cell cycle arrest where 96% of the cells were positive for SA-β-Gal (Supplementary 
Fig. S2.6A). To study the reversibility of this phenotype, we treated PML-ER expressing 
normal fibroblasts for 1, 2, 3, 4 and 7 days with OHT and then cultured them for another 5 
days without OHT. We found that induction of PML-ER for 1 or 2 days was not sufficient to 
induce a lasting senescence. However, induction of PML-ER with OHT for more than 3 days 
led to a stable senescent phenotype (Supplementary Fig. S2.6B). In contrast to normal cells, 
activation of PML-ER with OHT in PC3 prostate cancer cells only slightly reduced growth. 
Pre-treatment of the cells, 6 days prior to the growth assay but not during the assay, with 
palbociclib or 5-Aza-dC alone moderately reduced cell growth in a dose dependent manner 
(Fig. 2.6A and Supplementary fig. S2.6 C and D). However, inducing PML activation with 
OHT in tumor cells that were previously exposed to palbociclib or 5-Aza-dC lead to stronger 
growth arrest in response to both drugs (Fig. 2.6A and Supplementary fig. S2.6C and D). 
These results suggest that the effects of 5-Aza-dC or palbociclib leading to cooperation with 
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PML to induce senescence were imprinted in the cell population because they remained after 
the drugs were removed. In addition, most cells exposed sequentially to palbociclib or 5-Aza-
dC and PML activation were unable to proliferate even after removal of the PML-ER inducer 
OHT (Fig. 2.6B and Supplementary fig. S2.6 E and F). Interestingly, pretreatment with 
palbociclib dramatically increased the growth arrest response to the chemotherapeutic drug 
camptothecin (Fig.  2.6C), indicating that its epigenetic effects facilitate the cellular 
senescence response to different agents.  
Since the cooperation between PML and palbociclib led to changes in gene expression 
related to inhibition of DNA methylation and the DNMT1 inhibitor 5-Aza-dC has effects on 
tumor cells similar to palbociclib, we next explored whether palbociclib affected DNMT1 
levels. We found that palbociclib decreased DNMT1 levels in a dose dependent manner (Fig. 
2.7A and Supplementary Fig. S2.7A). Of note, it has been reported that CDK1 and CDK2 
phosphorylate DNMT1 at serine 154 stabilizing the protein (70). Using a phosphospecific 
antibody for this modification we found that the levels of DNMT1 phosphorylated at serine 
154 correlated with the levels of the total DNMT1 (Fig. 2.7A). Most likely, the reduced signal 
with the phosphospecific antibody is due to a corresponding reduction of the total levels of 
DNMT1. We next confirmed that reduction of CDK4 and CDK6 with shRNAs also reduced 
DNMT1 levels (Fig. 2.7B) suggesting that the effect of palbociclib is due to inhibition of these 
kinases and not an off target effect of the compound. Conversely, overexpression of CDK4 or 
CDK6 but not CDK2 dramatically increased DNMT1 levels in normal human fibroblasts (Fig. 
2.7C). This effect of CDK4 or CDK6 on DNMT1 was not observed at the mRNA level (Fig. 
2.7D) indicating an effect on translation or protein stability. The proteasome inhibitor MG132 
was not able to rescue the levels of DNMT1 in palbociclib treated cells (Fig. 2.7E). In 
contrast, the autophagy inhibitor bafilomycin A1 stabilized DNMT1 in palbociclib treated 
cells (Fig. 2.7F). Taken together, these results are consistent with a model where CDK4 and 
CDK6 protect DNMT1 from autophagy-dependent protein degradation. 
To investigate whether CDK4 can directly regulate DNMT1, we immunoprecipitated a 
flag-tagged allele of CDK4 expressed in HEK-293T cells with a Myc-tagged allele of 
DNMT1. We found DNMT1 after immunoblotting the CDK4 immunoprecipitates (Fig. 2.7G), 
suggesting a protein-protein interaction. Next, we used purified CDK4/cyclin D to assay for 
kinase activity on purified GST-DNMT1. We observed that CDK4/cyclin D phosphorylated 
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DNMT1 in vitro (Fig. 2.7H). Finally, we used gel purified GST-DNMT1 previously incubated 
with CDK4/cyclin D under kinase assay conditions to analyze the phosphorylation sites using 
mass spectrometry. We found that CDK4/cyclin D phosphorylated DNMT1 at serines 127, 
and 954 (Fig. 2.7I and Supplementary Fig. S2.7B). It has been reported that AKT can 
phosphorylate DNMT1 at serine 127 (278), however, this site fits better the consensus of a 
proline directed kinase such as the CDKs. We found a single peptide phosphorylated at serine 
247 but since this site does not fit the consensus of a proline directed kinase we think is not a 
relevant CDK4 phosphorylation site. Phosphorylation of DNMT1 at serine 954 has been never 
reported but the site is close to a cluster of acetylation sites controlled by SirT1 (279) 
suggesting that these two modifications may functionally interact. Together, the results 
support a model where CDK4/6 regulate DNMT1 stability via its phosphorylation although it 
is also possible that these kinases may affect the autophagy program as well. 
2.3.5 Discussion  
 Cellular senescence is a very efficient mechanism to prevent tumorigenesis that is 
triggered in normal cells after activation of oncogenes or a mitotic stress leading to telomere 
shortening (258). We show here that human cancer cells are resistant to PML–induced 
senescence due to hyperactive CDK4/6 signaling and that decreasing the activity of these 
kinases can restore the senescence response to PML activation. We found that CDK4/6 
kinases control the phosphorylation and stability of DNMT1, which is required to maintain an 
epigenetic mechanism that prevents PML- and chemotherapy-induced senescence.  
The epigenetic marks maintained by DNMT1 in tumor cells to prevent senescence can 
act by several mechanisms including repression of pro-senescence anti-proliferative genes, 
enhancement of gene repression by RB-E2F complexes and the control of genome stability. 
Our data supports these three nonexclusive possibilities. First, we identified several candidate 
tumor suppressors re-expressed in PC3 prostate cancer cells expressing PML and treated with 
the CDK4/6 inhibitor palbociclib. These genes were previously shown to be controlled by 
DNA methylation and include SerpinE1 (256, 280), IL23A (277), GKN2 (281), IGFBP3 
(282), TNFAIP3 (283), IFI44L (276), SSX (284), EDN1(274) and GADD45A (285). 
Consistent with this idea, it has been reported that DNA methylation inhibitors promote the 
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expression of interferon target genes (273) many of which are known to play a role in 
senescence (286). Second, several E2F target genes were better repressed by the combination 
of PML and palbociclib (Fig. 2.5C) suggesting that inhibition of DNA methylation can 
enhance E2F targets gene repression by RB. In support of this mechanism, it has been reported 
that DNA binding by E2F transcription factors is sensitive to DNA methylation (287). Third, 
we found increased DNA damage signals in cells treated with palbociclib and PML, a 
phenomenon that can be explained by the role of DNMT1 controlling genome stability via 
methylation of juxtacentromeric satellite DNA (288).  
The idea that DNA methylation prevents senescence is consistent with the widespread 
DNA hypomethylation observed in senescence cells using large scale DNA methylation 
analysis (289). Hypomethylation in cells approaching senescence was linked to 
mislocalization of DNMT1 (289) indicating that DNMT1 is a key target to reprogram the 
genome for senescence. We add here a new mechanism controlling DNMT1 in senescence: 
decreased stability due to lack of CDK4/6-dependent phosphorylation of DNMT1. In vitro, 
CDK4 was able to phosphorylate DNMT1 at serines 127, 243 and 954 but further work will be 
required to precisely determine the role of each of these phosphorylation sites in vivo. 
Nevertheless, inhibition of CDK4/6 activity allowed autophagy dependent degradation of 
DNMT1. Autophagy plays an important role in senescence controlling the expression of 
inflammatory cytokines (160, 166) and the nuclear envelope protein lamin B1 (165). We thus 
identified DNMT1 as a novel nuclear target of autophagy-dependent protein degradation in 
senescent cells. It is intriguing that lamin B1 and DNMT1 are targets for autophagy-dependent 
protein degradation and both control large-scale patterns of gene expression, suggesting that 
autophagy is mechanistically linked to genome reprogramming during cellular senescence.  
It is still not clear how tumor cells acquire DNA methylation changes that block 
cellular senescence. DNMT1 is the most abundant DNA methyltransferase in cells and 
maintains DNA methylation patterns initially laid out by the de novo methylases DNMT3A 
and DNMT3B (290). An abnormal and cancer specific gain of DNA methylation at promoters 
of tumor suppressor genes would require a mechanism to recruit de novo methylases to these 
promoters. Alternative, DNA methylation of tumor suppressors mediating senescence can be 
part of a normal mechanism that ensures self-renewal in stem cells and that requires DNMT1 
for its maintenance. Consistent with this idea, DNMT1 is normally required to maintain 
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populations of progenitor cells and prevent their exhaustion by cell differentiation (291). 
Reactivation of this program in tumor cells can explain why they acquire anti-senescence 
epigenetic marks and drugs that can revert it should be promising for cancer therapeutics. 
CDK4/6 inhibitors were conceived as cell cycle inhibitors and are in clinical trials for 
the treatment of breast cancer and other malignancies (292). Our results linking this drug 
family to the control of epigenetic programs is unexpected and may justify their use beyond 
cell cycle control. It is plausible that in addition to their cell cycle effects their clinical efficacy 
is related to their ability to inactivate DNMT1 and sensitize cells for irreversible senescent cell 
cycle arrest (Fig. 2.7J). Our results showing cooperation between CDK4/6 inhibitors and the 
senescence regulator PML may also indicate that PML status in tumors can predict the 
response to these drugs. It has been recognized that chemotherapeutic agents can induce tumor 
cell senescence (259) and CDK4/6 inhibitors can enhance this response acting as erasers of 
tumor epigenetic marks. Likely, these drugs could be widely used to improve the effect of a 
variety of chemotherapeutic agents. 
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2.3.7  Legends 
Figure 2.1: CDK4/6 kinases suppress PML-induced senescence.  
A, Cell growth estimated from a crystal violet retention assay of IMR90 cells expressing PML 
together with a vector control (V), CDK4 or CDK6. B, Relative growth of U2OS cells infected 
with empty vector (V) or a vector expressing PML (P) as well as a vector expressing either a 
control non-targeting shRNA (shNTC), an shRNA against CDK4 (shCDK4), CDK6 
(shCDK6) or two shRNAs targeting CDK4 and CDK6 (shCDK4/6). C, Relative growth of 
PC3 cells modified as in B. Error bars: mean +/- SD, * = p<0.05. D, Immunoblots against the 
indicated proteins using U2OS cells as in (B). E, Quantification of DNA damage foci per cells 
after indirect immunofluorescence for 53BP1 in IMR90 cells infected with control vector 
(normal) or oncogenic RAS (senescent) and in U2OS cells bearing an empty vector (V) or 
PML and further modified with a control non-targeting shRNA (shNTC), or double shRNAs: 
shCDK4/6-1 and shCDK4/6-2 (sh1 or sh2). *= p<0.05, **=p<0.01 and ***=p<0.005 using 
Student t-test. F, Immunoblots against the indicated proteins using U2OS cells as in (E). G, 
Fluorescent imaging of LC3B and p62 foci as markers of autophagy (red) of U2OS cells as in 
(E) and treated with 50 nM bafilomycin A1 for 24 hrs. PML staining is shown in green and 
nuclear DNA (DAPI) in blue. Scale bar= 10 µM. H, Quantification of LC3B and p62 foci per 
cells using data from multiple immunofluorescence images as in (G). Cells presenting more 
than 100 foci where considered positive for induction of autophagy. Three sets of 100 cells 
were looked at. Error bars: mean +/- SD, *=p<0.05, **=p<0.01 and ***=p<0.005 using 
Student t-test. 
 
Figure 2.2: CDK inhibitors enhance PML-mediated growth arrest and senescence in 
tumor cell lines.  
A-B, Relative growth of PC3 cells infected with empty vector or a vector expressing PML 
treated with flavopiridol (Fla) (A) or palbociclib (Pal) (B) at the indicated doses for six days. 
Error bars: mean +/- SD, *=p<0.05, **=p<0.01 and ***=p<0.005 using Student t-test. C, 
Senescence-associated-β-galactosidase assay (SA-β-Gal) in PC3 cells infected with empty 
vector (V) or a vector expressing PML treated with vehicle (Ctrl), 120 nM flavopiridol (Fla) or 
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500 nM palbociclib (Pal). D, Immunoblots for the indicated proteins in cells as in (C). E, 
LC3B and p62 foci (red) visualized after immunofluorescence staining of PC3 cells as in (C). 
PML staining is shown in green and nuclear DNA (DAPI) in blue. Scale bar= 10 µM. F, 
Quantification of LC3B and p62 foci per cells of immunofluorescence performed in (E). Cells 
presenting more than 100 foci where considered positive for induction of autophagy. Three 
sets of 100 cells were looked at. Error bars: mean +/- SD, *=p<0.05, **=p<0.01 and 
***=p<0.005 using Student t-test. 
 
Figure 2.3: CDK inhibitors enhance PML-mediated growth arrest and senescence in 
xenografts.  
A, Relative tumor growth of PC3 cells expressing a vector control or PML injected 
subcutaneously in nude mice. The red arrow indicates the time at which tumors attained ~2 
mm3 and treatment with flavopiridol (5 mg/kg/d for 5 days) or palbociclib (100 mg/kg/d for 5 
days) started, n=8/condition. The black arrow indicates the end of the five-day treatment.  
Each data point includes the standard error of the mean. B, Representative pictures of tumors 
in the flanks of nude mice 22 days after the start of the treatments. C, Box plot for the 
quantitation of tumor volume at day 22 in tumors as in (A), * = p<0.05 using Kruskal-Wallis 
test. D, Box plot of RT-qPCR for the expression of the retroviral vector used to prepare PC3 
vector control and PC3-PML cell populations using RNA extracted from tumors as in (A). E, 
Fluorescent imaging of LC3B and p62 as markers of autophagy vesicles (red) in tumors as in 
(A). PML expression was visualized by indirect immunofluorescence (green), nuclei were 
visualized by DAPI staining (blue). Scale bar= 10 µM. F, Quantification of cells positive for 
autophagic markers LC3B and p62 in tumors stained as in (E), Three sets of 100 cells each 
were looked at, *= p<0.05 using Student t-test.  
 
Figure 2.4: Transcriptome analysis reveals methylation sensitive genes as targets of PML 
and CDK-inhibitors.  
A-B, Gene Set Enrichment Analysis (GSEA) of microarray data comparing PC3 cells 
expressing PML and treated with palbociclib with PC3 cells expressing PML but not treated 
(A) or with PC3 cells with an empty vector and treated with palbociclib (B). The gene set 
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MISSIAGLIA_REGULATED_BY_METHYLATION_DN overlaps with genes altered in 
PC3 cells expressing PML and treated with palbociclib. The top 20 genes whose expression 
was most reduced in PML expressing and palbociclib treated PC3 cells are shown in heat 
maps for each comparison. C, QPCR of selective genes downregulated by the combination of 
PML and palbociclib in PC3 cells overlapping with those downregulated by DNA methylation 
inhibitors in pancreatic cancer from the gene set 
MISSIAGLIA_REGULATED_BY_METHYLATION_DN. *= p<0.05, **=p<0.01 and 
***=p<0.005 using Student t-test. D, QPCR of selected senescence regulatory genes normally 
repressed by DNA methylation and showing re-expression by the combination of PML and 
palbociclib in PC3 cells. 
 
Figure 2.5: A DNA methylation inhibitor enhances PML-mediated growth arrest and 
senescence in tumor cell lines.  
A, Relative growth of PC3 cells infected with empty vector (Vect) or a vector expressing PML 
and treated with 5-Aza-dC at the indicated concentrations. Error bars: mean +/- SD *= p<0.05. 
B, SA-β-Gal in PC3 cells expressing either PML or a vector control and treated with 5-Aza-dC 
(A40 = 40nM, A120 = 120nM, A250 = 250 nM) or vehicle (DMSO). C-D, Quantification of 
autophagy vesicles LC3B (C) and p62 (D) foci per cells after indirect immunofluorescence 
staining using specific antibodies. PC3 cells with and empty vector (V) or PML were treated 
with 5-Aza-dC at the indicated concentrations (A120 = 120nM, A250 = 250nM). 
 
Figure 2.6: Palbociclib or 5-Aza-dC confers sensitive to PML- or camptothecin-induced 
permanent growth arrest.   
A, Experimental timeline: PC3 cells expressing a PML-ER fusion are first treated with 
palbociclib (Pal-100: 100 nM or Pal-500: 500 nM, every three days for six days) or 5-Aza-dC 
(A-120: 120 nM or A-250: 250 nM, once over three days and then kept in normal medium for 
another three days). Cells are then treated with ethanol 0.1% (CTRL: control) or 4-
hydroxytamoxifen (OHT: 100 nM) every three days over the next six days without further 
palbociclib (left graph) or 5-Aza-dC (right graph). Growth was estimated by a crystal violet 
retention assay. Results are shown as relative growth compared to cells expressing ER with 
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only control treatments (see Supplementary Figure 6 C-D for full data set).  B, As in (A) but 
the initial palbociclib or 5-Aza-dC temporary treatment is followed by a temporary treatment 
with control (CTRL: ethanol 0.1%) or 4-hydroxytamoxifen (OHT: 100 nM) every three days 
over the next six days prior to plating for growth assay without any further treatment. Cells 
where fixed in glutaraldehyde and crystal violet retention was quantified. Results are shown as 
relative growth compared to cells expressing ER with only control treatments (see 
Supplementary Figure 6 E-F for full data set). C, Growth assay of co-treatments or serial 
treatments of PC3 cells with palbociclib and/or camptothecin. Co-treatments: PC3 cells were 
treated with vehicle control or 500 nM palbociclib (+ Pal) along with control or various doses 
of camptothecin (+1: 1nM, +5: 5nM, +25: 25nM) every three days for six days. Serial 
treatments: PC3 cells were first treated with vehicle control (-) or 500 nM palbociclib (+ Pal) 
every three days for six days and then treated with vehicle control or various doses of 
camptothecin (+1: 1nM, +5: 5nM, +25: 25nM) without further palbociclib. Growth was 
estimated by a crystal violet retention assay. (Test-student p values as follow: * = p<0.05, 
**=p<0.01, ***=p<0.005). 
 
Figure 2.7: CDK4 and CDK6 phosphorylate DNMT1 protecting it from autophagy-
mediated degradation. 
 A, Immunoblots for the indicated proteins using extracts of PC3 cells expressing or not PML 
and treated or not over six days with CDK inhibitors palbociclib (Pal-100: 100 nM, Pal-500: 
500 nM). B, Immunoblots for the indicated proteins using PC3 cells infected with a control 
non-targeting shRNA (shNTC) or double shRNAs against CDK4 and CDK6 (shCDK4/6). C, 
Immunoblots for the indicated proteins using extracts of IMR90 normal human fibroblast 
stably expressing a control vector, a flag-CDK2 (fCDK2), a flag-CDK4 (fCDK4), a flag-
CDK4 mutant in K35M (fCDK4mut) or CDK6. D, QPCR of DNMT1 mRNA in cells as in 
(C). E, Immunoblots for the indicated proteins of PC3 cells treated with control vehicle (Ctrl) 
or with palbociclib (500 nM) (Pal) and treated with control (-) or proteasome inhibitor MG-
132 (10 µM) for 16 hours. Myc stabilization proves proteasome inhibition. F, Immunoblots for 
the indicated proteins using extracts of PC3 cells treated for 24 hours with control vehicle 
(Ctrl) or palbociclib (500 nM) and treated for three hours with control (Ctrl) or an autophagy 
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inhibitor bafilomycin A1 (50 nM). G, Immunoblot for Myc-tag and CDK4 of an anti-flag co-
immunoprecipitation experiment of HEK293T cell extracts expressing a vector flag or flag-
CDK4 along with MycDNMT1. H, Autoradiography for 32P incorporation and Ponceau red 
staining of an in vitro kinase assay with purified CDK4/CyclinD and 32P-ATP with or without 
purified GST-DNMT1. I, Peptide sequences identified by mass spectrometry from gel purified 
GST-DNMT1 after in vitro kinase assay as in (H) but with cold ATP. Phospho-serine 127 was 
identified in all 43 peptides sequenced. Phospho-serine 954 was identified in all eight peptides 
sequenced. Phospho-serine 247 was identified in one of six detected peptides. J, Model for 
CDK4/6 inhibitors sensitizing cells to senescence as revealed in our study. 
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2.3.8  Figures 
 
Figure 2.1: CDK4/6 kinases suppress PML-induced senescence. 
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Figure 2.2: CDK inhibitors enhance PML-mediated growth arrest and senescence 
in tumor cell lines. 
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Figure 2.3: CDK inhibitors enhance PML-mediated growth arrest and senescence 
in xenografts. 
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Figure 2.4: Transcriptome analysis reveals methylation sensitive genes as targets of 
PML and CDK-inhibitors. 
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Figure 2.5: A DNA methylation inhibitor enhances PML-mediated growth arrest 
and senescence in tumor cell lines. 
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Figure 2.6: Palbociclib or 5-Aza-dC confers sensitive to PML- or camptothecin-
induced permanent growth arrest. 
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Figure 2.7: CDK4 and CDK6 phosphorylate DNMT1 protecting it from autophagy-
mediated degradation. 
 
 84 
2.3.9 Supplementary data  
2.3.9.1 Supplementary Material and Methods 
ShCDK4/6 vectors 
CDK4 and/or 6 shRNAs were cloned in retroviral vectors pMLP (MSCV based vector 
expressing shRNA in a miR30 context) or pMLPX (153).  
 
Table 2.1: ShRNA mature sequences:  
shNTC  5’-AATTGATGTGTTTAGTCGCTAG-3',  
shCDK4 #1  5’-TCGAGAGGTAGCCATTCTCAGA-3’,  
shCDK4 #2  5’-AACAACCACGGGTGTAAGTGCC-3’,  
shCDK6 #1  5’-TAGCTGGACTGGAGCAAGACTT-3’,  
shCDK6 #2  5’-AGATCGCGATGCACTACTCGGT-3’.  
 
Quantitative real-time PCR 
 
Table 2.2: Primers used for quantitative real-time PCR are as follow (using both 
HMBS and TBP as housekeeping genes in all experiments) 
Target gene 5’ forward primer (5’->3’) 3’ reverse primer (5’->3’) 
BLM GGATCAGAAAGCACCACCCATA TCAGCCATGGTGTCACATTC
CDC2 CCACTTTTCCATGGGGATTCAG GATTCAGTGCCATTTTGCCAGA
CDC6 AACCGTAACCTGTTCTCCTCGTG TGGGGAGTGTTGCATAGGTTGT
CENPA AATGGATTCTGCGATGCTGTCTGG TTTTCAGGCCTTTGGAACGGTGTT
CENPF TGCAGAGTCCTCCAAACCAACA GCTCCGCTGAGCAACTTTGAC
EDN1 CCTGCTCGTCCCTGATGGATAA AGTCCATACGGAACAACGTGCT
FANCD2 CCTTAGTAGCCGACTGAAACAGG TGCAAGTAATGGACGCTCTG
FOXM1 TCCCTACTTTAAGCACATTGCCAAG ACATGTCGTGCAGGGAAAGGTT
GADD45A TTGCAATATGACTTTGGAGGAA  CATCCCCCACCTTATCCAT  
HMBS AACGGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC
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HMGB2 GAAAAAGGACCCCAATGCTCCT ATCTTTGGGCGATGTTCAGAGC
IFI44L TGTGACACTATGGGGCTAGATGG TGCTCAGGTGTAATTGGTTTACGG
IL23A TGATGTTCCCCATATCCAGTGTG TCAGACCCTGGTGGATCCTTTG
KI67 AGAAGACAGTACCGCAGATGA CGGCTCACTAATTTAACGCTGG
LMNB1 TGAAGGCAGGCCAGACTGTTAC GCCCCACGAGTTCTGGTTCTT
MCM6 ATCCCTCTTGCCAAGGATTT GAAAAGTTCCGCTCACAAGC
MSH2 TCAGAGCCCTTAACCTTTTTCAGG TGAGGGGTTTTACACTTATTCAGCA
P107 CCTGGTCAAACTCTTCTAACAATGG TCTCCAGCATCATTTGCGACAC
P130 AGACTAGGAGACATGGATTTATCTGG CCCAGGAGGCTTATAAGAAAAAGTGA
P16 INK4A CCCAACGCACCGAATAGTTACG GCTGCCCATCATCATGACCT
P21 ACCCTTGTGCCTCGCTCAGG GCGTTTGGAGTGGTAGAAATCTGT
POLE2 GGATCCTGGATTTGGTTCCATC TGTGTACAGTACTGAATTCTGCAAGGA
Retroviral  
RNA 
CTCTGCAGAATGGCCAACCTTT
 
CTTCCCAGGTCACGATGTAGGG
RB GGATCAGATGAAGCAGATGGAA TGCATTCGTGTTCGAGTAGAAGTC
SERPINE1 CGGTCAAGCAAGTGGACTTTTC GGCTCCTTTCCCAAGCAAGTT
TBP GCTGGCCCATAGTGATCTTTGC CTTCACACGCCAAGAAACAGTGA
 
Immunoprecipitation (IP) 
5 x 106 HEK 293T cells were seeded in 10 cm tissue culture dishes and grown for 24 
hours. Three 10 cm plates for each condition were transiently transfected using the calcium 
phosphate method with 8 µg of pcDNA3-Myc-DNMT1 and 12 µg of either pLPC-3xFLAG or 
pBabe-3xFLAG-CDK4 (WT). After 24 hours, cells were scraped into IP buffer (50mM Tris-
HCl, pH 7.9, 1mM EDTA, 0.1mM EGTA, 12.5mM MgCl2, 400mM NaCl, 20% glycerol, 1% 
Triton X-100 (BioShop, Burlington, ON), 0.1% SDS and 1X Complete-EDTA free protease 
inhibitor cocktail (Roche Applied Science). Cell lysates were kept on ice for 15 min and then 
sonicated 40 seconds at the lowest intensity. Cell lysates were cleared by centrifugation at 
13,000 RPM for 1 min. Anti-FLAG M2 Affinity Gel (Sigma-Aldrich) was incubated for 1 
hour at 4oC in IP buffer containing 2.5% BSA, 0.16 µg/µL salmon sperm DNA (Sigma-
Aldrich) and 0.16 µg/µL E. coli tRNA (Sigma-Aldrich) and then washed twice with IP buffer 
before immunoprecipitation for 30 min at 4oC. Immunoprecipitates were recovered by quick 
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spin and washed three times 30 min in IP buffer. Proteins of immunoprecipitates and total cell 
lysates were separated by SDS-PAGE and transferred to nitrocellulose membranes and 
analysed by Western Blotting with anti-c-Myc rabbit polyclonal (1:1000, clone A-14, sc-789, 
Santa Cruz Biotechnology) and anti-CDK4 rabbit polyclonal (1:250, clone C-22, sc-260, Santa 
Cruz Biotechnology). 
 
In vitro protein phosphorylation 
0.5 µg of active CDK4/CyclinD1 (Cat#: C0620, Sigma-Aldrich, St. Louis, MO) was 
incubated alone or with 2 µg of human recombinant GST-DNMT1 (Cat#: 51101, BPS 
Bioscience, San Diego, CA) in kinase assay buffer I (Cat#: K01-09, SignalChem, Richmond, 
BC) (25mM MOPS (pH 7.2), 12.5mM ß-glycerol-phosphate, 25mM MgCl2, 5mM EGTA, 
2mM EDTA and 0.25mM dithiothreitol (DTT) with 40µM ATP and 1µCi (γ-32P)ATP at 30°C 
for 30 min. Then Laemmli buffer was added to stop the reactions. Samples were boiled at 
98°C for 5 minutes prior to SDS-PAGE migration and transfer to nitrocellulose membranes. 
32P incorporation was analysed by autoradiography. Membranes were stained with Ponceau 
red to see total protein levels.  
For identification of phosphorylated sites on DNMT1 by CDK4/CyclinD1, we 
performed the same kinase assay with “cold” ATP. Then GST-DNMT1 was separated by 
SDS-PAGE, stained with Coomassie and the band of GST-DNMT1 was cut for analysis by 
mass spectrometry by The Center for Advanced Proteomics Analyses at the Université de 
Montréal / Institute for Research in Immunology and Cancer. Gel bands were destained with 
50% acetonitrile, the proteins reduced with 5 mM TCEP for 30 min at RT and alkylated with 
20 mM 2-chloroacetamide for 1 hour at RT. The proteins were subjected to in gel digestion 
with 300 ng of trypsin for 16 hour at 37C. Peptides were extracted with 60% acetonitrile, 1% 
formic acid for 10 min and lyophilized to dryness in a speed vacuum. The peptides were 
analyzed on an orbitrap q-Exactive plus instrument operated in positive ion mode. Peptides 
were resolved on a reverse-phase analytical column (18 cm length, 150 µm i.d.). MS survey 
scans are acquired at a resolution of 70,000 at m/z 200 with a mass window of m/z 300-1,500, 
maximum injection time of 200 ms and an automatic gain control of 1e6. MS/MS scans were 
acquired using a data dependant acquisition approach with a Top12 method. The precursor 
isolation window was set to 2 m/z with an HCD normalized collision energy of 27, and a 
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resolution of 17,500 at m/z 200. Automatic gain control (AGC) target values for MS/MS scans 
were set to 2e5 with a maximum fill time of 200 ms. 
The bioinformatics search was performed with PEAKS studio version 7.5 using the 
uniprot human proteome database. The precursor search peptide tolerance was set to 10 ppm, 
and fragment ion tolerance to 10 ppm since the fragment ions are analyzed in the orbitrap. The 
maximum allowed number of missed cleavage was set to 2 using trypsin as enzyme with a 
maximum of 4 modifications per peptide. Carbamidomethylation of cysteine residues was set 
as a fixed modification, while methionine oxidation, asparagine and glutamine deamidation, 
phospho (STY), and protein N-acetylation were set as variable modifications. Data were 
filtered with a false discovery rate (FDR) set to 1%, and the minimum peptide length was set 
to 6. 
 
Antibodies 
Primary antibodies used were: anti-PML mouse monoclonal (1:250, Santa Cruz 
Biotechnology PG-M3), anti-PML rabbit polyclonal (1:1000, Bethyl Laboratories, A301-
167A), anti-RB mouse monoclonal (1:1000, Cell Signalling #9309), anti-phoshoSer795-RB 
rabbit polyclonal (1:1000, Cell Signalling #9301), anti-CDK4 mouse monoclonal (1:1000, 
Cell Signalling #2906), anti-CDK6 rabbit polyclonal (1:1000, Santa Cruz Biotechnology #sc-
177), anti-CDK2 rabbit polyclonal (1:200, Santa Cruz Biotechnology #sc-163), anti-LC3B 
rabbit polyclonal (1:1000, Cell Signalling #2775), anti-SQSTM1/p62 rabbit polyclonal 
(1:1000, Cell Signalling #5114), anti-DNMT1 rabbit polyclonal (1:1000, Cell Signalling 
#5032), anti-phosphoSer154-DNMT1 rabbit polyclonal (1:1000, Thermo Scientific PA5-
12963), anti-C-Myc rabbit polyclonal (1:1000, Cell Signaling #5605), anti--tubulin 
(1:20000, Sigma-Aldrich #T6074). Signals were revealed after incubation with horseradish 
peroxidase goat anti-mouse or anti-rabbit secondary antibodies (1:3000, BioRad #1706516 
and #1706515) by using enhanced chemiluminescence (ECL, GE Healthcare Life Sciences 
#RPN2106) or Clarity ECL (Bio-Rad #1705060). 
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2.3.9.2  Supplementary Figure Legends 
 
Supplementary Figure S2.1: Disabling RB bypasses PML-induced senescence in normal 
human fibroblasts.  
A, Immunoblots for the indicated proteins in IMR90 cells co-infected with a retroviral vector 
expressing PML-IV (PML) and either a vector control (V) or derivatives expressing CDK4 or 
CDK6. Samples were obtained from cell populations ten days after infection. B, Proliferation 
marker KI-67 qPCR from samples of cells as in A. C, Senescence-associated-β–galactosidase 
assay (SA-β-Gal) in cells expressing either a vector control (V) or PML and a vector control 
(V) or derivatives expressing CDK4 or CDK6. D, Summary of qPCR data for E2F targets 
gene expression showing cell cycle genes and DNA repair genes from samples of cells as in 
(A). Expression levels were encoded in a color gradient that helps to visualize the degree of 
derepression according to the intensity of the green color. E, QPCR for RB family members 
(RB, p107 and p130) in cells expressing PML and the indicated shRNAs. F, Knockdown of 
RB was sufficient to reduce PML-induced senescence and restore cell proliferation. Data 
shows percent of SA-β-Gal positive cells in cells expressing PML and the indicated shRNAs. 
ShNTC is a non-targeted shRNA control. G, Proliferation marker Ki-67 qPCR from samples 
of cells as in (F). H, Summary of qPCR data for E2F targets gene expression showing cell 
cycle and DNA repair genes in samples as in (F). Expression levels were encoded in a color 
gradient that helps to visualize the degree of derepression according to the intensity of the 
green color. 
 
Supplementary Figure S2.2: Cyclin-dependent kinase inhibitors p21 and p16INK4A 
cooperate with PML to inhibit cancer cell proliferation.  
A-B, QPCR for p16INK4a (A) and p21 (B) overexpressions. C-D, Relative growth of U2OS 
cells (C) and PC3 cells (D) infected with empty vector (V) or a vector expressing PML as well 
as a vector expressing either p21 or p16INK4A.  
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Supplementary Figure S2.3: CDK inhibitors enhance PML-mediated growth arrest and 
senescence in tumor cell lines.  
A-B, Relative growth of U2OS cells infected with empty vector or a vector expressing PML 
treated with flavopiridol (Fla) (A) or palbociclib (Pal) (B) at the indicated doses for six days. 
Error bars: mean +/- SD *=p<0.05, **=p<0.01 and ***=p<0.005 using Student t-test. C, 
Fluorescent imaging of LC3B and p62 forming foci, as markers of autophagy vesicles (red) in 
U2OS cells expressing empty vector (V) or a vector expressing PML and treated with 120 nM 
flavopiridol (Fla), 500nM palbociclib (Pal) or vehicle (Ctrl). Immunofluorescence staining for 
PML is shown in green and nuclear DNA (DAPI) in blue. Scale bar= 10 µM. D-E, 
Quantification of LC3B and p62 foci per cells of immunofluorescence performed in (C). Cells 
presenting more than 100 foci where considered positive for induction of autophagy. Three 
sets of 100 cells were looked at. Error bars: mean +/- SD, *=p<0.05, **=p<0.01 and 
***=p<0.005 using Student t-test. 
 
Supplementary Figure S2.4: Gene Set Enrichment Analysis (GSEA) showing homology 
to our gene expression profiling. 
GSEA of microarray data comparing PML-expressing PC3 cells with PC3 cells bearing a 
vector control (A-F) or PC3 cells treated with palbociclib vs. PC3 cells treated with vehicle 
(G-J). Sets showing significant enrichment with FDR values smaller than 0.11 are shown. 
Comparing control cells with PML expressing PC3 cells revealed upregulation of interferon 
target genes (A and B) while genes involved in the cell cycle were downregulated (C). Many 
of the PML-downregulated genes overlapped with E2F3 targets (D) as expected from the 
known effects of PML on E2F-targets gene expression. PML inhibited genes in the EGFR 
signaling pathway (E) and triggered a quiescence gene expression pattern (F), which is 
consistent with the induction of a reversible cell cycle arrest.  Comparing PC3 cells treated 
with palbociclib with PC3 cells treated with vehicle revealed a downregulation of cell cycle 
genes (G), E2F3 response genes (H) and EGFR targets (I). Palbociclib also increased the 
expression of genes in the interferon gamma signaling reactome (J). Since PML or palbociclib 
were unable to trigger a stable senescence in this tumor cell line, these changes are obviously 
not sufficient to trigger bona fide senescence. 
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Supplementary Figure S2.5: Gene Set Enrichment Analysis (GSEA) showing homology 
to our gene expression profiling. 
 A-L, GSEA of microarray data comparing PML-expressing PC3 cells treated with palbociclib 
with PC3 expressing PML or treated with palbociclib. Sets showing significant enrichment 
with FDR values close to 0 are shown. Interestingly, genes involved in chromosome 
maintenance were downregulated in cells treated with PML and palbociclib (Supplementary 
Fig. 5G and H), while genes involved in steroid biosynthesis (Supplementary Fig. 5I and J) 
and olfactory receptors (Supplementary Fig. 5K and L) were enriched in PML/palbociclib 
treated samples suggesting novel pathways that regulate senescence. 
 
Supplementary Figure S2.6: Palbociclib or 5-Aza-dC sensitise cells to PML-induced 
irreversible growth arrest.   
A-B, Activation of PML-ER in normal human fibroblasts induces an irreversible senescent 
cell cycle arrest after three days of induction. C-F, The data set corresponds to figure 6 but 
includes additional controls with the ER empty fusion vector (V-ER) to discard the effects of 
OHT. C-D, Schematic of the experiment timeline and results. PC3 cells expressing a V-ER or 
PML-ER fusion are first treated (left) with palbociclib (Pal-100: 100 nM or Pal-500: 500 nM, 
every three days for six days) or (right) 5-Aza-dC (A-120: 120 nM or A-250: 250 nM, once 
over three days and then kept in normal medium for another three days). Cells are then treated 
with ethanol 0.1% (CTRL: control) or 4-hydroxytamoxifen (OHT: 100 nM) every three days 
over the next six days without further palbociclib or 5-Aza-dC. Growth was estimated by a 
crystal violet retention assay. Results are shown as relative growth compared to cells 
expressing V-ER with only control treatments.  E-F, As in (C-D) but the initial palbociclib or 
5-Aza-dC temporary treatment is followed by a temporary treatment with control (CTRL: 
ethanol 0.1%) or 4-hydroxytamoxifen (OHT: 100 nM) every three days over the next six days 
prior to plating for growth assay without any further treatment. Cells were fixed in 
glutaraldehyde and crystal violet retention was quantified. Results are shown as relative 
growth compared to cells expressing V-ER with only control treatments. 
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Supplementary Figure S2.7:  Palbociclib decreased DNMT1 levels in a dose dependent 
manner 
A, Fluorescent imaging of DNMT1 (red) in cells PC3 cells infected with empty vector (V) or a 
vector expressing PML treated with vehicle (Ctrl) or either 100 nM or 500 nM palbociclib 
(Pal-100 and Pal-500 respectively). PML staining is shown in green and nuclear DNA (DAPI) 
in blue. Scale bar= 10 µM. B, Results of mass spectrometry (MS) for DNMT1 in vitro 
phosphorylation. A schematic representation of DNMT1 sequence is presented with yellow 
highlights showing peptide sequences covered by the analysis at least twice and green 
highlights pointing to amino acids with various modifications found at least once. Please note 
that region in a dashed orange box indicate the region where DNMT1 isoform 1 and 2 differ of 
16 amino acids (aa) changing the position of certain aa when referring to modifications The 
serine in a gray circle shows Ser-170 (Ser-154 as called by other authors) for which 
immunoblots are presented in figure 7 and which was not covered in the MS analysis. Serines 
in a red circle represent phosphorylated serines identified in the MS analysis with the MS 
spectrum presented under the protein sequence. Of note, CDK consensus phosphorylation 
sequence is “S/T P X K/R” with the first serine or threonine being the phosphorylation target. 
We thus underlined the aa following the identified phosphorylated serines. Ser-127 and Ser-
970 (or 954) follow the consensus site. Scale bar = 10 µM 
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Supplementary Figure S2.1: Disabling RB bypasses PML-induced senescence in 
normal human fibroblasts. 
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Supplementary Figure S2.2: Cyclin-dependent kinase inhibitors p21 and 
p16INK4A cooperate with PML to inhibit cancer cell proliferation. 
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Supplementary Figure S2.3: CDK inhibitors enhance PML-mediated growth arrest 
and senescence in tumor cell lines. 
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Supplementary Figure S2.4: Gene Set Enrichment Analysis (GSEA) showing 
homology to our gene expression profiling. 
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Supplementary Figure S2.5: Gene Set Enrichment Analysis (GSEA) showing 
homology to our gene expression profiling. 
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Supplementary Figure S2.6: Palbociclib or 5-Aza-dC sensitise cells to PML-
induced irreversible growth arrest. 
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Supplementary Figure S2.7: Palbociclib decreased DNMT1 levels in a dose 
dependent manner. 
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3 Quantitative SUMO proteomics reveals the 
modulation of many PML nuclear body 
associated proteins and an anti-senescence 
function of UBC9 
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3.1 Presentation of article 2 
 
Protein SUMOylation considered one of the major regulators of protein function 
including: protein stability, intracellular localization, transcriptional activity, and protein–
protein interactions. This modification regulates a wide range of cellular processes such as: 
transcription, replication, chromosome segregation, nuclear transport, cell-cycle progression, 
DNA repair, and signal transduction. Importantly, SUMO conjugation has been repeatedly 
associated to stress response and with senescence modulation. PML is well known to be 
SUMOylated, and more importantly, PML-NBs are known to be hubs for SUMO. Also, 
SUMOylation of PML regulates the localization of other components in PML-NBs. A number 
of proto-oncogenes and tumor suppressors, such as Mdm2, c-Jun, c Myb, BLM, TEL, p73α, 
SMAD4, p53 and pRB, are subject to SUMOylation, moreover, certain proteins including 
DAXX, SP100, CBP, and ISG20 are known to accumulate in PML-NBs, and are also 
occasionally SUMOylated in these sub nuclear compartments. PML-NBs are also regulated by 
stress and also have been implicated in the senescence response. In this second study we 
wanted to elucidate the role in SUMOylation in RAS-induced senescence, we performed a 
large scale profile of the SUMO proteome of senescent cells that allowed us to identify SUMO 
sites that are differentially regulated during the senescence process. In this sense, RAS 
expression induces expression of intrinsic PML and PML-NBs formation.    
3.2  Author’s contribution for paper 2 
 
Francis P. McManus and Véronique Bourdeau are first coauthors and contributed equally to 
this work. Both designed the experiments. Francis P. McManus, Véronique Bourdeau, 
Stéphane Lopes-Paciencia, Lian Mignacca, Frédéric Lamoliatte and me, we all conducted 
experiments.  
 
 
 
 101 
3.3  Article 2 
 
 
Quantitative SUMO proteomics reveals the modulation of 
many PML nuclear body associated proteins and an anti-
senescence function of UBC9 
 
 
Francis P. McManus1, Véronique Bourdeau2, Mariana Acevedo2, Stéphane Lopes-
Paciencia2, Lian Mignacca2, Frédéric Lamoliatte3, Gerardo Ferbeyre2* and Pierre 
Thibault1,3* 
 
1Institute of Research in Immunology and Cancer, 2Department of Biochemistry and 
Molecular Medicine, 3Department of Chemistry, Université de Montréal, Montréal, QC H3C 
3J7, Canada 
 
 
*Correspondence:  
Pierre Thibault, Phone: (514) 343 6910, E-mail: pierre.thibault@umontreal.ca 
Gerardo Ferbeyre, Phone: (514) 343 7571, E-mail: g.ferbeyre@umontreal.ca 
 
 
Running title: Dual Role of SUMOylation on Senescence 
Key words: SUMO/Senescence/RAS/UBC9/PML nuclear bodies/LC-MS/MS 
 
 
 
 102 
3.3.1 Abstract 
Several regulators of SUMOylation have been previously linked to senescence but 
most targets of this modification in senescent cells remain unidentified. Using a two-step 
purification of a modified SUMO3, we profiled the SUMO proteome of senescent cells in a 
site-specific manner. We identified 25 SUMO sites in 23 proteins that were significantly 
regulated during senescence. Of note, most of these proteins were PML nuclear body (PML-
NB) associated, which correlates with the increased number and size of PML-NBs observed in 
senescent cells. Interestingly, the sole SUMO E2 enzyme, UBC9, was found more 
SUMOylated in senescence on its Lys-49. Functional studies of a UBC9 mutant in Lys-49 
showed a decreased association to PML-NBs and the loss of UBC9’s ability to delay 
senescence. We thus propose both pro- and anti-senescence functions of protein 
SUMOylation, and discuss our findings in light of the well-known association between UBC9 
expression and cancer.  
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3.3.2  Introduction 
 
The genomic DNA of organisms and cells are under constant stress causing the 
accumulation of mutations, adducts and other detrimental alterations to the genetic code and 
potentially harmful mutations. Many cellular mechanisms of defense have evolved to reduce 
the onset of tumors and potential cancer development. One such mechanism is cellular 
senescence where cells undergo cell cycle arrest in response to various stressors (293, 294). 
Multiple triggers for the onset of senescence have been documented. While replicative 
senescence is primarily caused in response to telomere shortening (295, 296), senescence can 
also be triggered early by a number of exogenous factors including DNA damage, elevated 
levels of reactive oxygen species (ROS), high cytokine signaling, and constitutively-active 
oncogenes (such as H-RAS-G12V) (114, 297). Dysregulation of HRAS has also been linked 
itself to aberrant levels of ROS due mitochondrial dysfunction contributing to the senescent 
phenotype (298, 299). The node that connects all of these stressors to the same cellular fate 
remains elusive and has been the subject of much research. Although the biomarkers for 
senescence depend vastly on the basis of the stressor and cellular context, several markers 
have emerged such as the activation/upregulation of proteins from the DNA damage response 
pathway, increase in the number and the size of the promyelocytic leukemia (PML) nuclear 
bodies (PML-NBs), reduction in lamin B1 expression, depletion of linker histone as well as 
upregulation of p53 and some of its target genes, including DEC1(114, 163, 253, 297, 300-
302). 
PML-NB formation is driven by the PML proteins. These nuclear structures are 
regulated by stress and allow for the sequestration of target proteins for their regulation and/or 
post-translational modification. PML-NBs have been implicated in senescence, DNA damage, 
apoptosis, defense against viral infection and elevated ROS levels (236, 253). They are also 
known to be hubs for the protein small ubiquitin-like modifier (SUMO). Indeed, several 
proteins including p53, DAXX, SP100, CBP, and ISG20 are known to accumulate in PML-
NBs, and are also occasionally SUMOylated in this sub nuclear compartment (303, 304). 
There is still debate as to what causes the nucleation of PML-NBs though earlier reports 
suggest that PML itself must be SUMOylated for body formation (171). Since PML has a 
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SUMO interacting motif (SIM) and at least three well documented SUMO sites, it is thought 
that the SUMOylated regions of a PML protein interacts with the SIM of the neighboring 
PML allowing for a polymerization effect, ultimately leading to the formation of the mature 
assemblies (305, 306). A recent paper by Lallemand-Breitenbach et al. refutes this hypothesis 
and supports a model where PML oligomerization into PML-NBs does not require 
SUMOylation, nor its SIM, but rather requires PML oxidation (236). Upon PML-NB 
formation, UBC9 (the only SUMO conjugating enzyme) is recruited to the nuclear bodies 
where SUMOylation is activated toward PML (236). Subsequently, proteins that contain a 
SIM will associate to the PML-NBs where they can also be SUMOylated. The SUMOylated 
partner proteins are ultimately sequestered in the PML-NBs via a SUMO-SIM interaction with 
PML. 
Protein SUMOylation plays an important part in cellular functions and has been linked 
to changes in DNA repair, intracellular trafficking, cell signaling and stress responses (307-
311). Protein SUMOylation is a post-translational modification (PTM) that is targeted to the ε-
atom of certain Lys residues resulting in branched protein formation. SUMOylated Lys 
residues are often located in the consensus motif composed of ψKxE, where ψ represents a 
large hydrophobic residue and x any amino acid (312). Three SUMO paralogues are 
ubiquitously expressed in mammalian cells: SUMO1, SUMO2 and SUMO3. SUMO2 and 
SUMO3 are virtually identical and share 96% sequence identity and are often used 
synonymously. SUMO1 and the other SUMO paralogues only share 45% sequence identity 
(313). An important distinction between SUMO1 and the other paralogues is its failure to 
efficiently form poly-SUMO chains, where a new SUMO protein is attached to the lysine of 
another SUMO to create highly branched networks (314).  
The SUMO pathway draws a high degree of parallel with the ubiquitylation network. 
Both mechanisms necessitate a machinery with three enzymatic activities: E1 (activating), E2 
(conjugating) and E3 (ligating) (221). For SUMOylation, the SAE1/SAE2 heterodimer (E1) 
activates the C-terminal carboxyl moiety of SUMO with the aid of ATP. The activated SUMO 
protein is transferred to UBC9 (E2) via a trans-thiolation reaction. SUMO is subsequently 
transferred to the targeted Lys residue of the substrate protein with or without the aid of an E3 
ligase accessory protein (226, 315). Recent advances in proteomics based approaches that 
allow to identify SUMO sites in large scale studies has granted much insight into substrate 
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SUMOylation since the motif/region of the protein being modified can be identified. Vertegaal 
et al. used a Lys-deficient SUMO3 protein with an N-terminal His-tag to achieve SUMO site 
identification (316). Though this method has yielded roughly 4000 SUMO sites, this avenue is 
not optimal for biological assays since polySUMOylation may play a key role in the cell. 
Other groups have used the already available α-GlyGly antibody to recognize SUMO3 sites, 
while our group has developed a new antibody specific for our modified SUMO3 remnant for 
site identification (316-319).  
The aim of this study is to characterize the role of SUMOylation in H-RAS-G12V-
mediated cellular senescence. The potential role of protein SUMOylation in cellular 
senescence is relevant considering the crosstalk between this modification and ubiquitylation. 
Protein degradation by the proteasome, presumably due to ubiquitylation, is linked to the 
senescent phenotype (153). Moreover, SUMOylation likely plays a role in senescence 
considering that increased levels of ROS are detected during senescence and have the potential 
to activate PML-NB formation and promote substrate SUMOylation and sequestration (236).  
Our SUMO3 proteome of H-RAS-G12V-induced senescence reports 25 SUMO sites that are 
significantly regulated in the senescence process. Many of the targeted proteins are associated 
to PML-NBs. Moreover, the E2 SUMO ligase UBC9 was found to be SUMOylated during 
senescence, suggesting an unsuspected role of UBC9 SUMOylation that can be both pro- or 
anti-senescence particularly depending of its subcellular localization. 
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3.3.3  Materials and methods 
Cells, reagents, and plasmids 
U2OS cells were purchased from American Type Culture Collection (ATCC), IMR90 
cells were obtained from the Coriell Institute and Phoenix ampho packaging cells were a kind 
gift from S.W. Lowe. All cells were cultured in Dulbecco's modified Eagle medium (DMEM; 
GIBCO) supplemented with 10% fetal bovine serum (FBS; Wisent), 2mmol/L L-glutamine 
(Wisent) and 1% penicillin/streptomycin sulfate (Wisent). Retroviral-mediated transductions 
were performed as described previously (253). 
Retroviral vectors pBABE, pBABE-H-RAS-V12, pWZL and pWZL-H-RAS-V12 were 
described previously (253). To express SUMO3m from a retroviral vector, we PCR amplified 
the 6xHis-SUMO3m open reading frame and following sequence from pET28a (233) with the 
following primers: forward 5’-GATCAGATCTGCCACCATGGCTCATCATCATCATC-3’ 
where the BglII restriction site is underlined and the ATG is in bold, and reverse 5’-
CCCTCTAGATGCATGCTCGAGTTAACC-3’, where the XhoI cut site is underlined. The 
insert was introduced by BglII / XhoI digestion and ligation in a modified version of MSCV 
vector, MSCVneo-linker, creating MSCVneo-6xHisSUMO3m. The MSCVneo-linker itself 
was generated to introduce more cloning sites in the MSCV vector, first in MSCV with 
hygromycin resistance (Clonetech) through the ligation of previously BglII / HpaI digested 
MSCVhygro vector and with the following hybridized and digested oligonucleotides: sens-5’-
CACAGATCTGGATCCCAGTGTGGTGGTACGTAGATATCCATCCACTGGCGGCCGC
ACTCGAGCAATGCATGGTTAACCAC-3’ and antisens- 5’-
GTGGTTAACCATGCATTGCTCGAGTGCGGCCGCCAGTGGATGGATATCTACGTAC
CACCACACTGGGATCCAGATCTGTG-3’ where BglII and HpaI sites are underlined. The 
resulting enlarged multi-cloning sites were then transferred from MSCVhygro-linker to 
neomycin resistant MSCV (Clonetech) by digesting and ligating both vector with SgrAI and 
AgeI creating MSCVneo-linker. 
The K49R variant of UBC9 was introduced into the pET28a-MmUBC9 wild type gene 
(320) using site directed mutagenesis with the following primers: forward 5’-
GCTATCCCTGGAAAGAGGGGGACTCCATGGGAA-3’ and reverse: 5’-
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TTCCCATGGAGTCCCCCTCTTTCCAGGGATAGC-3’, where the mutation is underlined.  
Retroviral vectors pLPC-FLAG-UBC9WT and pLPC-FLAG-UBC9K49R were obtained after 
PCR amplification of the two UBC9 sequences from pET28a and subcloned into pLPC-
FLAG(251) with the primers: forward 5’-
CACTTTGAATTCTATGTCGGGGATCGCCCTCAGC-3’, where the EcoRI cut site is 
underlined and reverse 5’-CACTTTCTCGAGTTATGAGGGGGCAAACTTCTTCG-3’, 
where the XhoI cut site is underlined. The UBC9 inserts were digested by XhoI and EcoRI 
prior to their ligation into pLPC-FLAG that was digested with the same enzymes. 
Vector pWZL-Er was obtained by digesting pWZL with NaeI and SalI before ligating 
the Er fragment (ligand binding domain portion of the estrogen receptor) obtained by cutting 
pBABE-Er vector (king gift from Dr. K. Helin) with NaeI and SalI. The pWZL-Er-H-
RASV12 was obtained by subcloning the insert of pBABE-Er-H-RASV12 (kind gift from Dr. 
S. Lowe) into pWZL with BamHI and SalI digestion followed by ligation. The pBABE-GFP-
PML was constructed by PCR amplification of PML (isoform IVa) from pEGFP-C1-PML-IVa 
(king gift from Dr. P. Hemmerich) with the following primers: forward 5’-
AGTCTACGTAAGATCTCGAGCTCAAGCTTCG-3’ where the SnaBI restriction site is 
underlined and reverse 
5’GACTATGCATCAATTGGATGGATATCGCTGATTATGATCAGTTATCTAGA-3' 
where MfeI cut site is underlined. The PCR fragment was cut SnaBI / MfeI and inserted in 
frame after the GFP of pBABE-GFPN (kind gift from Dr. S. Lowe) digested SnaBI / EcoRI. 
Vectors pBABE-F-UBC9WT-PML and pBABE-F-UBC9K49R-PML for the fusion proteins 
were constructed by ligation of NgoMIV / SnaBI digested pBABE-GFP-PML and PCR 
amplifications of both versions of flag-tagged UBC9 with the following primers: forward 5’-
GCTACGCCGGCGTCCATGGACTACAAAGACCATGAC-3’ where the NgoMIV site is 
underlined and reverse 5’-GCTATACGTAACCTACATATGAGGGGGCAAACTTCTTCG-
3’ where SnaBI site is underlined. 
 
Purification of SUMOylated peptides from U2OS cells 
Five biological replicates consisting of U2OS cells (2-5 × 108 cells per replicate) stably 
expressing SUMO3m (6xHis-SUMO3-Q87R-Q88N) were collected by trypsinisation and 
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lysed in 15 mL hypotonic buffer (10mM Tris-HCl, pH 7.6, 1.5mM MgCl2, 20mM 2-
chloroacetamide, phosphatase inhibitors and proteases inhibitors) on ice for 30 min. The 
nuclear fraction was pelleted at 215 g for 10 min. The nuclear fractions was washed with 5 mL 
of hypotonic buffer and the nuclear fraction was pelleted once more at 215 g for 10 min. 10 
mL of Buffer A (6M guanidinium HCl, 0.1M NaH2PO4, 10mM Tris-HCl, pH 8, 10mM 
imidazole and 10mM β-mercaptoethanol) was added to the pellet, sonicated, and centrifuged 
at 16,000g. The soluble fraction was assessed with a Bradford’s assay. Typical protein yields 
ranged from 25-50 mg of nuclear proteins. 1 mg of material was set aside for the proteome 
analysis. 1 mL of 50% Ni-NTA slurry that was pre-equilibrated with buffer A was added for 
every 25 mg of nuclear material. The tubes were gently rotated at 4°C for 16 h. The beads 
were washed once with 10 mL of buffer A, 4 times with 10 mL of buffer B (8M urea, 0.1M 
NaH2PO4, 10mM Tris–HCl, pH 6.3, 10mM β-mercaptoethanol, 20mM imidazole) and once 
with 10 mL of 50 mM ammonium bicarbonate. The beads were resuspended in 10 mL of 
50mM ammonium bicarbonate. Proteins were quantified on the Ni-NTA beads using 
Bradford’s assay. Typically, a yield of 1-3% with respect to the input was obtained. The 
proteins were reduced with 5mM tris (2-carboxyethyl) phosphine (TCEP) for 30 min at 37°C 
and alkylated with 20mM 2-chloroacetamide for 30 min at room temperature. Sequencing 
grade trypsin was added to the beads at 1:50 (w:w) and allowed to digest 16 h at 37°C. 
After digestion, the peptide samples were acidified by adding trifluoroacetic acid to 1% 
and desalting on HLB cartridges (Waters) prior to lyophilization in a Speed Vac. Peptides 
were reconstituted in 500 µL of 50% glycerol in PBS. α-NQTGG antibody cross-linked to 
magnetic protein A/G beads (EMD Millipore) was added to the peptide solution at a 1:2 (w:w; 
antibody:peptide). The tubes were agitated by inversion for 1 h at 4°C. The tubes were then 
place on a magnetic rack, allowing for the beads to settle again and the solution removed. The 
antibody linked beads were washed 10 times with 1 mL of PBS, once with 1 mL 0.1 X PBS, 
once with 1 mL of water and eluted with 3 consecutive portions of 100 µL of 0.2% formic 
acid. The eluents were combined and lyophilized to dryness. The SUMO peptides were 
reconstituted in 25 µL of 0.2% formic acid in water for analysis on the MS. 
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Proteome Sample 
500 µg of nuclear-enriched proteins were reduced, alkylated, digested and desalted as 
for the SUMO peptide preparation. 150 µg of peptide were fractionated using basic porous 
graphite chromatography. Briefly, peptides were solubilized in PGC-A (5 mM triethylamine 
formate in water) at 10 µg/µL and resolved on a PGC column using the following program: 0-
5% PGC-B (5 mM triethylamine formate in 95% acetonitrile) over 5 min, 5-40% PGC-B over 
50 min, and 40-100% PGC-B over 5 min. 81 fractions of 200 µL were collected over the 
course of the chromatography. The fractions were pooled in the following order: A:8-24; 
B:25-32; C:33-40; D:41-48; E:49-53; F:54-64. Fractions A-F were lyophilized in a Speed Vac 
and resuspended in 250 µL of 0.2% formic acid in water for MS. 
 
LC-MS/MS analyses 
A Proxeon EASY-nLC system connected to either a Fusion or Q-Exactive mass 
spectrometer (Thermo Fisher Scientific) operated in positive ion mode was used for all 
experiments. 10 µL of each sample was injected on a reverse-phase pre-column (5 mm length, 
360 µm i.d.) and separated on a reverse-phase analytical column (18 cm length, 150 µm i.d.) 
(Phenomenex). Both columns were manually packed in-house. LC were run at a flow rate of 
0.6 µL/min using a linear gradient of 5-30 % aqueous acetonitrile (0.2% formic acid) over 56 
minutes for the proteome samples or over 106 minutes for the SUMO peptides.  
MS survey scans were performed at a resolution of 70,000 at m/z 200 with a mass 
window of m/z 350-1,500, maximum injection time of 200 ms and an automatic gain control 
of 1e6. MS/MS scans were acquired using a data dependent acquisition approach with a 
Top12 method for the proteome or Top speed of 3 s for SUMO peptides. The precursor 
isolation window was set to 2 m/z with a HCD normalized collision energy of 25, and a 
resolution of 17,500 at m/z 200. Automatic gain control (AGC) target values for MS/MS scans 
were set to 2e5 with a maximum fill time of 60 ms for proteome samples or an AGC of 5e3 
with a maximum fill time of 3 s for SUMO peptides. A dynamic exclusion of the previously 
acquired precursor ions was set to 15 s. 
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MS data processing and statistical analysis 
All raw files were analyzed with MaxQuant (v. 1.5.1.2) using the Uniprot Human 
database (released February 2013) (321, 322). The first search peptide tolerance was set to 20 
ppm, the main search to 10 ppm, and fragment ion tolerance to 7.5 ppm since all ions were 
analyzed in the orbitrap. The maximum allowed number of missed cleavage is set to 3 using 
trypsin as enzyme with a maximum of 5 modifications per peptide. For SUMO peptide 
searches carbamidomethylation of cysteine residues was set as a fixed modification, while 
methionine oxidation, asparagine and glutamine deamidation, lysine SUMO3(NQTGG)(323), 
protein N-acetylation, Lysine-GlyGly, and Phospho (STY) were set as variable modifications. 
For proteome searches carbamidomethylation of cysteine residues was set as a fixed 
modification, while methionine oxidation, asparagine and glutamine deamidation, and protein 
N-acetylation were set as variable modifications. The false discovery rate (FDR) for peptide 
and proteins were set to 1%, and the minimum peptide length was set to 6. The MaxQuant 
output files were analyzed with the Perseus software and all SUMO peptides were filtered 
with a SUMO site probability score of 0.75 or greater. Two-tailed, two sample student T-tests 
were performed in the Perseus software to determine statistical significances in the SUMO site 
fold-changes. SUMO sites present in at least 3 of 5 replicates and with p-values below 0.05 
were considered as statistically regulated. For the proteome analysis, proteins quantified in at 
least 4 of 5 replicates and a permutation-based FDR of less than 5% was considered 
significantly regulated. 
 
Bioinformatic analyses 
The global SUMO motif was generated using a 31 amino acid sequence window 
centered about the target Lys residue. Motifs were extracted using pLOGO v1.2.0 at 
https://plogo.uconn.edu/ (324). For possible senescence related motifs, the senescence 
regulated SUMO site sequences were compared to the identified SUMO proteome used to 
create the global SUMO motif. STRING networks were generated using STRING 
database(325). Networks were generated using all identified SUMOylated proteins in this 
study. Cytoscape 3.2.0 was used to visualize the network (326). Highly interconnected 
subclusters were extracted using the Cytoscape plugin Molecular Complex Detection 
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(MCODE) v. 1.4.1. (327) MCODE settings were the following: haircut, degree cut-off of 2, 
Node score cut-off of 0.2, a maximum depth of 2 and K-Core of 5. Gene ontology term 
enrichments were performed using Database for Annotation, Visualization and Integrated 
Discovery (328). The following terms were analyzed versus the human proteome: Biological 
Processes, Molecular Functions, and Cellular Compartments. 
 
In vitro SUMOylation Assay 
SAE1/SAE2, Mg-ATP, E2-25K used in the in vitro SUMO assay were obtained from 
Boston Biochem (Cambridge, MA). GST-RanGAP fragment 418–587 and GST-PML 
fragment 485–495 were purchased from Biomol International (Farmingdale, NY). MmUBC9 
WT and K49R variant proteins were expressed and purified from the pET28a backbone as 
described earlier (329). In vitro reactions were composed of 0.5 µM substrate (RanGAP, PML 
and E2-25K), 12.5 µM His6-SUMO3 Q92R, 65 nM SAE1/SAE2 and 0.5 µM wild type or 
K49R UBC9 in activity buffer (20 mM HEPES (pH 7.8), 50 mM NaCl and 1 mM DTT). The 
samples were incubated at 37°C for 10 min before the addition of MgATP to 5 mM (except 
for –ATP reactions where MgATP was omitted). At each time point, 5 µL (2.5 pmol of 
substrate) were withdrawn from the reaction mixture and placed into 10 µL of 1.5X laemmli 
buffer. The resulting mixture was loaded on a 4-12% Criterion XT Bis-Tris Gel and was 
electrophoresed in MES SDS-PAGE running buffer at 125 V for 90 minutes. 
 
Western blotting 
Nuclear extracts were boiled for 10 min in Laemmli buffer (10% (w/v) glycerol, 2% 
SDS, 10% (v/v) β-mercaptoethanol and 62.5mM Tris–HCl, pH 6.8) and separated on a 4-12% 
SDS–PAGE followed by transfer onto nitrocellulose membranes. Prior to blocking the 
membrane for 1 h with 5% non-fat milk in TBST, membranes were briefly stained with 0.1% 
Ponceau-S in 5% acetic acid to represent total protein content. Membranes were subsequently 
probed with the indicated primary antibody in blocking solution for 16 h at 4°C: (E2-25K, 
1:2000, ab52930, Abcam; GST, 1:500, ab9085, Abcam; HDAC1 was a kind gift from Dr, 
Alain Verreault; HIS-tag, 1:5000, 631212, Clontech; Histone H3, 1:1000, 9715, Cell 
Signaling; HSP-90, 1:5000, 4874, Cell Signaling; PML, 1:200, H-238, Santa Cruz; RAS, 
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1:1000, 3965, Cell Signaling; SP100, 1:300, ab43151, Abcam; SUMO2/3, 1:2000, 51-9100, 
Zymed; Tubulin, 1:1000, 2144, Cell Signaling; UBC9, 1:1000, 4786, Cell Signaling; 
TRIM28/KAP-1, 1:200; A300-274A, Bethyl Laboratories.) The membranes were incubated 
with secondary antibodies (goat anti-rabbit HRP, AP307P, EMD Millipore, 1:5,000 and goat 
anti-mouse HRP, AP308P, EMD Millipore, 1:5,000) for 1 h. Membranes were washed three 
times with TBST. Membranes were revealed using ECL (GE healthcare) as per the 
manufacturer's instructions, and chemiluminescence was captured on Blue Ray film (VWR) or 
with a BioRad ChemiDac MP Imaging System. 
 
Immunoprecipitation 
Frozen cells collected by trypsinisation from 4 x 15 cm petri were defrosted for 30 min 
on ice in 800 µL of LSB buffer (10 mM Tris-HCl pH 7.6, 1.5 mM MgCl2, 20 mM 2-
chloroacetamide, protease inhibitors (Sigma), 1 mM Na2MoO4, 1 mM Na3VO4 and 4 mM 
sodium tartrate). Samples were briefly vortexed and nuclei pelleted at 215 g for 10 min at 4°C. 
The nuclear pellets were washed with 300 µL of LSB buffer and pelleted again at 215 g for 10 
min at 4°C. The nuclei were resuspended in 500 µL of Extraction buffer (50 mM Tris-HCl pH 
7.6, 1.5 mM MgCl2, 420 mM NaCl, 420 mM EDTA, protease inhibitors (Sigma), 1 mM 
Na2MoO4, 1 mM Na3VO4 and 4 mM sodium tartrate) and sonicated for 5 seconds. Samples 
were clarified by centrifuging at 13 000 x g for 10 min in a microcentrifuge at 4°C. Protein 
quantities were obtained by Bradford assay and normalized for purification inputs (usually 
0.5-1.0 mg). 25 µL of Flag-agarose beads (Sigma) were prewashed 4 times with 500 µL of 
Extraction buffer and added to the protein samples. Volumes were adjusted to 1 mL with 
Extraction buffer. Samples were mixed under rotation for 2 h at 4°C. Immune complexes were 
precipitated at 215 g for 1 min at 4°C. The beads were washed 3 times with 1 mL of ice cold 
Extraction buffer followed by a wash with 1 mL of PBS. Immune complexes were eluted with 
three sequential incubations with 150 µL of Elution buffer (6 % ammonium hydroxide in 
water, pH 11-13). Eluats were combined and lyophilized to dryness in a speed vacuum. For 
LC-MS, samples were reconstituted in 20 µL of 0.2% formic acid in water and injected as 
indicated above. For western blot analysis, samples were resuspended in 100 µL of Laemmli 
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sample buffer (60 mM Tris-HCl pH 6.8, 2 % SDS and 10 % glycerol) and 20 µL were loaded 
on a 4-12% SDS-PAGE. 
 
Fluorescence microscopy 
Immunofluorescences were performed as previously described (251). In short, cells 
were grown on coverslips for at least 16 h before fixing with 4% paraformaldehyde in PBS for 
10 min at 4°C. In the case of SP100 and HSPA5 immunofluorescence, cells were pre-
incubated in CSK buffer (25 mM HEPES, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM 
sucrose). The cover slips were then washed with PBS and the cells were permeabilized with 
0.2% Triton X-100 in PBS/BSA 3%. Cells were then washed in PBS/BSA 3% and incubated 
overnight with the desired combination of the following primary antibodies: anti-
HSPA5/GRP78 (1:100, SPA-826; Stressgen), anti-PML (1:600, G-8, SantaCruz 
Biotechnology, or 1:600, A301-167A, Bethyl Laboratories), anti-FLAG M2 tag (1:400; 
F1804, Sigma-Aldrich), anti-UBC9 (1:150, 4786, Cell Signaling). The cells were then washed 
three times with PBS/BSA 3% and incubated with the secondary antibody of choice (1:4000, 
AlexaFluor 488 goat anti-mouse, AlexaFluor 488 goat anti-rabbit, AlexaFluor 568 goat anti-
mouse, or AlexaFluor 568 goat anti-rabbit; Molecular Probes-Invitrogen) for 1h at room 
temperature. Finally, cells were washed three times with PBS and mounted on slide with 
Vectashield Antifade Mounting Medium containing 1.5 µg/mL of DAPI DNA counterstain. 
Images were captured with an Axio-Image Z2 microscope from Zeiss or with a super 
resolution microscope Axio Observer Z1 Elvyra PS.1 from Zeiss for HSPA5. For super 
resolution structured illumination microscopy, image sets of 5 subsets were taken each after 
rotating the grid by 5 degrees. A high-resolution image was extracted from the raw data using 
the Structures Illumination Microscopy and the Maximum Intensity Projection algorithms at a 
lateral resolution (XY) of 120 nm and an axial resolution (Z) of 300 nm. 
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3.3.4  Results  
Profiling changes in the SUMO proteome of senescent cells  
To determine changes in protein SUMOylation and identify modification sites in the 
proteome of senescent cells, we used a recently developed quantitative proteomic approach 
whereby SUMO proteins are first enriched on an Ni-NTA column prior to tryptic digestion, 
immunoaffinity purification of SUMO remnant peptides, and analysis by mass spectrometry 
(MS) (Fig. 3.1a). Specific enrichment of SUMO peptides was applied to nuclear enriched 
extracts of growing or senescent U2OS cells stably expressing a modified SUMO3 
(SUMO3m) containing a N-terminus His tag and a C-terminus Q87R-Q88N mutation that 
upon tryptic digestion releases a five amino acid SUMO remnant recognized by a custom 
antibody (318).   
Senescence was induced in human osteosarcoma U2OS cells using the oncogene H-
RAS-G12V that promote a senescence growth arrest in these tumor cells, independently of the 
p16 and ARF tumor suppressors (330). We therefore introduced a control vector or a vector 
expressing oncogenic H-RAS-G12V (referred to as RAS) in U2OS cells modified to already 
express the SUMO3m. We studied the resulting senescent phenotype once well established at 
10 days following HRAS transduction. To ascertain the effect of RAS-mediated senescence on 
the global SUMO proteome and to identify subcellular location of protein SUMOylation, cells 
were fractionated into the cytoplasmic and nuclear-enriched fractions prior to western blotting 
(Fig. 3.1b). We noticed that > 90% of the SUMO2/3 signal is observed in the nuclear fraction. 
Accordingly, we opted to fractionate samples and use the nuclear-enriched fraction for SUMO 
site identification and quantification. Interestingly, the global SUMOylation pattern was 
greatly increased upon the onset of senescence (Fig 3.1b). This is in marked contrast to other 
treatments including DNA methylating agents such as methyl methanesulfonate (MMS) and 
replicative stress induction using hydroxyurea, which show no substantial effect on the global 
SUMOylation level in the cell (331). Of note, the greatest gain in SUMO signal upon 
senescence occurs at high molecular weight, suggesting a role for polySUMOylation. 
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The protein level enrichment using the Ni-NTA beads generally reduces sample 
complexity by ~50 fold, and facilitates the subsequent immunoaffinity enrichment of 
SUMOylated peptides (Fig. 3.1c). This tandem purification protocol yields peptide samples 
containing more than 30% SUMO peptides. This level of enrichment is impressive 
considering that the best SUMO enrichment reported in the literature is of the order of 50% 
only when inducing protein SUMOylation by heat shock, a cell stimulus known to 
dramatically increase protein SUMOylation (319, 332). Our methodology allowed for the 
identification of 244 SUMO sites (localization probability >0.75) on 168 proteins 
(Supplementary Table S3.1 and Supplementary Fig. S3.1a). Changes in the proteome were 
also investigated to validate that RAS-mediated senescence phenotype was observed in all our 
senescent samples. Moreover, the proteome analysis allowed corrections of SUMOylation 
levels for any changes in protein abundance occurring during the course of these experiments. 
Accordingly, we fractionated U2OS protein extracts into 6 fractions using basic PGC 
separation to extend the comprehensiveness of proteome analysis. Quantitative proteomic 
analyses enabled the profiling of 1738 proteins, of which 32 proteins were identified as 
SUMO substrates. These analyses also revealed that 65 proteins were significantly regulated 
during senescence (5% FDR) (Supplementary Fig. S3.2 and Supplementary Table S3.2), but 
only 2 of these were also SUMOylated. Both HNRNPUL1 and RSF1 protein abundances were 
decreased in the senescent samples.  
 
Senescence Affects the SUMOylation of PML-Associated Proteins  
  Out of the 244 SUMO sites identified (Supplementary Data S3.1 and Supplementary 
Table S3.1), 25 were statistically regulated by RAS-mediated cellular senescence (after 
proteome correction) based on the analysis of five biological replicates: 13 sites were 
increased upon senescence while 12 were decreased (Table 3.1). These 25 regulated SUMO 
sites are located in 23 proteins, 8 of which are directly associated with PML-NBs, representing 
roughly a third of all regulated targets (gene names shown in bold in Table 1 represent 
proteins known to be associated with PML-NBs (333). We validated five proteins with 
SUMOylation changes by western blot analysis (Fig. 3.2). The western blot results 
corroborated the MS data, where we observed an increase in SUMOylation for PML, SP100 
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and UBC9 and a decrease in SUMOylation of TRIM28 and HDAC1 in senescent cells. 
Interestingly, we observed an increased in polySUMO chains at Lys 41 of SUMO 3 (or Lys 42 
of SUMO 2) in senescent cells (Table 3.1), consistent with the increased SUMOylation pattern 
of high molecular weight proteins (Fig. 3.1b). Whether this poly-SUMOylation linkage is 
characteristic of PML-NBs remains to be elucidated. Of note, we also observed a decrease in 
the abundance of both α-catenin and β-catenin (Supplementary Data S3.2), and an increase in 
total HDAC1 (Fig. 3.2g). These changes in protein abundances suggest suppression of the 
WNT responsive genes in senescent cells, some of which are known to promote cell 
proliferation (334). These observations are consistent with the WNT signaling pathway being 
inhibited during senescence (334). 
Motif analysis around all the SUMO3 sites we found in U2OS was virtually identical 
to those reported in the literature by both our group and others for HeLa and HEK293 cells, 
where SUMO sites reside primarily in the consensus motif ψKxE (where ψ is a hydrophobic 
residue and x any amino acid) (Supplementary Fig. S3.1b) (316, 318, 319). Motif analysis 
comparing the senescence regulated SUMO sites to those identified in the global SUMO 
proteome analyses revealed no enrichment of amino acid or motif around the site of 
SUMOylation (Supplementary Fig. S3.1c). To gain further insights into the role of 
SUMOylation in senescence, we performed a network analysis of the identified SUMO 
proteome to determine the interconnectivity of proteins and the enrichment of particular 
pathways (Fig. 3.3a). Not surprisingly, the majority of the network is centered on SUMO1, 
SUMO2, SUMO3 and the SUMO conjugating enzyme UBC9. However, a prominent network 
around HDAC1 was also observed. MCODE was used to extract the tightest subnetwork from 
the primary network (Fig. 3.3b). The tightest subnetwork comprised SUMO1, SUMO2, 
SUMO3, SAE1, UBC9, PML, SP100 and TRIM28, and was found to be associated with 
PML-NBs. More interestingly, this subnetwork harbored 6 of the 23 proteins whose 
SUMOylation was regulated by senescence. This observation suggests that changes in 
SUMOylation occurring during senescence could be associated with PML-NBs or contribute 
to the target’s localization to nuclear bodies. This is consistent with the increase in the size 
(~2.5 time bigger) and number (~2.5 times more) of the PML-NBs observed upon RAS-
mediated senescence (Fig. 3.3c) (254). Interestingly, one of the strongly regulated SUMO site 
we identified was found on HSPA5 (also known as GRP78), a protein that usually resides in 
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the ER. We performed immunofluorescence experiments on HSPA5 and found that HSPA5 is 
partly located in the PML-NBs of only RAS senescent cells (Fig. 3.3d). This unexpected 
relocalization of HSPA5 highlights the possibility that many other proteins from the list of 
regulated SUMO sites maybe residents of the PML-NBs under specific conditions. 
 
Important role of UBC9’s Lys-49 
UBC9, the sole E2 responsible for all protein SUMOylation in mammalian cells, was 
found to be more SUMOylated at Lys-49 in senescent cells. Since it has been extensively 
documented that lysine residues found to be SUMOylated can often be modified by other 
PTMs such as acetylation and ubiquitylation (316), we examined all detectable PTMs for 
UBC9 during senescence and more specifically the occurrence of modifications at Lys-49. We 
constructed a Flag-UBC9, and performed anti-Flag immunoprecipitations (IP) of nuclear 
extracts from senescent cells followed by MS analysis (Fig. 3.4a). Our IP/MS results garnered 
several PTMs on UBC9, including the SUMOylation of Lys-48 and Lys-49, acetylation of 
Lys-18, Lys-49 and Lys-65, and ubiquitylation of Lys-30. Surprisingly, we did not detect any 
ubiquitylation of UBC9 at Lys-49, though this site was previously reported to be modified in 
large scale ubiquitylome studies (335, 336). However, all studies that have identified Lys-49 
ubiquitylation have used bortezomib, a proteasome inhibitor, suggesting that under steady 
state levels UBC9 is not ubiquitylated since this could lead to its rapid degradation.   
We used the crystal structure of UBC9 (3UIP) to map the identified PTM on the 
protein surface to gain insights on the potential roles of these modifications on structure-
function relationships (Fig. 3.4b). Of all the PTM residues observed, only acetylation of Lys-
18 appears to lead to a possible distinguishable function based on known UBC9 domains, 
since Lys-18 acetylation could affect UBC9’s backside SUMO interaction, which is believed 
to mediate SUMO chain formation (337). Indeed, UBC9‘s Lys-18 is in contact with glutamic 
acid residues of SUMO1 in the 3UIP crystal structure (Glu-83, Glu-84 and Glu-85 of 
SUMO1), which are conserved in SUMO2/3 (Glu-78, Asp-79 and Glu-80 of SUMO3). Hence, 
acetylation of Lys-18 of UBC9 could act as an on/off switch for polySUMOylation or at least 
for the backside SUMO interaction with the SUMO interacting motifs (SIM) of UBC9. 
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In contrast, based on a general topological level, SUMOylation of Lys-49 could 
promote a fixed appendage on UBC9 that favors its interaction with SIM containing proteins. 
Moreover, Lys-49 is located in close proximity to the backside SIM of UBC9. SUMOylation 
of UBC9 at Lys-49 could not only promote its interaction with SIM containing proteins, but 
also with proteins that are both SUMOylated, and contain a SIM (Fig. 3.4c). The latter 
interaction would provide a mechanism by which bidirectional SUMO-SIM binding generates 
an interaction that is directional and potentially stronger since it would promote two SIM-
SUMO interactions. The cooperativity of multiple SUMO binding interactions has been shown 
in vitro where RNF4 shows a 10-fold increase in affinity for SUMO2 dimers than for SUMO2 
monomers (338). One such candidate protein that is known to have a SIM and be heavily 
SUMOylated is PML. Indeed, PML is known to be heavily SUMOylated at Lys-65, Lys-160 
and Lys-490, and also harbors a SIM towards its C-terminus (236, 306). Since most of the 
senescence regulated SUMO sites are associated with PML-NBs it is plausible that the 
SUMOylation of UBC9 could indeed have a role in its PML-NB association. In addition, Lys-
49 is on the backside of UBC9 far away from the active site (Cys-93) and should therefore not 
alter UBC9 catalytic function, suggesting that it may rather play a role in 
scaffolding/interactions. 
Prior to performing in cell assays, we validated that the K49R variant of UBC9 was 
functional through in vitro assays. Time course SUMOylation of RanGap, of a SUMOylatable 
peptide of PML and of E2-25K showed virtually identical kinetics for the wild type and the 
K49R variant forms of UBC9 highlighting that the K49R alteration has no effect on the 
conjugating activity (Supplementary Fig. S3.3a). To investigate the role of SUMOylation of 
UBC9 at Lys-49 in vivo, we produced cells expressing either a Flag-UBC9-K49R or a Flag-
UBC9 wild type construct and performed Flag IP to determine if UBC9 SUMOylation was 
lost in the K49R variant versus the wild type. Western blots of IP material indeed revealed that 
Lys-49 is the major site of UBC9 SUMOylation by SUMO2/3 (Supplementary Fig. S3.3b). 
This result is in contrast to the major site of SUMOylation observed in vitro for UBC9, which 
is Lys-14 (339). This difference can be attributed to many factors including the fact that in 
vitro assays are conducted without E3 ligases and other scaffold proteins that may physically 
occlude Lys-14 under physiological conditions. The K49R variant of UBC9 is still slightly 
SUMOylated (~10% of the wild type levels) suggesting the presence of other SUMO acceptor 
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sites on UBC9 contributing normally to the band shift or compensating for the loss of Lys-49, 
most likely the Lys-48 that we identified in our Flag IP/MS (Fig. 3.4a). 
To address our hypothesis that SUMOylation of UBC9 promotes its association with 
PML (Fig. 3.4c) and PML-NBs, we opted to use immunofluorescence assays. We found that 
the wild type UBC9 colocalized more readily than its K49R variant in both control cells and 
upon RAS-induced senescence (Fig. 3.4d and Supplementary Fig. S3.4). Importantly, we 
observed a 3-fold increase in colocalization of Flag-UBC9 with PML in RAS-induced 
senescent cells compared to control cells. This is in perfect agreement with our quantitative 
SUMO proteomics approach that showed a 3.36-fold increase in SUMO abundance on Lys-49 
of UBC9 in senescent cells. Similarly, UBC9-K49R mutant localized less efficiently to PML-
NBs in cells treated with arsenic trioxide (ATO), a compound known to induce ROS and to 
promote UBC9 localization to PML-NBs and enhance their formation especially after short 
treatment (Fig. 3.4e and Supplementary Fig. S3.5) (236). Two important pieces of information 
can be drawn from these results. First, UBC9 does not localize readily or accumulates to 
PML-NBs under basal conditions (95% of cells don’t present significant colocalization, Fig. 
3.4d and e) but rather requires a stimulus. Second, the integrity of Lys-49 is important for 
UBC9 colocalization to PML-NBs. We suspect that SUMOylation at Lys-49 is responsible for 
this colocalization though we cannot rule out the possibility that acetylation may play some 
role since we observed this PTM at Lys-49 in our IP/MS results (Fig. 3.4a). However, these 
results also suggest that ubiquitylation of Lys-49 is not responsible for the observed phenotype 
since this PTM was not observed in our IP/MS results, and is therefore absent or at extremely 
low levels under our experimental conditions. 
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Recruitment of UBC9 to PML-NBs Serves an Anti-Senescent Function 
To further understand the biological role of UBC9 SUMOylation at Lys-49 we studied 
the effect of the K49R variant on the onset and amplitude of RAS-induced senescence. Fig. 
3.5a demonstrates that under basal conditions expression of Flag-UBC9 wild type or Flag-
UBC9-K49R has an only slight adverse effect on cellular growth. However, under senescence 
promoting conditions (when Er-RAS is expressed and 4-hydroxytamoxifen: OHT, is added to 
activate it) there is a clear delay for the onset of senescence when cells express the wild type 
form of UBC9 while the K49R variant shows no effect and undergoes senescence like the 
control cells. Considering that the K49R alteration has no effect on UBC9 activity 
(Supplementary Fig. S3.3a) but hinders its association to PML-NBs (Fig. 3.4d and e), these 
results suggest that SUMOylation of UBC9 at Lys-49 promotes its localization to PML-NBs 
where it can serve an anti-senescent function. This concept was further validated by studying 
the effect of expressing UBC9 wild type and K49R in fusion with PML to force their 
localization to follow PML in PML-NBs, and evaluate the effect on both PML-induced 
senescence and RAS-induced senescence. As expected, both UBC9-PML and UBC9-K49R-
PML fusion proteins localized to nuclear bodies (Supplementary Fig. S3.6). Expressing either 
UBC9-PML or UBC9K49R-PML fusion proteins counteracted the senescence induced by 
PML as compared to GFP-PML fusion in control cells (grey curves, Fig. 3.5b). Cells treated 
with OHT to activate Er-RAS (black curves, Fig. 3.5b) entered RAS-induced senescence as 
before but GFP-PML further strengthen the growth arrest while both UBC9-PML or 
UBC9K49R-PML did not do so even in the context of RAS senescence. Bypass of PML-
senescence by fusion with UBC9 is not unique to U2OS cells as we observed similar results in 
normal primary fibroblasts (Supplementary Fig.S3.7). These results further strengthen the 
concept that localization of UBC9 to PML-NBs harbors an anti-senescent property that is 
independent of UBC9 Lys-49 integrity (Fig. 3.5c). 
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3.3.5  Discussion  
This study presents the first large scale SUMO proteome in cells subjected to RAS-
induced senescence. We opted to use the SUMO site identification methodology rather than 
the classic SUMOylated protein approach, since the added information of SUMO site allowed 
for easier biological validation of target proteins, namely UBC9 in this study. Moreover 
quantifying changes in SUMO sites rather than SUMO proteins allowed to quantify multiple 
sites on proteins, as observed for TRIM28 and XPC, that is otherwise not achievable when we 
quantify SUMOylated proteins as a whole (Table 3.1). Despite detecting a considerable 
increase in the intensity of the SUMOylated bands observed by western blot for the senescent 
cells (Fig. 3.1b), the proteomics data revealed that only a few targets had an increased 
SUMOylation (Table 3.1). Although poly-SUMOylation could explain some of the changes 
seen on western lot, there was otherwise almost the same number of up and down regulated 
SUMO sites upon RAS-mediated senescence. This leads to the notion that performing 
SUMO2/3 blots to study the effect of a stressor may not be ideal and that an in depth analysis 
should be adopted. 
The vast majority of the senescence regulated SUMO sites were from proteins 
associated to PML-NBs (Fig. 3.3b). This is in line with their increased number and size in 
senescent cells (Fig. 3.3c). We also studied the localization of HSPA5, a protein known to 
localize to the endoplasmic reticulum, and found the protein to be localized in part in PML-
NBs upon senescence (Fig. 3.3d). This observation strengthens the notion that proteins that are 
not considered residents of PML-NBs could localize to this nuclear sub compartment under 
certain conditions. Therefore, it is likely that more proteins from our regulated list are 
localized in PML-NBs during senescence. 
We found that SUMOylation of UBC9 at Lys-49 is more present in senescent cells 
(Fig. 3.2e) and showed that integrity of this site is important for UBC9 association to PML-
NBs (Fig. 3.4 d and e). This is reminiscent of our observations with the proteasome in 
HEK293 cells, where SUMOylation of members of the proteasome promoted its association to 
PML-NBs in a SIM dependent manner. The mode by which the interaction between UBC9 
and PML occurs could deviate from the simple and classic single SUMO-SIM interaction. 
From the crystal structure of UBC9, we propose that the UBC9/PML interaction is bridged by 
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two SUMO-SIM interactions, where each protein has a SIM and a SUMO, making this 
binding stronger but also directional (Fig. 3.4c). There is a growing body of research that 
describes PML as a genuine SUMO E3 ligase (235, 333). This leads to the idea that dual 
SUMO-SIM interaction may not be unique to UBC9 and PML. Indeed, most SUMO E3 
ligases are SUMOylated and harbor SIM motifs (CBX4, PIAS1, PIAS2, PIAS3, PIAS4, 
RANBP2 and NSE2) (316, 318, 319, 340). Whether these E3 ligase properties promote their 
interactions with UBC9 or PML and PML-NBs remains to be evaluated.  
We also determine that the overexpression of wild type UBC9 produced a delay on the 
onset of RAS senescence whereas the overexpression of the K49R variant entered senescence 
with the same dynamic as the control cells. These observations along with the localization 
SUMOylatable UBC9 to PML-NBs (Fig. 3.4 d and e) suggest that UBC9 in PML-NBs might 
have a different role during senescence than UBC9 localized in other cellular regions. By 
forcing UBC9 into PML-NBs when expressing UBC9-PML fusion proteins in U2OS-S3m 
cells, we demonstrate that SUMOylation activity occurring at nuclear bodies inhibits 
senescence driven by PML expression. The concept of PML-NB associated SUMOylation 
performing an anti-senescent function was unexpected considering that global SUMOylation 
is thought to promote senescence. Indeed, Bischof et al. have shown that activating the SUMO 
conjugation machinery by overexpressing the PIAS4 SUMO E3 ligase induces senescence in a 
p53 dependent manner (225). Moreover, overexpression of PML is known to promote 
senescence by promoting the SUMOylation of p53 by SUMO1 (341). Conversely, inhibiting 
the SUMO deconjugation machinery by knocking down SENP1 also leads to a senescent 
phenotype in a p53 related manner (342). PML has been implicated in the repression of 
multiple E2F target genes during senescence (150) and SUMOylation of proteins in chromatin 
helps to repress multiple genes during senescence (343). Lastly, the western blots depicted in 
Fig. 3.1b indicated that global changes and increases in SUMOylation and/or poly-
SUMOylation on nuclear proteins do occur during senescence. 
To reconcile the conflicting notions of SUMOylation acting both as a senescence 
inducer and inhibitor, we propose the model depicted in Fig. 3.5c. We have shown that 
SUMOylation of Lys49 of UBC9 (a fraction of the overall UBC9) favors its localization to 
PML-NBs and that upon localization it can delay or oppose the onset of senescence. The anti-
senescence function of UBC9 is consistent with its role supporting transformation by 
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oncogenic RAS (344). On the other hand, SUMOylation globally (and presumably mostly 
outside of the nuclear bodies) has been reported to serve a totally different role and to promote 
senescence consistent with the work of Dejean and colleagues who found an increase in the 
SUMOylation of chromatin proteins in senescent cells (343). It is also intriguing that during 
RAS-induced senescence we found a decrease in the SUMOylation of TRIM28 while Luo and 
colleagues found an increase in the SUMOylation of this protein during RAS-driven 
oncogenic transformation (344). TRIM28 is degraded by the ubiquitin-proteasome pathway 
during RAS senescence (153) suggesting that defects in TRIM28 ubiquitination may explain 
its accumulation in tumor cells. 
The role of SUMOylation on the onset of senescence has been documented to be linked 
to p53 activation, but we were unable to either quantify or identify SUMOylation of p53 by 
SUMO3 in our proteomic dataset (341, 345). We did however notice some proteins whose 
levels and SUMOylation occupancies were affected by the senescent phenotype that are linked 
to p53 activation/inactivation. We observed a decrease in both TRIM28 protein and 
SUMOylation levels in response to senescence. TRIM28 is known to interact with the E3 
ubiquitin ligase MDM2 and promote the ubiquitylation and degradation of p53 (346). Hence, 
lower levels of TRIM28 may limit the degradation of p53 during senescence. Also, TRIM28 
depletion was reported to increase the levels of PML-NBs, which are known to stabilize p53 
through phosphorylation and acetylation events (254, 255, 347). Moreover, we observed 
increased levels of SUMOylation of MORC3 in senescent cells, a protein known to promote 
p53-mediated senescence (348). 
Overall, we report changes in SUMOylation levels on various substrates during 
senescence using a proteomic approach. Indeed, we found 25 regulated sites and uncovered 
the unexpected SUMOylation of UBC9 at Lys-49 during senescence. Future studies are 
required to determine the effect of SUMO1 in senescence since this paralog is thought to be 
different than SUMO2 and SUMO3. Moreover, the action of SUMO1 on p53 as a senescence 
activator has been documented, leading to the possibility that other substrates are modulated 
by this paralog during cell cycle arrest (341). It is also likely that other PTMs including 
methylation and acetylation may have important implications on the senescent phenotype, and 
the further understanding of PTM cross-talk will yield a more in depth knowledge of processes 
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mediating cellular arrest. Ultimately, this knowledge will allow for the development of drugs 
or agents that can promote senescence and aid in cancer treatments. 
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Table 3.1: List of SUMO Sites Regulated by Senescence. 
Protein 
Gene 
Name 
SUMO 
site 
FCa Uniqueb 
Known 
PTMc 
78 kDa glucose-regulated protein HSPA5 352 29.58 x 
Sm, Ac, 
Ub 
Actin, cytoplasmic 1 ACTB 113 16.59 x 
Sm, Ac, 
Ub 
Ribosome biogenesis protein BRX1 
homolog 
BRIX1 322 15.58 x Sm, Ub 
NGFI-A-binding protein 1 NAB1 480 8.86  Sm 
Promyelocytic leukemia protein PML 490 8.53  Sm, Ac 
Class E basic helix-loop-helix protein 
40 
BHLHE40 279 8.00  Sm 
Exosome component 10 EXOSC10 583 6.74 x Sm 
Unconventional myosin-Ib MYO1B 287 5.65  Sm, Ub 
Small ubiquitin-related modifier 3 SUMO3 41 3.72  
Sm, Ac, 
Ub 
Small ubiquitin-related modifier 2 SUMO2 42 3.72  
Sm, Ac, 
Ub 
Nuclear autoantigen Sp-100 SP100 297 3.57  Sm 
SUMO-conjugating enzyme UBC9 
UBE2I/U
BC9 
49 3.36  Sm, Ub 
MORC family CW-type zinc finger 
protein 3 
MORC3 740 3.13  Sm 
Zinc finger MYM-type protein 4 ZMYM4 250 0.74  Sm 
Scaffold attachment factor B2 SAFB2 230 0.74   
Putative oxidoreductase GLYR1 GLYR1 176 0.57   
Transcription intermediary factor 1-beta TRIM28 779 0.41  
Sm, Ac, 
Ub 
Transcription intermediary factor 1-beta TRIM28 377 0.36  Sm, Ac, 
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Ub 
Histone deacetylase 1 HDAC1 476 0.31  Sm 
Symplekin SYMPK 483 0.24  Sm 
Zinc finger protein 646 ZNF646 1168 0.19  Sm 
Cleavage stimulation factor subunit 2 CSTF2 189 0.17  Ub 
DNA repair protein complementing 
XP-C cells 
XPC 81 0.16  Sm 
B-cell lymphoma/leukemia 11A BCL11A 799 0.15   
DNA repair protein complementing 
XP-C cells 
XPC 89 0.13   
aFC: fold-change of SUMO site abundance in senescent cells divided by their abundance in 
controls cells, P-value <0.05. 
bUnique SUMO sites are defined as SUMO sites only observed in the senescent samples. FC 
are estimated using imputations of 1.8 standard deviations below the median for samples 
lacking a peptide abundance. 
cKnown PTM reported at this site based on “PhosphoSite Plus” accessed on November 10, 
2016. Sm: SUMOylation; Ac: Acetylation; Ub: Ubiquitylation. 
Gene names in bold correspond to proteins known to be associated with PML-NBs. 
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3.3.7 Figure Legends 
Figure 3.1: Method for SUMO Site Identification. 
(a) Amino acid sequence of human SUMO3 and the modified SUMO3 (SUMO3m) used in 
this work. A 6xHis tag was introduced at the protein N-terminus for Ni-NTA purification. 
Q87R and Q88N alterations were introduced for trypsin cleavage and peptide identification 
purposes, respectively. (b) Western blots for 6xHis, SUMO2/3, histone H3 or tubulin of total 
cell extract (TCE), cytoplasmic fraction (CYT) and nuclear enriched fraction (NUC) from 
U2OS cells expressing SUMO3m and an empty vector (Control) or H-RAS-G12V (RAS). (c) 
Workflow adopted for SUMO3 site identification and proteome quantification. U2OS cells 
expressing SUMO3m were transduced with either an empty or H-RAS-G12V expressing 
vector. Cells were collected 10 days after transduction and fractionated under hypotonic 
conditions. For SUMO site identification, the nuclear enriched fractions were subjected to Ni-
NTA purification, followed by trypsin digestion and finally subjected to immunopeptide level 
enrichment with an antibody recognizing the NQTGG SUMO remnant left on the peptide 
backbone. For proteome analysis, the nuclear proteins were digested with trypsin, desalted and 
fractionated by PGC. The resulting peptides were analyzed on a Q-exactive plus mass 
spectrometer and data analyzed using MaxQuant. 
 
Figure 3.2: Western blot validation of SUMO targets regulated in senescence. 
(a) Ponceau-S staining of 20 µg of nuclear enriched proteins (Crude) transferred on 
nitrocellulose showing the constant loading between U2OS expressing SUMO3m plus a 
control vector (Control) or H-RAS-G12V (RAS) to induce senescence. Extracts from both 
conditions were subjected to Ni-NTA purification to purify proteins SUMOylated with 
SUMO3m and used for blotting in panels c through g. (b) Anti-HSP90 blotting used as loading 
control and anti-RAS blotting depicting the increased levels of steady state RAS in the 
senescent cells (crude extracts as in a). (c-d) Immunoblots showing an increase in total protein 
and an increased SUMOylated PML (c) and SP100 (d) in the senescent samples (cells as in a). 
(e) Anti-UBC9 blot showing an increased SUMOylated UBC9 in the senescent samples (cells 
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as in a). (f-g) Immunoblots showing a decrease in SUMOylated TRIM28 (f) and in 
SUMOylated HDAC1 (g) in the senescent samples (cells as in a). 
 
Figure 3.3: SUMOylated Protein Network.  
(a) STRING network of all SUMOylated proteins with a high interaction confidence (0.7 or 
greater). Proteins whose SUMOylation sites were statistically increased upon RAS-mediated 
senescence are represented in green and those whose SUMOylation sites were decreased are 
shown in red (p-value < 0.05). The size of the nodes correlates to the number of interactors 
while the size of the edge depicts the confidence of the interactions. Highlighted in grey is the 
highest scoring cluster extracted using MCODE. (b) The extracted cluster from (a) is shown 
with its associated GO term and p-value. (c) Double immunofluorescence with anti-SP100 and 
anti-PML antibodies to show colocalization and induction of PML-NBs upon senescence in 
U2OS cells expressing SUMO3m plus a control vector (control) or H-RAS-G12V (RAS) 
(scale bar, 10 µm). (d) Double immunofluorescence with anti-HSPA5 and anti-PML 
antibodies to probe for colocalization upon senescence of cells as in (c) (scale bar, 10 µm). 
 
Figure 3.4: Post-Translational Modifications on UBC9.    
(a) UBC9 is a heavily post-translationally modified protein as shown by the distribution of 
SUMOylation, Ubiquitylation and Acetylation sites identified on UBC9 from IP-MS 
experiments. (b) Modified sites depicted on the UBC9 crystal structure (3UIP), using the color 
scheme from (a). (c) Model of the interaction brought about by the SUMOylation of UBC9 at 
Lys-49 and PML as an example of a protein with both SUMOylated site and SIM (SUMO 
interacting motif). (d) U2OS cells stably expressing SUMO3m and wild type UBC9 (F-UBC9 
WT) or its K49R variant (F-UBC9K49R) were transduced with and empty vector (Vector) or 
H-RAS-G12V expressing vector (RAS). 10 days after transduction, the cells were fixed for 
immunofluorescence. Quantification for the colocalization of UBC9 and PML were obtained 
from double immunofluorescence analyses using monoclonal mouse anti-Flag and rabbit anti-
PML antibodies (scale bar, 10 µm). (e) U2OS cells stably expressing SUMO3m and wild type 
UBC9 (F-UBC9 WT) or its K49R variant (F-UBC9K49R) were treated with 1 µM ATO 
(arsenic trioxide) for 2 h or vehicle treated (Control). Quantification for the colocalization of 
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UBC9 and PML were obtained as in e. (scale bar, 10 µm). (For panels d and e: *P<0.05, 
**P<0.01, ***P<0.005 Student’s t-test with three counts of at least 50 cells. Cells were 
considered positive if at least four colocalization foci were seen). 
 
Figure 3.5: UBC9 Can Exhibit Anti-senescent Properties when Forced to PML-NBs. 
(a) Growth curves of U2OS-SUMO3m cells expressing an Er-H-RAS-G12V construct (fusion 
of the ligand-binding domain of the estrogen receptor with H-RAS-G12V to control its 
activity) (Er-RAS) and transduced with a control vector, Flag-UBC9 wild type (F-Ubc9 WT) 
or Flag-UBC9 with the K49R mutation (F-Ubc9-K49R). Cells grew normally in the absence 
of the inducer for Er-RAS (control, grey curves) but enter senescence upon induction with 4-
hydroxy-tamoxifen (OHT, 100 nM changed every two days, black curves). (b) Growth curves 
of U2OS-SUMO3m cells expressing an Er-H-RAS-G12V (Er-RAS) construct and transduced 
with a control vector, GFP-PML fusion, fusion of PML with wild type UBC9 (F-UBC9 WT-
PML) or its K49R variant (F-UBC9K49R-PML). Cells were either control treated (grey 
curves) to observed growth effect of the fusions alone or treated with 4-hydroxy-tamoxifen 
(OHT, 100 nM changed every two days, black curves) to observe the effects of the fusion in 
the context of RAS-induced senescence. (c) SUMOylation of UBC at Lys-49 favors it 
relocalization to PML-NBs and promotes the SUMOylation of substrates in the nuclear 
bodies, conveying an anti-senescence phenotype. Whereas SUMOylation taking place outside 
of the PML-NBs by the non-SUMOylated UBC9 promotes senescence. 
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Figure 3.1: Method for SUMO Site Identification. 
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Figure 3.2: Western blot validation of SUMO targets regulated in senescence. 
 
 
 
 
 
 
 
 
 
 
 
 
 132 
 
Figure 3.3: SUMOylated Protein Network. 
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Figure 3.4: Post-Translational Modifications on UBC9. 
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Figure 3.5: UBC9 Can Exhibit Anti-senescent Properties when Forced to          
PML-NBs. 
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3.3.9  Supplementary Materials 
 
Supplementary Table S3.1: Statistics on the Identification and Quantification of 
SUMO Sites. 
Control RAS All 
# SUMO Sites Identified  181 243 266 
# SUMO Sites Identified with Localization Probability > 
0.75 171 228 244 
# SUMO Sites Quantified in ≥ 60 % of replicates 90 93 108 
# Up Regulated SUMO Sites (RAS/Control) 13 
# Down Regulated SUMO Sites (RAS/Control) 12 
 
 
 
Supplementary Table S3.2: Statistics on the Identification and Quantification of 
Proteins 
Control RAS All 
# Proteins Identified 4373 4385 4714 
# Proteins Quantified in ≥ 80 % of replicates 1738 1662 2368 
# Up Regulated Proteins (RAS/Control) 16 
# Down Regulated Proteins (RAS/Control) 49 
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Supplementary Figure S3.1: Volcano Plot of Quantified SUMO Sites and Motif Analysis 
of Identified SUMO sites. 
(a) Volcano plot of the SUMO site abundance in senescent cells over control cells where each 
data point represents a site. Sites in the green quadrant are up regulated and in the red quadrant 
down regulated in senescent cells. (b) Motif-X analysis of all identified SUMO sites. (c) 
Motif-X analysis of the regulated SUMO sites compared to all the sites identified in this study. 
 
Supplementary Figure S3.2: Volcano Plot of Quantified Proteins and their Associated 
GO Terms.  
(a) Volcano plot of the protein abundance in senescent cells over control cells where each data 
point represents a protein. Proteins in the green quadrant are up regulated and in the red 
quadrant are down regulated in senescent cells. (b) GO term associated with the regulated 
proteins found in the red and green quadrants of panel (a). 
 
Supplementary Figure S3.3: SUMOylation of UBC9 Occurs Primarily at Lys-49 and 
does not affect its Catalytic Activity   
(a) The K49R alteration on UBC9 does not affect its activity in vitro. Time course 
SUMOylation of RanGap, a SUMOylatable peptide of PML and E2-25K by wild type UBC9 
and the K49R variant. (b) Flag-IP results from U2OS cells expressing SUMO3m and a control 
vector, Flag-UBC9 (F-UBC9 WT) or its K49R variant (F-UBC9K49R) showing Lys-49 as the 
main SUMO acceptor site.  
 
Supplementary Figure S3.4: Immunofluorescence of F-UBC9 WT Co-localizing into 
PML-NBs More Readily than F-UBC9-K49R Upon RAS Mediated Senescence.  
Double immunofluorescence with anti-FLAG and anti-PML antibodies to show colocalization 
of F-UBC WT (wild type) or K49R variant in U2OS cells expressing SUMO3m plus (a) 
control vector or (b) H-RAS-V12 (RAS) to induce senescence. Percent of cells considered 
positive for Flag/PML colocalization - with at least 4 common foci - is indicated in the “Merge 
Flag + PML” panels. DAPI: DNA counterstain. (scale bar: 10 μm, Magnified frame = 8.0x) 
 
 137 
Supplementary Figure S3.5: Immunofluorescence of F-UBC9 WT Co-localizing into 
PML-NBs More Readily than F-UBC9-K49R upon ATO Treatment.  
Double immunofluorescence with anti-FLAG and anti-PML antibodies to show colocalization 
of F-UBC WT (wild type) or K49R variant in U2OS cells expressing SUMO3m and either (a) 
control treated (CTRL) or (b) treated with 1 mM arsenic trioxide (ATO) for 2 hours. Percent 
of cells considered positive for Flag/PML colocalization - with at least 4 common foci - is 
indicated in the “Merge Flag + PML” panels. DAPI: DNA counter stain. (Scale bar: 10 μm, 
Magnified frame = 6.3x) 
 
Supplementary Figure S3.6: PML Fusion Proteins Localize to PML-NBs.  
Double immunofluorescence with anti-PML (green) and anti-UBC9 (red) antibodies to show 
colocalization signals for F-UBC9 wild type (WT) or its K49R variant with PML signal in 
U2OS cells expressing SUMO3m and either control vector, or one of the PML fusion proteins. 
DAPI: DNA counter stain. Scale bar: 20 μm. 
 
Supplementary Figure S3.7: In normal primary cells, UBC9 bypasses PML senescence 
when forced in PML-NBs. 
a) Growth curves of primary human fibroblasts IMR90 expressing a control Vector, a GFP-
PML fusion or the fusion of PML with wild type UBC9 (F-Ubc9WT-PML). b) Counts for 
cells positive for the senescence-associated-beta-galactosidase assay as a marker of senescence 
in the cells as in a). Three sets of 100 cells were counted. ***p<0.005 Student’s t-test. 
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Supplementary Figure S3.1: Volcano Plot of Quantified SUMO Sites and Motif 
Analysis of Identified SUMO sites. 
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Supplementary Figure S3.2: Volcano Plot of Quantified Proteins and their 
Associated GO Terms. 
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Supplementary Figure S3.3: SUMOylation of UBC9 Occurs Primarily at Lys-49 
and does not affect its Catalytic Activity 
 141 
 
 
Supplementary Figure S3.4: Immunofluorescence of F-UBC9 WT Co-localizing 
into PML-NBs More Readily than F-UBC9-K49R Upon RAS Mediated Senescence. 
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Supplementary Figure S3.5: Immunofluorescence of F-UBC9 WT Co-localizing 
into PML-NBs More Readily than F-UBC9-K49R Upon ATO Treatment. 
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Supplementary Figure S3.6: PML Fusion Proteins Localize to PML-NBs. 
 
 144 
 
Supplementary Figure S3.7: In normal primary cells, UBC9 bypasses PML 
senescence when forced in PML-NBs. 
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4  Discussion 
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4.1  General discussion 
 
Cellular senescence is a general anti-proliferative program that avoids the expansion of 
cells bearing oncogenic mutations, for this reason is considered to be one of the main barriers 
against tumorigenesis (209, 349). Depending on the cell type, senescence activation program 
requires activation of p53 and pRB pathways either alone or in combination (350) and it can 
be initiated by inappropriate oncogene activation. The pRB is considered a bona fide tumor 
suppressor and gate keeper of cell division; under its activated state, it controls the cell cycle 
transition at the transcriptional level via repression of E2F target genes. These organized steps 
for a proper cell division are controlled by the modification and expression of several proteins 
upstream and downstream of the pRB pathway that can modulate the cellular fate.  
Our laboratory has focused their investigation on the mechanisms that regulate the 
senescence pathway induced by the expression of oncogenes such as Ras. One of the main 
characteristics of the oncogene-induce senescence is the activation of tumor suppressors like 
p53, pRB and PML that reinforce growth arrest. PML is able to induce senescence in normal 
cells; however, the senescence phenotype is not as strong in cancer cells. Tumor cells have, 
among their characteristics, gain functions that help them to activate or suppress several 
pathways in order to bypass the tumor suppressor barriers that could induce either apoptosis or 
senescence. 
Despite that deletions and mutations of tumor suppressors such as PML and aberrant 
elevations of oncogenes at the genetic level are reported to cause cancers, emerging evidence 
has revealed that cancer progression is largely regulated by epigenetic alterations. They 
include aberrant methylation patterns and post-translational modifications (PTMs) such as 
SUMOylation.    
The main goal of this thesis is to investigate such epigenetic and PTMs modifications 
that can confer resistance on tumor cells in order to bypass cellular senescence and progress to 
malignancy.   
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4.2 Discussion of chapter 2  
4.2.1 Resume of results in chapter 2 
 The results obtained in chapter 2 uncover a new role for the CDK4/6 kinases as 
epigenetic modulators that protect cancer cells from senescence.  
The CDK4/6 kinases govern the G1 transition of the cell cycle by phosphorylating 
pRB and its upregulation is often found in human cancers. In addition to modulate the cell 
cycle, these kinases display non-cell cycle functions that have high impact in cancer 
development. For these reasons, the CDK4/6 selective inhibitors are expected to have an 
expanded therapeutic role. 
Our results show that in cancer cells, either CDK4/6 inhibition or PML overexpression 
alone are not sufficient to induce a stable growth inhibition and to trigger a strong senescence 
response. However in combination, cancer cells undergo an irreversible growth arrest. This 
senescence response observed in cancer cells is accompanied of several senescence markers 
such as change in morphology, SA-β-Gal expression, induction of autophagy and 
hypophosphorylation of pRB. When the combinatory therapy was tested in mice xenografts, 
we could observe tumor regression in some mice harboring PML expressing cells treated with 
palbociclib, a selective inhibitor for CDK4/6. 
PML-expressing cells and treated palbociclib showed an upregulation of several 
cytokine genes and a stronger down regulation of E2F target genes that play a role in DNA 
repair compared non senescent cancer cells. This data is consistent with previous findings 
during PML-induced senescence in primary fibroblasts which suggest the persistent DNA 
damage response seen in senescent cells (150). Also, the gene expression profile of 
PML/palbociclib treated cells overlaps with the pattern observed in pancreatic cancer cells 
treated with DNA methylation inhibitors. CDC2, CDC6, CENPF, FOXM1, LMNB1, and 
HMGB2, were among the genes downregulated in cells treated with DNA methylation 
inhibitors (273). We were able to confirm a better down regulation of those genes in PML-
expressing cells and treated palbociclib when compared with control growing cells expressing 
empty vectors, control cells treated with palbociclib, or cells expressing PML alone. In 
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addition, we confirmed that PML/palbociclib treatment increased the levels of several 
senescence-regulatory genes repressed by DNA methylation. 
Reversibility assays showed that upon serial combinatory treatments, first with 
palbociclib and then with senescence inducers such as PML expression or the 
chemotherapeutic agent Camptothecin (CPT), cancer cells have a more lasting permanent 
growth arrest. Surprisingly, under these conditions cancer cells showed also a decrease in the 
expression of the methyltransferase DNMT1. We could observe the same phenotype in PML-
expressing cancer cells treated with 5-Aza-20-deoxycytidine (5-aza-CdR: DNA methylation 
inhibitor).  
Given the fact that DNA methylation plays a central role in the control of gene 
expression, cellular differentiation and development, is not surprising that aberrant DNA 
methylation is associated with aging and carcinogenesis. For this reason we investigated if it is 
possible that cancer cells are able to modulate the expression of DNMT1 by direct interaction 
with CDK4. In fact by immunoprecipitation assays we were able to show protein-protein 
interaction between DNMT1 and CDK4, further, by kinase activity assays we showed that 
CDK4/Cyclin D phosphorylate DNMT1 in vitro.  
The main objective of this project was to show that given the fact that human cancer 
cells are resistant to PML induced senescence possibly by the hyperactive CDK4/6 signaling, 
decreasing the activity of these kinases will restore the senescence response to PML induction 
and activate an efficient senescence response in cancer cells. CDK4/6 are able to stabilize 
DNMT1, which can promote DNA hypermethylation of tumor suppressor genes in cancer 
cells, decreasing CDK4/6 activity allowed autophagy-dependent degradation of DNMT1 and 
reactivation of the senescence program. 
Cancer cells display changes in methylation compared with its normal tissue, given 
this, we wondered if our combinatory treatment that can induce a strong senescence response 
in cancer cells is accompanied with changes in DNA methylation, To study this, we performed 
a global methylation analysis for assessing Differentially Methylated Regions (DMRs). The 
results obtained from this will be discussed in Annex 1.  
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4.2.2 Annex 1: Differentially Methylated Regions 
 
Figure 4.1: Differentially Methylated Regions. 
A)  Differentially Methylated Regions (DMRs): Genomic regions that are differentially 
methylated after Roche SeqCap EPI 4M CpGiant + Illumina HiSeq sequencing in PC3 cells 
expressing either empty vector or PML and treated with or without Palbociclib 500nM for 
6 days. Median p-value=0.05, minimum methylation difference of 2.5%. B) Known motif 
search by HOMER (Hypergeometric Optimization of Motif EnRichment) in DRMs as in 
(A) corresponding to SBE (Smad Binding Element). C) Overlap of genes near DMRs found 
in conditions as in (A). 
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4.2.3 An insight into DNA methylation patterns in normal and in 
cancer cells 
Epigenetics refers to alternate phenotypic states that are not based in differences in 
genotype, and are potentially reversible, but are generally stably maintained during cell 
division. A much more expanded view of epigenetics has recently emerged in which multiple 
mechanisms interact to collectively establish alternate states of chromatin structure, histone 
modification, associated protein composition, transcriptional activity, and in mammals, 
cytosine-5 DNA methylation at CpG dinucleotides. It has long been known that cancer cells 
undergo changes in 5-methylcytosine distribution including global DNA hypomethylation and 
the hypermethylation of promoter CpG islands associated with tumor suppressor genes. It is 
now realized that CpG island hypermethylation is just one facet of an integrated change in 
chromatin structure and in histone modifications, including histone H3 and H4 deacetylation, 
histone H3 lysine 9 methylation, histone H4 sumoylation and reduced histone H3 lysine 4 
methylation, among others, collectively resulting in a transcriptionally silenced state (351, 
352). 
DNA methylation is one of the principal epigenetic signals that participate in cell 
specific gene expression in vertebrates. It plays a central role in the control of gene expression, 
cellular differentiation and development by regulating the preservation of chromatin structure 
and chromosomal integrity, parental imprinting, X-chromosome inactivation, aging and 
carcinogenesis. The family of enzymes known as the DNMTs (DNA cytosine-(C5)-
methyltransferases) DNMT1, DNMT3A and DNMT3B are involved in DNA methylation, and 
among them, DNMT1, the maintenance methyltransferase, occupies an imperial status. It 
faithfully maintains and propagates the existing methylation marks across successive cell 
generations, hence becomes essential for the genomic integrity (291, 353).  
Alteration in the established DNA methylation patterns involving gene-specific 
hypermethylation and genome-wide hypomethylation is a characteristic hallmark of cancer 
cells. In general, DNA hypomethylation is thought to cause expression and recombination of 
repetitive sequences leading to instability of the cancer genome, whereas hypermethylation at 
 151 
CpG islands can contribute to cell transformation by silencing tumour suppressor genes 
involved in apoptosis or senescence preventing then their activation.  
Hypomethylation of specific proto-oncogenes such as c-Myc, c-Fos, H-Ras, K-Ras, 
ERB-A1, and BCL-2 has been observed, particularly in hepatocellular carcinomas and 
leukemia’s (354). In several types of cancers such as liver, ovarian, pancreatic, leukemia and 
lung, one of the most common genetic events is DNA hypermethylation that inactivates and 
decreases the expression of tumor suppressors like pRB (355, 356), BRCA1 (357, 358), and 
CDKN2A which encodes for the CKIs p16INK4A and p15INK4B (359-361).  
This aberrant DNA methylation in cancer can be generated either prior to or following 
cell transformation through mutations (362). However, the actual source of abnormal 
methylation or the trigger that initiates this process is not known. Low-level de novo 
methylation of CpG islands is known to take place in normal tissues and has been shown to 
increase with age. Genome-wide studies in aging cells and tissues have uncovered stochastic 
DNA methylation drift (gradual increases or decreases at specific loci) that reflects imperfect 
maintenance of epigenetic marks. Drift creates epigenetic mosaicism in aging cells that could 
potentially restrict their plasticity and worsen phenotypes such as focal proliferative defects 
that can lead to cancer (363). Besides aging, changes in DNA methylation can occur in a 
subpopulation of cells exposed to cellular stresses such as chronic inflammation and/or ROS 
accumulation (364) and it is very possible that these methylation drifts are actually 
interconnected and may promote clonal expansion of cells with epigenetic abnormalities 
thereby promoting a tumor-like methylation profile (362, 365). 
Several regulatory mechanisms are set into place to monitor the stability and 
interactions of DNMT1 with other epigenetic manipulators and chromatin remodelers. Its 
enzymatic activity is rigidly controlled to ultimately accomplish its duty as a transcriptional 
repressor (366, 367).  Different signal transduction pathways including: RAS/AP-1, PI3/PKB, 
p53/SP122 and pRB/E2F regulate DNMT1 activity. These signaling systems induce higher 
expression of the enzyme in a programmed manner in distinct biological settings. Therefore 
malfunctioning, especially upregulation of these pathways as seen in tumorigenic conditions 
results in constitutive activation of DNMT1 enzyme leading to aberrant regional 
hypermethylation of the genome in cancer (366). 
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In normal or resting cells, the constitutive expression levels of DNMT1 are usually 
low. Elevated expression of DNMT1 has been shown in carcinomas of the colon, lung, liver, 
breast and prostate. Based on the nearly ubiquitous alterations of both DNA methylation and 
pRB pathway found in human cancers, there is no surprise that both proteins have a potential 
regulatory link in a cell cycle dependant manner. During G1, hypophosphorylated pRB binds 
to E2F, recruits HDAC to this complex and prevents turning on of the cell cycle proteins such 
as Cyclin E, PCNA, Pol α, E2F-1 and DNMT1 to maintain basal level expression of DNMT1. 
As the cell passes into the S phase, increased DNA synthesis initiates a need for maintaining 
the methyl marks on hemimethylated daughter strands. Consequently, CDK4/6 phosphorylates 
pRB disrupting the binding to E2F, releasing the transcription factor and resulting in 
functional level expression of DNMT1. The progression into G2 results in dephosphorylation 
of the pRB and subsequent inactivation of the DNMT1 gene (366, 367). Loss of functional 
pRB, for example by over-expression of CDK4/6 kinases, may grant DNMT1 free access to 
the genome, which could allow aberrant methylation of CpG islands to silence the 
transcription of diverse tumor suppressors. In fact, has been proven that Hepatitis B Virus X 
protein (HBx) induce DNA hypermethylation of p16INK4A promoter to repress its expression. 
This event subsequently leads to activation of CDK4/6, phosphorylation of pRB, activation of 
E2F1, and finally transcriptional activation of DNMT1, an event that is often found in 
hepatocellular carcinoma (368). This association point to a complicated network of 
connections between DNMT1 and several cellular proteins involving gene regulation and 
epigenetic signaling during cell cycle and tumor transformation (369).  
The re-activation of tumor suppressor genes silenced by hypermethylation can be done 
by using a demethylating agent that might sensitize tumours to the action of chemotherapy. 
The methylase inhibitor 5-aza-CdR is a cytosine analogue that is incorporated into DNA 
during replication. It covalently binds DNMT1 and inhibits its activity, leading to genome-
wide demethylation (273). The action of this compound has been proved, for example; when 
leukemia cancer cells grown in culture are treated with 5-aza-CdR, de novo methylation of 
p15INK4B is lost provoking the loss of cancer-like properties in these cells (370, 371). Also, a 
study in Breast Cancer Stem Cells (BCSCs) showed that low doses of 5-aza-2-CdR reduce 
breast cancer cell survival and induce differentiation through re-expression of tumor 
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suppressor genes like p16INK4A, p15INK4B, BRCA1 and BRCA2 and p53 expression suggesting 
that differentiation therapy to reduce self-renewal of BCSCs is a promising approach in 
targeting specific chemotherapy-resistant cells within a tumor (372). 
Even though the association between cancer and alterations in DNA methylation has 
been well established, DNA methylation marks have a crucial role in normal development, for 
this reason it is important to assess the possibility that genetic disruption of epigenetic 
components such as DNMTs also has an impact in cancer development. Pharmacological 
inhibitors like 5-aza-CdR, have pleiotropic effects, which could include those unrelated to 
activation of methylated silenced genes.  
For example; complete genetic knockout of DNMT1 causes abnormal development 
and embryonic lethality (373). A study using hypomorphic DNMT1 allele, which reduces 
DNMT1 expression to 10% of wild-type levels and results in substantial genome-wide 
hypomethylation in all tissues, showed that the mutant mice were runted at birth, and at 4 to 8 
months of age they developed aggressive T cell lymphomas that displayed a high frequency of 
chromosome 15 trisomy. This indicates that DNA hypomethylation plays a causal role in 
tumor formation, possibly by promoting chromosomal instability (374). Furthermore, crossing 
DNMT1 hypomorphic mice with murine tumor models, the tumor progression is altered, it 
results in either increased or decreased tumor development, depending on the disease stage 
and tissue site, suggesting that DNMT1 has diverse effects on cancer development, which are 
dependent on tissue context and tumor stage (375, 376). 
Besides transcription regulation, covalent reversible Post-Translational Modifications 
(PTMs), such as methylation, acetylation, phosphorylation, SUMOylation and ubiquitination, 
augment the functional potential of DNMT1 by influencing its activity, stability and/or 
interaction with other proteins (366). 
DNMT1 activity can be affected by its phosphorylation at Ser-515. This modification 
facilitates the interaction between the N-terminal domain of DNMT1 and its catalytic C-
terminal domain to increase the activity of the enzyme (377). DNMT1 is also phosphorylated 
at residues Ser-127/143 and Ser-127 by V-Akt Murine Thymoma Viral Oncogene Homolog 1 
(AKT1) and Protein Kinase C (PKC), respectively, contributing toward its stability. 
Phosphorylation in these sites lowers the interaction of DNMT1 with PCNA and UHRF1 at 
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the replication fork in early and mid S-phase. This leads to inactivation of the enzyme to 
prevent erroneous methylation of DNA in late S- and early G2-phase when no hemimethylated 
targets are available (378).  
Importantly, a recent study by Lavoie and St-Pierre has shown that CDKs such as 
CDK1, CDK2 and CDK5 can phosphorylate DNMT1 at Ser-154 residue. The Ser-154 
phosphorylation affects domain-domain interactions between N-and C-termini and 
consequently controls DNMT1 activity and protein stability. This post-translational 
manipulation of the enzyme is of paramount significance as deregulation of CDKs can cause 
aberrant phosphorylation of DNMT1 and lead to DNA hypermethylation, as seen during 
tumorigenic progression (70). 
Since that altered DNA methylation and associated destabilization of genome integrity 
and function is a hallmark of cancer is not surprising that this phenomena is associated with 
senescence bypass during oncogenic transformation. It has been shown by whole-genome 
single-nucleotide bisulte sequencing that replicative senescent human cells exhibit widespread 
DNA hypomethylation and focal hypermethylation. Hypomethylation occurs preferentially at 
gene-poor, late-replicating, lamin-associated domains and is linked to mislocalization of 
DNMT1 in cells approaching senescence. Low-level gains of methylation are enriched in CpG 
islands, including at genes whose methylation and silencing is thought to promote cancer. 
Gains and losses of methylation in senescence are thus qualitatively similar to those in cancer, 
and this `reprogrammed' methylation landscape is largely retained when cells bypass 
senescence. Consequently, the DNA methylome of senescent cells might promote malignancy, 
if these cells escape the proliferative barrier (289). 
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4.2.4  Discussion Annex 1 
As mentioned before, our results show that in cancer cells the senescence response is 
better induced after combining senescence inducers like PML or camptothecin and CDK4/6 
selective inhibitor palbociclib. Besides the senescence markers like SA-β-Gal induction and 
increase in autophagy markers observed in PML-expressing cells treated with palbociclib, we 
also show that in these senescent cells there is a reduction of DNMT1 protein levels associated 
directly by CDK4/6 inhibition. CDK4 can interact with and phosphorylate DNMT1.  
To address the question if the senescence observed in our model is accompanied with 
changes in DNA methylation; we performed a global methylation analysis to search for 
Differentially Methylated Regions (DMRs).  We introduced 744 DMRs sequences of cells 
expressing Vector treated and none treated with Palbociclib and 598 DMRs sequences of cells 
expressing PML treated and none treated with Palbociclib. 
We used the same conditions used before during our study: PC3-Vect + control, PC3-
Vect + Palbo (500mM, treated for 7 days), PC3-PML + control, PC3-PML + Palbo (500mM, 
treated for 7 days). The samples were sent to McGill University and Génome Québec was a 
Roche SeqCap EPI 4M CpGiant analysis was performed.  Once the methylation profile 
obtained a compute differentially methylated regions (DMRs) was performed using the 
Bioconductor's bsseq package (Figure 4.1). 
DMRs are genomic regions of adjacent CpG sites that are differentially methylated 
among multiple samples, are regarded as possible functional regions involved in gene 
transcriptional regulation. After the DMRs analysis, we performed an analysis with HOMER 
(Hypergeometric Optimization of Motif EnRichment) which is a suite of tools for Motif 
Discovery and next-generation sequencing analysis (Figure 4.1A).  
We could observe that the genomic regions of CpG sites are differentially methylated 
in PC3 cells expressing either empty vector or PML and treated with or without Palbociclib. 
However, when we compare PC3-PML cells with or without treatment with palbociclib, the 
program detected enrichment for Smad 2 motif binding sites among the DMR probes which 
sequence correspond to Smad Binding Elements (SBEs) (379) (Figure 4.1B). This enrichment 
was no detected on PC3-vector cells either treated or not treated with palbociclib, which could 
indicate that the change in methylation on Smad 2 motif correspond only to the cancer cells 
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where senescence phenotype was induced. We haven’t been able to figure it out to which gene 
region for Smad 2 binding site correspond this DMR enrichment, further computational 
analysis are going to be required to give a physiological and mechanistic relevance to this 
result.  
The Smads are intracellular proteins that transduce extracellular signals from the TGF-
β ligands to the nucleus and activate downstream gene transcription that potently inhibits cell 
proliferation by causing cell cycle arrest at the G1 phase. In the basal state, Smad 2 and Smad 
3 are distributed throughout cells. In response to TGF-β, Smad 2/3 are phosphorylated at the 
carboxyl terminus by TGF-β receptor and form complexes with or without Smad 4. The 
complexes are translocated to the nucleus where then regulate the transcription of specific 
target genes. Activated Smad oligomers have been reported to bind to sequences containing 
GTCT or AGAC (SBEs sequences) (379). Recent ChIP-chip/ChIP-seq studies have confirmed 
that the SBE is enriched in the Smad2/3-binding regions (380-383). These complexes then 
accumulate in the nucleus and regulate the transcription of target genes that include cell cycle 
regulators such as the CKIs p16INK4A, p15INK4B and p21CIP1 and the proto-oncogene c-Myc 
(71). TGF-β is a cytokine that plays a fundamental role in various cellular functions, such as 
embryonic development, wound healing, angiogenesis, proliferation, differentiation, apoptosis 
and senescence. However, deregulation of this pathway can lead to various pathological 
conditions, including cancer. In normal epithelial cells, TGF-β causes G1 cell cycle arrest and 
inhibits proliferation, and promotes differentiation or apoptosis. In fact, during the early stages 
of hyperplasia and tumor development, TGF-β has a suppressive role; however, its function 
switches to a tumor promoter by enhancing angiogenesis, migration, and metastasis during the 
advanced stages of cancer (384, 385) such as breast and prostate cancers (386, 387). 
 Interestingly, as mentioned in the introduction; other report showed that Smad 2/3 can 
be phosphorylated by CDK4 inhibiting its transcriptional activity and antiproliferative 
functions. This imply that inactivation of Smad2/3 by extensive CDK4 phosphorylation may 
provide an important mechanism for resistance to the TGF-β growth-inhibitory effects in 
cancers (71). Due to the fact that TGF-β is a component of the SASP, its function has also 
been studied in senescence. Upon induction of the TGF-β pathway, Hepatocellular Harcinoma 
(HCC) cell lines display a strong senescence response by increase of the CKIs p21CIP1 and 
p15INK4B and arrest at G1 phase. In mice xenografts Human HCC tumors also displayed 
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senescence after treatment with TGF-β induction (388). Another study also showed that 
attenuation of TGF-β signaling suppresses premature senescence in a p21CIP1-dependent 
manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary 
epithelial cells (389). In fact, TGF-β secreted factors are found in high concentrations in 
prostatic fluid and areas of Benign Prostatic Hyperplasia (BPH) and a substantial population 
of epithelial cells are positive for SA-β-Gal (386). All this data correlates the fact that in 
normal and in senescent cells, TGF-β has an anti-oncogenic role, but more importantly show 
that the senescence program can be reactivated and reinforced in tumor cells. The recognition 
that a senescence programme may be re-induced in immortalised and tumorigenic cells by 
exposure to selected drugs presents a putative target for blocking cancer cell growth (390). 
Cancer cells are fully transformed cells in which the tumor suppressor mechanisms are 
completely disabled and although DNA methylation marks are already established, can be 
reverted. All these acquired oncogenic characteristics allow cancer cells to gain drug 
resistance and mechanisms to bypass the tumor suppressor barriers in order to proliferate 
(Figure 4.2-A1).   
We have proved that palbociclib have an impact in inhibiting CDK4/6 kinases, as 
previously reported, but also we have shown that palbociclib can decrease DNMT1 
expression. This can modify the DNA methylation marks that are known to be altered in 
several forms of cancers opening a new window in cancer treatments. This effect of 
Palbociclib acting as epigenetic modulator may be help to convert or revert cancer cells in a 
targeted therapy or chemotherapy sensitivity state that was not effective for the original cancer 
population (Figure 4.2-A2). As a consequence, this sensitivity state could help to reinforce a 
senescence phenotype on cancer cells that could induce its clearence by the immune system or 
its elimination by conventional chemotherapy (Figure 4.2-A3). 
Given our results, CDK4/6 can modulate the expression of DNMT1 by direct 
phosphorylation. In the absence of these kinases, DNMT1 is downregulated and target it to 
degradation via autophagy; this can induce demethylation and expression of tumor suppressor 
genes that can revert cancer cells into a pre-senescent state sensible to chemotherapy (Figure 
2-B1). When PML is induced via over-expression or by CPT (391, 392), the senescence 
response is strongly triggered by induction of PML-NBs formation and persistent DNA 
damage response (Figure 4.2-B2). This allows secretion of cytokines and SASP components 
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that could reinforce the growth inhibition through the activation of the TGF-β pathway and 
activate expression of proteins such as Smad 2 to act as a tumor suppressor and reinforce the 
senescence response (Figure 4.2-B3).  
Up-regulation of the CDK4/6 kinases is often found in human cancers. Its unbalance 
expression leads to elevated catalytic function that increase cell division and decrease 
dependence on extracellular mitogenic growth factors for cell proliferation (393). Given their 
importance in controlling cell cycle progression, promoting tumor transformation and 
impairing the senescence response (72, 132, 133), there have been significant efforts to 
develop selective CDK4/6 inhibitors with the hope that such entities would have significant 
anti-cancer benefit.  
Now a day’s the CDK4/6 inhibitor Palbociclib has been shown to be highly efficacious 
in a variety of cell culture models with regard to its capacity to suppress cell cycle progression 
through inhibition of CDK4/6 kinase activity in a pRB-dependent manner. This compound is 
currently entering into phase III clinical trials in several cancers pRB positive such as mantle 
cell lymphoma, breast cancer, liposarcome, prostate and colorectal cancer with reversible 
neutropenia as the main toxic effect (101, 104). It has been well documented that Palbociclib 
treatment on cancer cells can trigger irreversible withdraw, leading to senescence (67, 72, 107, 
394). In addition to inhibiting the cell cycle, palbociclib has been shown to alter several 
recently described non–cell cycle functions of CDK4/6, a finding expected to expand its 
therapeutic role. 
However, not all tumors respond favorably to these drugs and acquired de novo 
treatment resistance mechanisms started to emerge (106, 108).  
The major barrier to successful therapies for advanced cancers is treatment resistance. 
In the case for targeted therapies, such resistance can be due to new mutations arising directly 
in the targeted molecule or in genes in the direct downstream pathways or complementing 
pathways. However, it may be that epigenetic alterations could also play an important role in 
this resistance that will give cancer cells survival advantages. As an integrated disease, every 
cancer has multiple genes with epigenetic alterations and altered key fundamental pathways to 
its tumor development.  
Notably, the reversibility of epigenetic abnormalities in cancer subpopulations with 
inherent drug tolerance also provides a potentially exciting therapeutic strategy. Drugs that 
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could function as epigenetic modulators (like palbociclib) could be utilized as a priming 
therapy that may sensitize cancer cells, which are otherwise drug resistant, to 
conventional/targeted chemotherapy. The future success of combinatory therapies lies in the 
use of potential drugs capable to erase oncogenic methylation marks and by doing so, delay or 
reverse resistance to current cancer therapies.  
 
Figure 4.2: Model.  
Panel A. Cancer cells as fully transformed cells are drug resistant (1). CDK4/6 inhibition by 
treatment with palbociclib can revert cancer cells into a pre-senescent/drug sensitive state 
(2). When senescence is induced by PML or CPT, the senescence pathway is completely 
triggered into cancer cells (3). Panel B. Upon CDK4/6 inhibition, pRB cannot be 
phosphorylated and maintain its repressor activities on E2F genes. DNMT1 is destabilized 
due to the lack of phosphorylation from CDK4 and its targeted to autophagy dependant 
degradation. De-regulation of DNMT1 allows de-methylation of tumor suppressor genes 
(1). When PML is induced via over-expression or by CPT the senescence response is 
triggered by induction of PML-NBs formation and persistent DDR (2). Activation of the 
senescence pathway allows secretion of cytokines and SASP components that can reinforce 
the growth inhibition through the activation of the TGF-β pathway (3).  
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4.3 Discussion chapter 3 
4.3.1 Resume of results in chapter 3 
 The results obtained in chapter 3 uncover novel pro- and anti-senescence functions of 
protein SUMOylation. 
SUMOylation is a post-translational modification often associated as a stress response, 
and is been implicated in a several cellular processes that include from chromatin structure and 
transcription regulation to protein stability, activation and transportation. Lately, it has been 
uncovered that proteins with active roles in the control of cell survival and proliferation are 
substrates for SUMOylation and have an impact on modulate cellular outcomes such as 
differentiation, apoptosis and cellular senescence. 
By a large scale SUMO-3 proteome in cancer cells subjected to HRAS-induced 
senescence we were able to identify 25 SUMO sites that are significantly regulated in the 
senescence process. Many of the targeted proteins are associated to PML-NBs, suggesting that 
changes in SUMOylation occurring during senescence could be associated with PML-NBs or 
contribute to the target’s localization to nuclear bodies. 
The mass spectrometry analysis revealed an increase in SUMOylation for PML, SP100 
and UBC9 and a decrease in SUMOylation of TRIM28 and HDAC1 in senescent cells. By 
western blot analysis we were able to validate the SUMOylation changes in these five 
proteins. Interestingly, UBC9, the only E2 SUMO ligase was found to be SUMOylated during 
senescence at Lys-49. Given the fact that UBC9 can be recruited into PML-NBs, can also 
interact with PML through its SIM domain and most of the senescence regulated SUMO sites 
are associated with PML-NBs (127, 153), we wondered if this SUMO modification of Ubc9 
could have a role in its PML-NB association. 
To investigate the role of SUMOylation of UBC9 at Lys-49 in vivo, we produced cells 
expressing either an UBC9-K49R (unable to be SUMOylated, but catalytically active) or an 
UBC9 WT. By immunofluorescence assays we were able to show that SUMOylation of UBC9 
at Lys-49 promotes its localization to PML-NBs. A similar phenomenon was observed for 
cells treated with arsenic trioxide (ATO), a compound known to induce ROS and to promote 
UBC9 localization to PML-NBs. Also, by growth assays we show that overexpression of 
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UBC9-WT produced a delay on the onset of Ras-induced senescence. Conversely, 
overexpression of UBC9-K49R was unable to delay Ras-induced senescence and cell grew 
with the same dynamics as the control cells. These results suggest that if UBC9 is unable to 
traslocate to PML-NBs is unable to delay cellular senescence; indicating a pro-senescence role 
for UBC9. However, when UBC9 is forced into PML-NBs by the expression of UBC9-PML 
fusion proteins, SUMOylation occurring at nuclear bodies inhibits senescence driven by PML 
and Ras expression, suggesting in this case, an anti-senescent function for UBC9. These 
results indicate that SUMO modification at Lys-49, allows UBC9 a dual function on the onset 
of cellular senescence.  
Even though there is a general concept that global SUMOylation promote senescence, 
several studies have revealed that upregulation of SUMOylation can promote impairment in 
the senescence pathway leading to cancer cell proliferation. Given this last results, we 
wondered if constitutively expression of SUMO-3 has an impact in PML-induced senescence 
bypass by UBC9. This will be discussing in Annex 2. 
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4.3.2  Annex 2: Overexpression of SUMO-3 stimulate PML-induced 
senescence bypass by UBC9. 
 
Figure 4.3: Overexpression of SUMO-3 stimulate PML-induced senescence bypass 
by UBC9. 
Growth curves of U2OS and U2OS-SUMO3m cells expressing a control vector, PML, 
fusion of PML with wild type UBC9 (UBC9 WT-PML) or K49R variant (UBC9K49R-
PML). 
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4.3.3 Role of up-regulated SUMO pathway impairing cellular 
senescence and promoting cancer cell proliferation 
SUMOylation, as a post-translational modification, has been implicated in a number of 
cell processes, such as regulation of transcription, nuclear transport, DNA repair, protein 
stability, cell cycle control, signal transduction, cell migration and chromatin structure. 
SUMOylation and de-SUMOylation reversing steps, are tightly regulated to maintain a 
balanced homeostasis on proteins in normal cells; in fact, under normal physiological 
conditions, only a fraction of the total number of proteins expressed in the cell is SUMO 
modified (395). 
Recent discoveries demonstrate that proteins with active roles in the control of cell 
survival and proliferation have been identified as substrates for SUMOylation and enzymes 
partaking in the SUMO modification pathway have been associated with the onset of cellular 
senescence (395, 396). In this sense, deregulation of the SUMO pathway makes essential 
contribution to cancer development by directly attenuating protein functions of tumor 
suppressors and/or potentiating the hyperactive roles of oncogenes signaling pathways (397). 
Transcription factors are frequent targets of SUMOylation and modification by SUMO can 
affect subcellular localization, transcriptional activity, and stability of a specific protein (398). 
Altered forms of SUMOylation cause an abnormal accumulation of oncoproteins and 
transcriptional factors in subcellular compartments such as PML-NBs, which can modulate 
several cellular functions through regulation of gene expression and cell reprogramming (395). 
Global SUMOylation, SUMO pathway components and SUMO peptides, can induce 
or hinder senescence, thus supporting an association of SUMOylation with cell growth arrest 
(220, 222, 223, 247, 248, 399). Equally to senescence, SUMOylation has been associated with 
responses to various types of cellular stress. For example, the expression of SUMO-1 has been 
shown to increase during hypoxia (400), oxidative stress, induced by H2O2 results in increased 
levels of SUMO-2/3-modified p53 (247). Because of the close and often causative, association 
between environmental and cellular stress and the onset of senescence; the involvement of the 
SUMO pathway in stress response provides an important, though indirect, link between 
SUMO, senescence, aging process and, very likely, oncogenic transformation (395, 401). 
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Results on comparative analysis of proteomics and mRNA levels between young and 
old murine spleen tissues show elevated levels of global protein SUMOylation (402). Also, 
elevated numbers of SUMOylated proteins have been shown to accumulate in senescent cells 
compared to normal replicating cells (220). Specifically, elevated SUMOylation of certain 
target proteins such as the E3 SUMO ligase PIASγ can induce premature cellular senescence 
(225) and over-expression of SUMO-2/3 in cultured cells can SUMOylate p53 and pRB 
resulting also in premature senescence (247). 
It is well documented that SUMOylation regulate function, structure and stability of 
PML and the PML-NBs (176, 222, 230, 232, 403). SUMO-1 and SUMO-3 modifications can 
modulate the nuclear localization of PML and its retention on the PML-NBs (230, 234). 
Cellular senescence, as a tumor suppressor mechanism, has to be bypass by 
transformed cells in order to progress to cancer, given this, is possible that cancer cells acquire 
mechanisms to alter the SUMO pathway to promote cell proliferation.    
Recent studies have revealed that deregulation of SUMOylation promotes impairment 
in the senescence pathway that can lead to cancer cell proliferation, migration, invasion, 
metastasis and drug resistance (218, 404). 
For example; knockdown of SAE2 in osteosarcoma cancer cells induce a senescence 
response. Cells display growth arrest, positive staining for SA-β-Gal, and elevated expression 
levels of p53 and p21CIP1 (399). Another study showed that low doses of H2O2 induce an 
increase of SENP3 which removes SUMO2/3 from PML causing reduction in the number of 
the PML-NBs and accelerated cell proliferation. Importantly, SENP3 is over-expressed in a 
variety of primary human cancers including colon adenocarcinoma in which PML is hypo-
SUMOylated (249). It was reported also, that SUMO-2/3 modifies the transcription factor 
C/EBPbeta1 (CCAAT/Enhancer Binding Protein Beta). The non-SUMOylated C/EBPbeta1 
form: p52-C/EBPbeta1 plays a role in oncogene-induced senescence and is expressed in 
normal mammary epithelial cells but not breast cancer cell lines. Exogenously expressed 
C/EBPbeta1 is SUMOylated in breast cancer cells. This SUMOylation is enhanced by 
phosphorylation of C/EBPbeta1 at Thr-235 by ERK-2 in vitro. Finally, the fusion protein 
C/EBPbeta1-SUMO (which is constitutive SUMOylated) completely blocks its capability to 
induce senescence in WI38 fibroblasts expressing hTERT. These results suggest that 
SUMOlylation of C/EBPbeta1 in breast cancer cells may be a mechanism to circumvent 
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oncogene-induced senescence (398). Also, an analysis by quantitative mass spectrometry of 
endogenous SUMO-2/3 conjugates tagged by Stable Isotope Labeling by Amino acids in Cell 
culture (SILAC) identified 66 putative SUMO-2/3-conjugated proteins of which 15 proteins 
show a significant increase/decrease in SUMO-2/3 modification in metastatic cells compared 
with non metastatic cells. Targets with altered SUMOylation are involved in cell cycle, 
migration, inflammation, glycolysis, gene expression, and SUMO/ubiquitin pathways, 
suggesting that perturbations of SUMO-2/3 modification might contribute to metastasis by 
affecting these processes. Up-regulation of PML SUMO-2/3 modification corresponds to an 
increased number of PML-NBs in metastatic cells, whereas up-regulation of global SUMO-2/3 
modification promotes 3D cell migration (396). According to this, it has been shown that 
SUMO-1 and global SUMOylation (SUMO2/3) levels are much higher in Cancer Stem Cells 
(CSC) than in non-CSCs of colorectal cancer cells (405).  
 Besides the observations of aberrant global SUMOylation levels in cancer cells, it has 
been reported that increased enzymes of the SUMO pathway are present at higher levels in 
cancer cells than in normal cells. For example; a genome wide shRNA–mediated screen in 
cancer and in normal cells revealed that several SUMO pathway components scored as 
essential genes for cell proliferation (406). Among these SUMO pathway components, UBC9 
has been widely associated with oncogenic transformation. Elevated levels of UBC9 have 
been observed in several malignancies including lung, colorectal, prostatic, ovarian, breast 
cancer and melanoma (407-411). 
In more detail; it has been shown that stable overexpression of UBC9 in the breast and 
lung and osteosarcoma cancer cell lines increases SUMOylation, tumor volume and migration 
when xenografted into mice (399, 404, 412, 413). Supporting this, decreasing SUMOylation 
with the expression of the Dominant Negative UBC9 (catalytically inactive form: UBC9-DN) 
inhibits tumor volume in the xenograft models (407, 412), indicating that preventing enhanced 
SUMO conjugation of cellular substrates in cancer cells reduces tumorigenesis (414). Also, it 
has been shown that loss of SUMOylation induces rapid regression of Myc-driven lymphoma 
(415) and knockdown of UBC9 suppresses 3D growth of K-Ras mutant colorectal cancer cells 
in vitro and attenuates tumor growth in vivo (416).   
Importantly, a detailed analysis of colon, lung, prostate, and breast cancer tissue and 
their normal tissue counterparts by microarrays showed that in primary colon and prostate 
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cancer, UBC9 expression is increased compared with their normal tissue, whereas in 
metastatic breast, prostate, and lung cancer, it is decreased in comparison with their 
corresponding normal and primary adenocarcinoma tissues (408).  
A role for UBC9 in tumor drug responsiveness has been also suggested. For example; 
by blocking UBC9 expression in primary and metastatic melanomas cells, cell sensitivity to 
the cytotoxic effects of chemotherapeutic drugs is increased (409). Also, breast cancer cells 
expressing UBC9-DN display decreased activity of Topo I and are more sensitive to topotecan 
and other anticancer agents such as VM-26 and cisplatin (412).  
4.3.4 Discussion Annex 2 
On chapter 3 we were able to show that overexpression of UBC9-WT produced a delay 
on the onset of Ras-induced senescence and that overexpression of UBC9-K49R mutant does 
not have the same effect. However, when UBC9 is forced into PML-NBs by the expression of 
UBC9-PML fusion proteins in U2OS-S3m cells, SUMOylation occurring at nuclear bodies 
inhibits senescence driven by PML and Ras expression suggesting an anti-senescent function 
for UBC9. Contradicting the general idea that global SUMOylation promote senescence. 
Given this last results, we wondered if constitutively expression of SUMO-3 has an 
impact in PML-induced senescence bypass by UBC9. To study this we overexpressed UBC9 
WT-PML and K49R-PML fusion proteins in U2OS and in U2OS+SUMO3m cells. 
Preliminary data shown in figure 4.3 reveals that SUMO-3 overexpression favors the anti-
senescent role of UBC9. PML is able to induce growth inhibition in both cell lines (U2OS and 
U2OS+SUMO3) (Figure 4.3-B), suggesting that increased SUMO-3 per se do not affect PML-
induced senescence. Conversely, when UBC9-WT-PML and UBC9-K49R-PML fusion 
proteins are also expressed, the growth inhibition imposed by PML expression is completely 
bypass (Figure 4.3-C and D). Both UBC9-PML (WT and K49R) fusion proteins showed the 
same growth dynamics as vector control cells. Consistent with these results, as shown in 
chapter 3; forced localization of UBC9 to PML-NBs do not induce growth inhibition due to an 
anti-senescence function of UBC9 in PML-NBs. In this context, is possible that 
overexpression of SUMO-3 further stimulate the anti-senescence function of UBC9. 
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In this sense, UBC9 could have other functions besides the E2-SUMO conjugating 
activity, and probably, under oncogenic stimuli, UBC9 will display its anti-senescent role into 
PML-NBs by targeting specific proteins to be SUMOylated and/or by modulating certain 
proteins activity modifying its cellular localization. For example; it has been proposed that 
UBC9 can be auto-SUMOylated at Lys-14 and by this auto-SUMOylation, UBC9 combine its 
role as an E2-conjugating enzyme with the function of an E3-ligases in a distinct form of the 
canonical UBC9-SUMO thioester recruitment but in a SIM domain dependant manner. This 
E3-ligase function of UBC9 regulates SUMO target discrimination enhancing sumoylation of 
the transcriptional regulator Sp100 (339). Sp100 is known to interact with PML and is also a 
resident of the PML-NBs, interestingly, our study revealed an increased expression of Sp100 
on the nuclear fractions of senescent cells. Another study also showed that breast cancer cells 
expressing UBC9-DN accumulate more cytoplasmic Daxx than the control cells, interestingly, 
Daxx cytoplasmic expression increase cancer cells sensitivity to chemotherapeutic drugs. 
Given the fact that cytoplasmic Daxx participate in cellular apoptosis, it is suggested that the 
interaction of UBC9 with Daxx and subsequent alteration in its subcellular localization may 
contribute to the increased sensitivity to anticancer drugs in the cells expressing UBC9-DN. 
According to this; overexpression of Daxx sensitizes cells to anticancer drugs possibly in part 
through alterations of the ratio of cytoplasmic and nuclear Daxx (417). Daxx is also a resident 
of the PML-NBs; it is possible too that UBC9 can recruit of Daxx into PML-NBs blocking 
then Daxx’s cytoplasmic apoptotic action and protect cancer cells from chemotherapy drugs 
effects.  
Acording to our results, it could be possible that besides Daxx and Sp100; UBC9 is 
able to modify the localization or promote specific SUMOylation of other proteins residents of 
the PML-NBs and besides impairing apoptosis, also be able to impair the senescence response.  
During PML-NBs formation, UBC9 is recruited and enhances PML SUMOylation, this 
process allows partner recruitment through SIM interactions, and ultimately enhance partner 
SUMOylation. Intermolecular SUMO–SIM interactions then enforce partner sequestration 
within the PML-NBs inner core (236). Besides harboring a SIM domain, it is known that PML 
can be SUMOylated at Lys-65, Lys-160, and Lys-490 (229) and in response to arsenic trioxide 
at Lys-380, Lys-400, and Lys-497 (233). Preliminary data from our laboratory have shown 
that mutations in these sites for SUMOylation on PML do not affect its capacity to induce 
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senescence, however it could be interesting to explore if this SUMOylation sites on PML have 
an impact on growth, formation and/or integrity of the PML-NBs or other proteins of the 
PML-NBs when fusioned to UBC9. 
Conjugation of SUMO can block the sites of attachment for ubiquitin and can thus 
protect proteins from degradation. During oncogenic transformation, this could induce 
overexpression of specific proteins than in normal conditions will be targeted to degradation. 
Although SUMO function is as diverse as its substrates, one generalisation could be that 
modification of a protein substrate by SUMO alters its interactions with other proteins and 
DNA molecules. This has an impact in gene expression, protein function, stabilization and 
cellular localization. By altering this pathway, cancer cells can be protected from the 
activation of the tumor suppressor pathways, impair cellular senescence and promote cancer 
cell proliferation. 
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In conclusion, the results presented in this thesis revealed some of the resistance 
mechanisms that cancer cells acquire to overcome an intrinsic antitumor barrier such as 
cellular senescence. Much of our current understanding of cancer is based on the central 
dogma that it is a genetic disease, arising as a clone of cells that expands in an unregulated 
fashion because of mutations that can be either inherited or somatically acquired due to 
environmental and life-style factors. Cancer cells must modulate several pathways to allow 
them to survive the pressure impose by the tumor suppressor mechanism to continue 
proliferating. One important mechanism is changes in global DNA methylation patterns 
associated with tumor suppressor genes silencing.  
Our study provided evidence that CDK4/6 kinases can modulate the expression and 
stability of the DNMT1 protein and protect cancer cells from PML and chemotherapy-induced 
senescence. This novel association of CDK4/6 with DNMT1 greatly highlight the potential 
value of specific CDK4/6 inhibitors such as palbociclib as epigenetic modulators to potentiate 
the activation of the cellular senescence program in cancer cells.  
The major barrier to successful therapies for advanced cancers is treatment resistance. 
As an integrated disease, every cancer has multiple genes with epigenetic alterations and 
altered key fundamental pathways to its tumor development.  For this reason; epigenetic 
alterations could play an important role in treatment resistance, giving cancer cells survival 
advantages. Notably, the reversibility of epigenetic abnormalities in cancer subpopulations 
with inherent drug tolerance provides a potentially exciting therapeutic strategy. Drugs that 
could function as epigenetic modulators (like palbociclib) could be utilized as a priming 
therapy, which may sensitize cancer cells, which are otherwise drug resistant, to 
conventional/targeted chemotherapy.  
Along with DNA methylation patterns, PTMs like SUMOylation modulate the 
senescence response. Importantly, SUMOylation plays an important role in the scaffold 
function of PML and the formation of the PML-NBs. The results shown in this thesis also 
revealed a pro- and an anti-senescence function of protein SUMOylation, specifically for 
UBC9, the only E2 conjugating enzyme in the SUMO pathway. 
SUMOylation can modulate UBC9 localization into PML-NBs and promote its anti-
senescent function. More importantly SUMOylation activity occurring at nuclear bodies 
inhibits senescence driven by PML expression. SUMOylation has an impact in gene 
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expression, protein function, stabilization and cellular localization. By altering this pathway, 
cancer cells can be protected from the activation of the tumor suppressor pathways, impair 
cellular senescence, increase chemotherapy drug resistance and promote cancer cell 
proliferation. 
In general, epigenetic mechanisms such as DNA methylation and post-translational 
modifications such as SUMOylation can have important implications on the senescent 
phenotype and further progression to malignancy. The further understanding of how these 
mechanisms are modulated will yield a more clear understanding of the processes and/or 
pathways regulating cellular senscence. This knowledge will contribute to the development of 
combinatory therapies that will lie on the use of potential drugs capable to increase drug 
susceptibility in cancer cells to delay or reverse resistance to current anticancer therapies.  
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